Fronto-Temporal Dementia: a clinical and genetic-epidemiological study by Stevens, M. (Martijn)
FRONTO-TEMPORAL DEMENTIA 
a clinical and genetic-epidemiological study 
CIP-Gegevens KONINKLIJKE BIBLIOTHEEK, DEN HAAG 
Stevens, M. 
Pronto-temporal dementia: a clinical and genetic-epidemiological study 
Thesis Erasmus University Rotterdam (with summary in Dutch). 
ISBN 90-9011653-2 
Subject heading: fronto-temporal dementia 
© 1998 M. Stevens 
Printed by Pasmans, 's-Gravenhage. 
No part of this thesis may be reproduced or transmitted in any form by any 
means, electronic or mechanica!, including photocopying, recording or any 
information storage and retrieva! system, without pemlission in writing from the 
author (M. Stevens, Department of Neurology, University Hospita! Dijkzigt, 
P.O. Box 1738, 3000 DR Rotterdam, The Netherlands). 
FRONTO-TEMPORAL DEMENTIA 
a clinical :and genetic-epidemiological study 
FRONTO-TEMPORALE DEMENTIE 
een klinische en genetisch-epidemiologische studie 
PROEFSCHRIFT 
Ter verkrijging van de graad van doctor 
aan de Erasmus Universiteit Rotterdam 
op gezag van de Rector Magnificus 
Prof.dr P.W.c. Akkermans M.A. 
en volgens beslui.t van het College voor Promoties 
De openbare verdediging zal plaatsvinden op 
woensdag 24 juni 1998 om 11.45 uur 
door 
Martijn Stevens 
Geboren te Meppel 
Promotiecommissie: 
Promotoren: 
Co-promotor: 
Overige leden: 
Prof.dr F.G.A. van der Meché 
Prof.dr M.F. Niermeijer 
Dr J.C. van Swieten 
Prof.dr R.A.C. Roos 
Prof.dr P.J. Koudstaal 
Prof. dr B. A. Oostra 
The work presented in this thesis was made possible by grants of the 
Netherlands Organization for Scientific Research (NWO project no. 95-
10-620), and the JANIVO Foundation. 
This study was carried out at the Department of Neurology, Erasmus 
University Rotterdam and University Hospital Rotterdam, The 
Netherlands (Prof.dr F.G.A. van der Meché), and at the Department of 
Clinical Genetics, Erasmus University Rotterdam and University Hospital 
Rotterdam, The Netherlands (Prof.dr H. Galjaard). 
Financial support for the publication of this thesi.s by 'Stichting Fronto-
Temporale Dementie', 'Stichting Alzheimer Fonds Bunnik', 'Stichting 
Remmer! Adriaan Laan Fonds', 'Novartis' and 'UCB Pharma' is 
gratefully acknowledged. 

CONTENTS 
Chapter 1 General introduction: 11 
review and objectives of the study 
1. 1 Historical review of Piek' s disease 
1.2 Epidemiology 
1. 3 Familial occurrence 
1.4 Clinical heterogeneity in fronto-temporal dementia 
1.5 Neuroimaging 
1.6 Genetic studies 
1. 7 Molecular pathology 
1. 8 Psychological and ethical issues 
1.9 Objectives of the present study 
1.10 Appendix 
Chapter 2 Familial forms of Fronto-Temporal Dementia 29 
Published in: Ned Tijdschr Geneeskd 1995;139:871-875. 
Chapter 3 Familial aggregation in 45 
Fronto-Temporal Dementia 
N eurology. in press. 
Chapter 4 Apolipoprotein E gene and 61 
sporadic Fronto-Temporal Dementia* 
Published in: Neurology 1997:48:1526-1529. 
Chapter 5 Hereditary Fronto-Temporal Dementia 73 
is Iinked to chromosome 17q21-q22; 
a genetic and clinico-pathological study 
of three Dutch families 
Published in: Ann NeuroI1997;41:150-159. 
Chapter 6 Clinical heterogeneity in 99 
Fronto-Temporal Dementia 
linked to chromosome 17 
Submitted for publication. 
6 
Chapter 7 Once revealed, no more to be concealed: 115 
pitfans in genetic research 
on neurodegenerative disease: 
the (:ase of Fronto-Temporal Dementia 
Subrnitted for publication. 
Chapter 8 Preparing for presymptomatic DNA testing 135 
for l!arly onset Alzheimer's disease! 
cerelOral haemorrhage and Hereditary 
Fronto-Temporal Dementia* 
Published in: J Med Genet 1997;34:63-72. 
Chapter 9 Gen.eral discussion 161 
9.1 Introduction 
9.2 Methodological considerations 
9.3 Genetic-epidemiological data 
9.4 Apo E4 genotype in FTD 
9.5 Psychosocial and ethical aspects of genetic 
family studies on neurodegenerative disease 
9.6 Attitudes towards future presymptomatic testing 
9.7 Future studies 
Chapter 10 Summary 171 
10.1 Summa!')' 
10.2 Samenvatting 
Dankwoord 185 
Curriculum vitae 189 
List of publications 190 
* For reason of uniformity, the term 'hereditary Piek disease' (chapter 8) 
and 'frontal lobe dementia' (chapter 4) in earlier, published, papers has 
been consistently changed into 'fronto-temporal dementia' (FTD), as used 
in the later papers. Accordingly the terminology in chapter 2-10 is 
uniform. 
7 
8 
The main results in this thesis are reported in the following papers: 
Familiaire vormen van frontotemporale dementie. 
Stevens M, Van Swieten JC, Van Duijn CM, Tibben A, Niermeijer MF. 
Nederlands Tijdschrift voor Geneeskunde 1995;139:871-875. 
Preparing for presymptomatic DNA-testing for early onset Alzheimer 
disease / Cerebral Haemorrhage and Hereditary Pick Disease. 
Tibben A, Stevens M, De Wert GMWR, Niermeijer MF, Van Duijn CM, 
Van Swieten JC. 
Joumal of Medical Genetics 1997 ;34:63-72. 
Apolipoprotein E gene and sporadic frontal lobe dementia. 
Stevens M, Van Duijn CM, De Knijff P, Van Broeckhoven C, Heutink P, 
Oostra BA, Niermeijer MF, Van Swieten JC. 
Neurology 1997;48:1526-1529. 
Hereditary frontotemporal dementia is linked to chromosome 17q21-q22: 
a genetic and clinico-pathological study of three Dutch families. 
Heutink p', Stevens M', Rizzu P, Bakker E, Kras JM, Tibben A, 
Niermeijer MF, Van Duijn CM, Oostra BA, Van Swieten JC (bath 
authors contributed equally to this study). 
Annals of Neurology 1997;41: 150-159. 
Familial aggregation in fronto-temporal dementia. 
Stevens M, Van Duijn CM, Kamphorst W, De Knijff P, Heutink P, Van 
GooI WA, Scheltens Ph, Ravid R, Oostra BA, Niermeijer MF, Van 
Swieten JC. 
Neurology 1998, in press. 
Clinical heterogeneity in fronto-temporal dementia linked to chromosome 
17. 
Stevens M, Kamphorst W, Kros JM, Van Duijn CM, Heutink P, Ravid 
R, Kuyt LP, Tibben A, Oostra BA, Niermeijer MF, Van Swieten Je. 
Submitted for publication 
Once revealed, no more to be concealed: pitfalls in genetic research on 
neurodegenerative disease: the case of fronto-temporal dementia. 
Stevens M, De Wert GMWR, Niermeijer MF, Van Swieten JC, Tibben 
A. 
Submitted for publication 
9 

Chapter 1 
General introduction: 
review and objectives of the study 
Chapte/" 1 
GENERAL INTRODUCTION 
1.1 HISTORICAL REVIEW OF PICK'S DISEASE 
At the turn of the nineteenth century into the 20th century many 
leading neurologists were active to devise new pathological or clinical 
classifications of the large group of dementing illnesses in later life, the 
'dementia senilis' . Until then that eponym included every psychiatrie, 
behavioral and cognitive disturbance, occurring after middle age and 
leading to complete deterioration of the mental functions. 
In 1892, Arnold Piek (1851-1924), professor in neurology and 
psychiatry at the German University of Prague, reported a patient with a 
two-year history of progressive 'feeble-mindedness' , behavioral 
disturbances and eventually aphasia. 1 Focal temporal atrophy of the brain 
was found at autopsy. Piek subsequently described a few more cases with 
frontal and temporal atrophy and considered this focal pathology as a 
localized type of 'seniIe dementia' and not a distinct disease-entity.2 
However he suggested a possible clinical-pathological relation without 
being specific. 
Alois Alzheimer (1911) described the microscopical findings to 
become associated with 'Piek's disease": neuronalloss, spongiosis and 
gliosis in the frontal and temporal cortex, argentophilic granules in the 
neuronal cytoplasm pushing the nucleus towards the cell body (Pick 
bodies), and swollen neurons (Piek cells) in the absence of neurofibrillary 
tangles and plaques. 
Van Mansvelt (1953), in a review, classified Pick's disease according 
to the localization of atrophy into three types: frontal, temporal and 
mixed' Piek bodies were reported in only one third of the cases. For a 
diagnosis of Piek' s disease at that time, Piek bodies were not essential. 
Constantinidis (1974) classified frontotemporal atrophy into three types 
based on the presence of Piek bodies and Piek cells: (1) cases with: Piek 
bodies and swollen neurons, (2) cases with only swollen neurons, and (3) 
cases without Pick bodies and Piek cells.' 
Fronto-temporal dementia in the absence of Piek bodies became also 
described by Brun as 'frontal lobe degeneration of non-Alzheimer type'. 6 
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Neary reported 15 cases with 'dementia of frontal lobe type'.' Recently, 
the Manchester and Lund groups introduced the term 'fronto-temporal 
dementia' (FTD) to include new entities as 'dementia of non-Alzheimer 
type', 'dementia lacking distinctive histologie features' and 'dementia of 
frontal lobe type', whereas the diagnosis Piek's disease is set aside for 
fronto-temporal dementia with Pick bodies 8,' 
1.2 EPIDEMIOLOGY 
Since the recent nature of the definition of FTD, including Pick's 
disease, and continuing use of old classifications of early onset dementias, 
accurate figures on pn~valence and incidence of FTD and Pick's disease 
are not available. Moreover, the few clinical and post-mortem studies on 
FTD often give no data on the proportional occurrence of this condition 
within the total group of demented patients, Heterogeneous case-finding 
and diagnostie methodologies do not allow any reliable epidemiological 
figures before the second half of this century, and in recent years only 
estimates are possible (see chapter 3 of this thesis). Pick's disease, as 
defined by Tissot including Pick bodies, was found in a post-mortem 
study in a ratio of 1 : 10 to Alzheimer's disease, JO In a Swedish pathology 
department series 20 cases with FTD (= 12 %) in 158 cases with organic 
dementia were seen between 1967-1987, and four cases of Pick's disease 
were diagnosed 6 FTD was found in 3 % of an autopsy series (n =460) 
with dementia, and in 10% of cases younger than 70 years.' Another such 
series (n = 345) gave a figure of 9 % for FTD without Pick bodies and 1 % 
for Piek's disease,ll In other studies Piek's disease has also been 
diagnosed in a minority of FTD cases.'·12 
1.3 FAMILlAL OCCURRENCE 
Piek's disease in a 56-year-old woman with psychosis, behavioral 
changes and mutism, having a mother dying of dementia at 50 years 
prompted Gans (1923) to propose a genetic connection, similar as he had 
found in a reported family with dementia in a grandfather , father and two 
13 
Chapter 1 
cousins. 13•14 Dementia wilh a long prodromal hiswry of personality and 
behavioral changes in multiple cases in one or multiple generations 
became reported between 1930-1940. 15.19 
Sanders and Schenk reported an autosomal dominant transmission in a 
family of 4 generations with 17 affected persons; the diagnosis was 
confirmed by neuropathological study in 4 cases. 20,21 
A significant difference in age of onset of dementia in two families 
and a tendency toward an earlier age of onset in successive generations 
was also observed.22 
A family history positive for dementia has been reported in 
19-60% in recent studies (see also chapter 3 of this thesis).14,23." 
However, the relationship with the index case in the family was not 
always specified. Possibly related non-Alzheimer dementias transmitted in 
families became also reported. 26,27 
1.4 CLINICAL HETEROGENEITY IN FRONTO-TEMPORAL 
DEMENTIA 
(usually sporadic or genetic status undetermined) 
The age of onset of FTD is usually between 40 and 60 years, with a 
peak around SS years.4,7,23,28,29 Occasionally an earlier « 30 years) or 
later onset (> 70 years) were observed 4 . 15,29.30 The mean duration of 
illness varied between S and 10 years in large pathologieally verified 
series 7,9,1l.22,23,28 Women seemed more of ten affeeted than men in older 
reports, whereas the ratio is about 1 : 1 in recent series 4 .7,10,23 
FTD can be clinicaily differentiated from Alzheimer's disease 
(AD) 7,28.31 A structured questionnaire using clinieal information has 
shown distinct profiles for FTD and AD 32 Changes in behavior, 
especially disinhibition, roaming and hyperorality are significantly more 
frequent in FTD than AD, whereas early amnesia is consistent with AD. 
Speech changes mayalso differentiate FTD from AD 28,33,,, 
Loss of initiative, disinhibition, and stereotypie and perseverative 
behavior are prominent early features in FTD. Loss of insight, lack of 
judgement and of emotional concern develop invariably. Some clinical 
symptoms may predominate, like an apathetic , a disinhibited or a 
14 
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stereotypic form. 31 Social withdrawal is a prominent feature in some 
patients. 29 Changes in eating habits (preference for sweets) and 
considerable weight gain are frequent (60_80%).'·23.29.35 
Speech production becomes gradually reduced in all patients. Some 
experience word-finding problems. 29•36 Stereotypie phrases and echolalia 
frequently occur before mutism eventually develops.'·3o 
Early psychiatric symptoms like psychotic episodes, delusions and 
hallucinations were observed in one series (6/20) of FTD23, but not in 
others.'·28 
NeuropsychologicaJ testing shows distractibility and impaired 
attention. Orientation in time and place, and memory for recent events 
remain intact, although formal memory testing is frequently impaired. 
Impulsivity, impersiswnce, loss of abstract thinking, reduced verbal 
fluency, perseveration and difficulties in set shifting (for example in the 
Wisconsin Card Sorting test) are characteristic features in FTD. 
Comprehension is usually intact.'·29 Selective language deficits and word 
retrieval problems are incidentally found. 37 Visuospatial functions 
generally remain intact. 
These features are included in the consensus statement of criteria for 
FTD proposed by the Manchester and Lund groups (Appendix). 8 
1.5 NEUROIMAGING 
An enlarged Sylvian fissure in a patient with progressive language 
deficits and behaviora.l changes was the first reported CT anomaly 
(1982)'8 Subsequent (3 years) neuropathology showed frontal and 
temporal degeneration with Pick bodies. The CT pattern of frontal and 
temporal atrophy became confirmed in other pathologieally confirmed 
cases of Pick's disease and clinical series of FTD.'·28.29.36.39 However, the 
CT scan may be normal, especially in the initial phase of the disease. 28 
A frontotemporal or anterior hypoperfusion on SPECT, found in 
clinical series of FTD, correlated strongly with the pathologieal 
diagnosis.'·29.33.40.41 An asymmetric pattern of perfusion has been reported 
in some cases. 42 A decreased glucose metabolism on PET scan was 
reported in cases with a neuropathologieal diagnosis of Pick's disease 43.44 
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1.6 GENETIC STUDIES 
A search for a possible prion mutation as cause for hereditary FTD 
was negative. 45 •46 
The first attempt of gene Iocalization (Wilhelmsen) demonstrated 
linkage to chromosome 17 in a family with autosomal dominant 
inheritance of disinhibition-dementia-parkinsonisrn-amyotrophy complex, 
characterized by initial behavioral changes followed by cognitive decline 
and parkinsonism. 39•47 The locus was mapped 10 a 12 cM region on 
17q2I-22. Subsequently, progressive subcortical gliosis (2 families) and 
autosomal dominant parkinsonism and dementia with pallido-ponto-nigral 
degeneration (one family) were mapped to this region (Tabie 1).48.49 These 
conditions show clinical and pathological similarities with respect to the 
age of onset, presenting and subsequent symptoms and most affected brain 
regions, but there are also differences as discussed in chapter 8.39.50.51 In 
1997 an international conference proposed 'fronto-temporal dementia and 
parkinsonism linked to chromosome 17' (FTD-17) as the new term 
including all such families with evidence for linkage to a 2 cM region on 
17q2I-q22 (Tabie 1).52 
An early study on the distribution of apolipoprotein E genotypes in 
FTD cases, established as a risk factor in Alzheimer's disease, showed no 
association of a specific Apo E allele with FTD.53•54•55 However, our 
studies suggested an association of ApoE4 with FTD, most pronounced in 
the cases with a negative family history for dementia.25•56 
1.7 MOLECULAR PATHOLOGY 
Until now neither electron-microscopical nor biochemical analyses 
have given a clue on a possible disease mechanism in FTD. The recently 
introduced designation of tauopathy for one form of familial FTD-17 does 
suggest such a mechanism and seems attractive by the localization of a 
gene involved in tau synthesis in the chromosomal region of interest."·59 
How attractive this hypothesis might be, it is still too early to explain any 
possible molecular pathology. Recently a possiblt' classification based on 
different types of tau pathology was described. Immunoblotting of tau 
protein extracted from filaments shows variabie bands, enabling 
differentiation of some types of FTD-17 and Alzheimer's disease. 58 
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Table 1. 
Clinical and pathological characteristics of families with fronto-temporal 
dementia and parkinsonism linked to chromosome 17." 
Characteristics Original nomenclature 
DDPAC PPND FM$T PDP HFTD Duke HDD AusF 
Number of cases! 
total relatives 13/33 35/303 41/383 18/60 113/475 16/41 21/475 26/172 
Mean age of onsel (yr} 45 43 49 53 46·63 55 62 53 
Mean duration (yr) 13 8.6 10 13 8.2·8.7 9.2 8 9 
Clinical symptomatology 
dementia + + + + + + + + 
franIaI symptoms + + run + + + + + 
disinhibition + nrn run + + + + + 
loss of initiative nm + run + + + run + 
parkinsonism + + + + + + + 
Distribution of degeneration 
frcntal cortex + + + + + + + + 
temporal cortex + + + + + + + + 
basal ganglia + + + + + + + + 
substamia nigra + + + + + + + + 
Microscopie neuropathology 
neuronalloss + + + + + + + + 
gliosis + T + + + + + + 
spongiosis + + + + run + + 
ballooned cells + + + nm + run + 
Ag and/or 'f + inclusions* + + + + 
white matter gliosis + + + nm + run nOl 
DDPAC41.50 = disinhibition*demcntia-parkinsonism-amyotrophy complex 
PPND49.s, = aUlosomal dominant parkinsonism and demcmÎa with pallido-ponto-nigral 
degeneration 
FMSTs~.~ = Familial multiple system tauopathy with preseniIe dementia 
PDpw·61 = Familial presenile dementia with psychosis and neurofibrillary tang les 
HFfD61 .6J = hereditary Fronto-temporaldementia (three Dutch families) 
Duk:eM = Frontotemporaldementia (Duke university family) 
HDD6S•66 = hered itary dysphasic dementia 
Ausf67 = autosomal dominant non-Alzheimer dementia (Australian family) 
+ = present; - = absent; run = not mentioned 
• = argyrophilicand/or tau positivc neuronal inclusionsH 
17 
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1.8 PSYCHOLOGICAL AND ETHICAL ISSUES 
An increasing nurnber of late-onset neurodegenerative diseases 
became defined at the molecular level in the last decade, enabling 
improved diagnosis and presymptomatic testing. Examples are 
Huntington's disease, hereditary cerebral haemorrhage with amyloid 
(Dutch type) and some types of familial, early onset Alzheimer's 
disease. 68 Although gene localization and identification of mutations in a 
gene may lead to fundamental insight into the functions of this gene, 
participation in pedigree and linkage studies is a potential burden to 
patients and family members spanning several generations . Follow-up 
studies in families with Alzheimer's disease or Huntington's disease 
showed a variety of psychosocial, legal and ethical problems and 
dilenunas in individuals at risk. 69." Psychosocial effects of predictive 
DNA-testing have been extensively studied in Huntington's disease, and 
guidelines for predictive testing have been formulated n However, these 
guidelines did not address the effects of family studies for establishing 
!inkage and gene identification, which is usually the first confrontation of 
a family with their genetic problem. Some individuals become aware of 
the genetic risk for a still incurabie disease and only a possible 
expectation for a future predictive testing program. 69•7l •76 
l.9 OBJECTIVES OF THE PRESENT STUDY 
The first question addressed in this study was the estimation of 
familial aggregation in fronto-temporal dementia in the Netherlands . 
A review and analysis of part of our family study on FTD were 
presented to the Dutch medical specialists (chapter 2). This facilitated a 
nation-wide inventory (updated during more than 3 years) for FTD cases. 
All patients with the clinical diagnosis FTD and with an age of onset 
before the age of 65 years were included in a genetic-epidemiological 
study, and the occurrence of dementia in first degree relatives was studied 
(chapter 3). This study will also provide prevalence data on FTD in the 
Netheriands (population 15 millions), as ascertainment was as complete as 
possible. 
18 
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A possible association with Apo E alleles in FTD, as were found as 
risk factors for Alzheimer's disease, was analyzed in our series (chapter 
4). 
Gene localization of hereditary FTD by linkage studies in the Dutch 
material was possible by the extent of the families and their participation. 
The linkage to chromosome 17q21-q22 allowed comparison with other 
neurodegenerative disorders in the same region (chapter 5). 
Clinical data on the manifestations of FTD in the three Dutch families 
with linkage to chromosome 17 allowed analysis of inter and intrafamilial 
differences of the disease phenotype and possible indications for allel ic 
genetic heterogeneity (chapter 6). 
Special emphasis was given to the potential psychosocial effects of 
participation in a genetic family study, like in this study. The 
psychosocial impact and medical-ethical dilemrnas of a family study were 
also considered to assess the acceptability of future predictive testing 
(chapter 7 and 8). 
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APPENDIX 
Consensus staterneut ou clinical criteria for fronto-temporal dementia 
by the Manchester and Lood groups (1994).8 
1. Core diagnostic features: 
20 
Behavioral disorder 
insidious onsel and slow progression 
early loss of personal awareness (neglec!: of personal hygiene and 
grooming) 
early loss of social awareness (Iack of social lact, misdemeanors 
such as shoplifting) 
early signs of disinhibition (such as unrestrained sexuality, violent 
behavior, inappropriate jocularity, restIess pacing) 
mental rigidity and inflexibility 
hyperorality (oral/dietary changes, oyereating, food fads, excessive 
smoking and alcohol consumption, oral exploration of objects) 
stereotyped and perseverative behavior (wandering, mannerisms 
such as clapping, singing, dancing, ritualistic preoccupation such as 
hoarding, toileting, and dressing) 
utilization behavior (unrestrained exploration of objects in the 
environment) 
distractibility, impulsivity, and impersistence 
early loss of insight into the fact that the altered condition is due to 
a pathological change of own mental state 
Affective symptoms 
depression, anxiety, excessive sentimentality, suicidal and fixed 
ideation, delusion (early and eyanescent) 
hypochondriasis, bizarre somatic preoccupation (early and 
eyanescent) 
emotional unconcern (emotional indifference and remoteness, lack 
of empathy and sympathy, apathy) 
arnimia (inertia, aspontaneity) 
General introduction 
Speech disorder 
progressive reduction of speech (aspontaneity and economy of 
utterance) 
stereotypy of speech (repetition of limited repertoire of words, 
phrases, or themes) 
echolalia and perseveration 
late mutism 
Spatial orientation and praxis preserved 
intact abilities to negotiate the environment 
Physical signs 
early primitive reflexes 
early incontinence 
late akinesia, rigidity. tremor 
low and labile blood pressure 
Investigations 
normal EEG despite clinically evident dementia 
brain imaging (structural or functional, or both): predominant 
frontal or anterior temporal abnormality, or both 
neuropsychology (profound failure on 'frontal lobe' tests in the 
absence of severe arnnesia, aphasia, or perceptual spatial disorder) 
2. Supportive diagnostic features 
onset befon: 65 
positive family history of similar disorder in a first degree relative 
bulbar palsy, muscular weakness and wasting, fasciculations (motor 
neuron disease) 
21 
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FAMILIAL FORMS OF FRONTO·TEMPORAL DEMENTIA 
INTRODUCTION 
The tenn fronto·temporal dementia (FTD) has been recently 
introduced for a primary degenerative neuronal disorder of the frontal and 
temporal cortex. I'" Frontal lobe dementia (FLD) is the most frequently 
occurring type of FTD.' Clinical features in frontal lobe dementia, usually 
presented at preseniIe age (between 40 and 65 years) are predominantly 
characterized by changes in personality and behavior, especially in neglect 
of social and domestic responsibilities, socially disinhibited behavior, 
excessive eating and drinking, restlessness or apathy, roaming behavior, 
and stereotyped behavior. 1.2.4.6 Eventually, af ter a duration of 5·8 years, a 
state of apathy with incontinence, bradykinesia, rigidity and mutism will 
develop.5 Frontal lobe dementia can be distinguished from Alzheimer's 
disease by the absence of early memory disturbances, and can be 
distinguished from Huntington's disease by the absence of involuntary 
movements. Vascular dementia is almost always accompanied by focal 
neurological abnormalities. 
A second, less frequently occurring, fonn of FTD is frontal lobe 
dementia in association with clinical features of motor neuron disease 
(FLD + MND). A third form is progressive aphasia with behavioral 
changes. 
These three clinical variants of FTD have a similar pathological 
substrateY·8 Macroscopically, lobar atrophy of frontal and often temporal 
cortex is present, while at microscopical examination aspecific changes 
(neuronalloss, gliosis and spongiosis) are found in the cortex and some 
subcortical areas 3.5 SeniIe plaques and neurotlbrillary degeneration, 
characteristic for Alzheimer's disease, are absent. 
In this paper we discuss familial occurrence, diagnostic criteria, 
including imaging techniques, and progress in genetic molecular research 
concerning FTD. 
30 
Familial forms of Fronto-Temporal Dementia 
EPIDEMIOLOGY AND GENETICS 
The preva!ence of FTD, the number of patients with this disorder 
within the popu!ation, and the incidence, the number of new cases per 
100,000 persons per annum, are not known. The ratio of FTD compared 
to A!zheimer's disease ranges from 1:10, within the group of patients 
with preseniIe dementia, to 1: 30 within the tota! group of demented 
patients.3.9 A cause for the disorder has not yet been discovered. No 
environmenta! factors associated with FTD are known. Apart from a 
sporadic occurring type of FTD, a familia! type with an autosomal 
dominant pattern of inheritance is known. 1O A Dutch and a Swedish 
family with a dominant type of inheritance have been described 
earlier. Il •12 In the Dutch family clinical features, noted in 25 family 
members in 3 consecutive generations, were presented between the fourth 
and fifth decade. II Results in research concerning the ratio between the 
sporadic and the fam:i\ial type are rather contradictory. Until recently 
familial occurrence was generally estimated to be 20 % . 10 However, in 
recent reports in a fraction of 40-50 % of FTD patients. first degree 
relatives with dementia were found.1.2·13 However all the reports present 
series with less than 20 patients and the pattern of inheritance is not 
mentioned. For further clarification we present a case report from a not 
earl ier published family with the hereditary type of FTD. 
CASE REPORT 
During the three years before diagnosis was made, a 57 year old 
woman developed slowly progressive behavioral changes. Previously 
punctual and tactful, she made increasingly more socially inappropriate 
remarks and used abusive language in public. The patient showed lack of 
initiative and apathy, she neglected her domestic responsibilities and 
spontaneous speech gradually occurred less often. She appeared only to be 
interested in watching television. She was unaware of her ill-health. 
Eating and drinking ha.bits became disinhibited and she exhibited a bland 
affect. The father of the patient had previously developed identical 
features and died aged 65. Confirmation of the diagnosis of frontal lobe 
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dementia with similar features was also established by pathologieal 
examination in an aunt and two uncles. Substantial neuronalloss was 
found in the frontal and temporal cortex with some inflated cells 
('ballooned' cells), but without Pick inclusion bodies . 
During neurologieal examination orientation in time and place, 
memory, and visual-spatial functions were intact. 
Neuropsychologieal studies revealed severe deficiencies in tasks testing 
planning, organizing abilities and executive functions like category 
restricted naming, sequencing pietures, and Wisconsin Card Sorting test. 
No word finding difficulties were present. The patient displayed 
perseveration and echolalia. Proverbs were explained literally, but not 
figuratively. In complex drawings all the elements were named, but 
relationships between these elements were not understood. The electro-
encephalogram (EEG) showed no abnormalities. Single Photon Emission 
Computed Tomography (SPECT) showed severe hypoperfusion in the 
frontal cortex and mild hypoperfusion in parietal and temporal cortex 
(Figure 1). In MRI studies, transversal T2 wf,ighed Spin-Echo, and 
transversal and corona! 'Invers ion Recovery' scans showed marked 
atrophy of frontal cortex and caudate nucleus with slight dilated ventricles 
(Figure 2). 
The fact that this patient had the disease had a strong impact on other 
relatives, particularly a son and a brother of the patient. The son had been 
aware that the disease ran in his mother's family since he was an 
adolescent. Before starting a relationship he decided to undergo 
sterilization. Since quite some time the patient's spouse had suspected his 
wife's disease to be identical to the one from which her father had died, 
and he was thus worried about the consequences for his children from that 
moment on. When his wife was diagnosed as having FTD, the risk for his 
children of developing the disease was estimated to be 50 %. The son 
assumed that he would develop the disease, but had already decided to 
refrain from using possible presymptomatic testing in future. He had 
arranged with his wife if he should become 'unmanageable' she would 
admit him into a nursing home. The brother of the patient had become 
increasingly anxious afier his sister was diagnosed, even though he had 
been aware of hereditary dementia running in the family for more than 
twenty years. 
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Figure 1. 
Severe perfusion deficit of ""'Tc-hexamethylpropyleenamine-oxime (HMPAO) in 
the fronta! lobes (upper position in the figure) and in less extent in the parieta! 
lobes on a 'single-photon emission computed tomography' (SPECT)-scan in 
patient A. 
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Figure 2. 
Marked atrophy of the frontal gyri (upper position of tbe figure) on a T2-weighed 
spinresonance-tomograrn (spin-echorelaxation time (TRSE): 2222ms; echotime 
(TE): 30ms) in patient A, witb local hyperimensity in the subcortical and 
periventricular white matter. 
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His expectation was that he should eventually develop the disease as weil. 
He had two adult daughters and a son and had since undergone 
sterilization. In these children we observed, because of a 25 % risk for 
developing frontal lobe dementia, a retarded individual personality 
development. The daughters, in their twenties, did not want to start a 
steady relationship. One daughter has already considered sterilization. The 
son was eager to get a job as soon as possible and wanted to waste no 
time in studying. Reaching the possible age at which the disease could 
begin to develop, the brother of the patient was increasingly pre-occupied 
with possible symptoms, especially forgetfulness, although this is not an 
initial characteristic in FTD. His wife was constantly watching for 
possible changes in her husband's conduct (symptom-search). Although 
the threat of the disease was experienced by every family member, there 
was no communication between them over this topic. The patient's 
brother was hoping that presymptomatic testing would be possible in the 
future. He would participate in such testing if his children wanted 
counselling concerning their risk of developing the disease. He was 
particularly concerned about his oldest son. In previous years, spanning 
several generations, intrafamilial relations had been dramatically disturbed 
because of the disease of the patient's father. Interviewing risk-carriers 
from various branches of the family often revealed the reproach that 
closely related family members of a patient were let down by other 
relatives during the course of the disease. Our request for participation in 
a research project investigating the cause of the disease evoked very 
emotional responses in some family members. The sudden confrontation 
with frontal lobe dementia broke through the psychological blockade 
(predominantly consisting of denial and avoidance behavior) which was 
used as a shield against the threat of the disease. 
DISCUSSION 
Frontal lobe dementia 
The described patient is related to a large family with frontal lobe 
dementia. Data on history given by healthy family members reveal the 
occurrence of dementia in 28 fan1ily members in 5 successive generations. 
35 
Chapter 2 
Retrospectively, diagnosis of probable frontal lobe dementia was made on 
the basis of contemporary clinical criteria in 18 out of 28 demented family 
members. The diagnosis was confirmed pathologically in 10 family 
members. Clinical features, the age at which initial symptorns appeared, 
and the duration of the disease are remarkably similar in the affected 
family members. Apart from behavioral changes, decreased spontaneous 
speech, stereotypical remarks and verbal perseveration are the most 
characterizing features. 2,10, I' 
In a later phase of the disease imaging studies of the brain often 
support the clinical diagnosis , The CT-scan shows atrophy of the frontal 
lobe, and in some patients atrophy of the anterior pole of the temporal 
lobe and atrophy of the caudate nucleus is demonstrated,3,15,16 In SPECT 
imaging decreased uptake of the radioactive phannacon is noticed in the 
mentioned cortical areas, even before atrophy on CT is detected.2 Both 
atrophy and hypoperfusion can be asymmetric, Pathological abnormalities 
are most prominent in the frontal cortex, whereas the severity in 
degeneration of temporal cortex and subcortical structures is variable"",17 
The diagnosis Pick's disease is appropriate if Pick inclusions (round 
intraneuronal argentophilic structures) and ballooned neurons are present 
in the cortex. Pick's disease, which is the most known type of frontal lobe 
dementia, is however only responsible for a small part (about 20%) of the 
total group of patients with frontal lobe dementia, and is clinically not 
differentiabie from frontal lobe dementia without Pick inclusions 10 
Frontal lobe dementia with motor neuron disease 
Dementia of the frontal type is in some cases accompanied by features 
of motor neuron disease (FLD + MND),18,19 Patients with this combined 
disorder develop slurred speech, difficulties in swallowing and muscular 
weakness in the upper limbs within from a few months up to even more 
than one year after the start of the behavioral changes, In contrast with 
amyotrophic lateral sclerosis, motor features in FTD+MND (dysarthria, 
muscular weakness, fasciculations) are often limited to the tongue and 
upper extremities, 20 Brisk tendon reflexes and extensor plantar responses 
can be found in few patients, Generally Ihis disorder is fatal within a few 
years, Electromyographic investigations reveal loss of anterior hom cells 
(fasciculations, fibrillations, giant potentiais), 
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As in frontal lobe dementia, in FLO + MNO EEG is normal and changes 
in CT, MRI and SPEeT are identical as described above,I9 A familial 
type of FLO + MNO with an autosomal dominant pattern of inheritance 
has been described 20 Apart from abnormalities in the frontal cortex, 
nucleus hypoglossus and anterior hom cells in the cervical and thoracal 
region are degenerated,IJ,I9,20 
Progressive aphasia 
Progressiveaphasia is a slowly developing disorder with wordfinding 
difficulties, gradually decreased speech and finally mutism,21,22 In some 
patients stereotyped and/or disinhibited behavior develops, often a few 
years but sometimes several years after onset of the aphasia, CT scanning 
shows uni- or bilateral atrophy of the anterior part of the temporal lobe, 
accompanied by widening of fissura cerebri lateralis (Sylvii), whereas the 
frontal lobe is less severely affected,16,2I,23,24 Within one family this 
disorder can develop in slightly different ways, Two brothers are 
described both developing progressive aphasia at the age of 60; in one 
brother the clinical picture with alternating apathy and aggressive conduct 
was present within a few months, whereas in the other brother the same 
features developed only after 7 years, 25 In progressive aphasia 
pathologieal studies reveal the same changes as in FTO, however these 
are most prominently present in the tempora! lobes,16,2I,23,24 Although 
aphasia in Alzheimer's disease is usually aceompanied by memory 
disturbances, this entity ean only be excluded by pathological 
examination, 
Coherence between different types of fronto-temporal dementia 
Up until now it is unclear whether the different variants of fronto-
temporal dementia are distinct in regard to etiology, They are all 
designated, in neutral terminology, as 'lobar atrophies' , 8 The different 
clinical entities show a partial overlap in symptomatology, pathological 
abnormalities and familial occurrence, The three types are pathologically 
distinguishable by their variabie severity and localization of abnormalities 
in the frontal and temporal cortex, and the involvement of subcortical 
structures, such as corpus striatum, amygdala and hippocampus.' 
Moreover, in both clinical and pathological respect FTO has much in 
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common with other closely related syndromes, such as hereditary 
dysphasic dementia and aphasic dementia with motor neuron disease.26•27 
Etiology 
As far as etiology is concerned the different types of fronto-temporal 
dementia are possibly one disease expressed in different ways. It should 
not be ruled out that clinical heterogeneity may be caused by variability in 
one gene defect or by the presence of several gene defects at the same 
chromosomal locus or even different loci. 
Fronto-temporal dementia as a familial disease 
The presence of a hereditary disease, already known to family 
members for several generations, often causes uncertainty and anxiety. 
Family life is overshadowed by the continuous threat of an untreatable 
atrocious disease. We often observe preoccupation with early symptoms 
and symptom-search in apatients' children and Other family members at 
risk to be characteristic features, but also denial. and avoidance of the 
confrontation with the disease (' as long as nobody talks about the disease 
it does not exist'). Symptom-search in families with fronto-temporal 
dementia particularly involves behavioral changes like loss of decorum, 
disinhibition, roaming, and neglect of social activities and personal 
hygiene. The phenomenon 'preselection' , the 'prophesy' by the family 
members themselves who wil! and who wil! not develop the disease, 
which was earl ier observed in families with Huntington's disease, was 
also seen in families with hereditary FTD." Similarities in personality and 
physical features with the affected relative are mistakenly connected with 
preselection and symptom-search. These psychological mechanisms can be 
regarded as defensive reactions, aimed at the anxiety for the future; thus 
anxiety is allayed and manageable. These mechanisms can be seen as a 
kind of 'mental rehearsal': one gradually gets familiar with the 'worst 
case' scenario concerning this threatening and frightening disease. 
Genetic research can have significant impact on the intrafamilial 
relations.29•30 This can often be traced back to the effects that the disease 
had on intrafamilial relations in the past. Conflict may lead to several 
family members refraining from the essential approval in participation in 
DNA linkage research. The request for participation can evoke feelings of 
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guilt and shame. If latent family conflict is encountered during medical 
interference, psychological support should of course be offered. If 
presymptomatic testing should be available in the future, it will have far-
reaching consequences for the rest of the lives, including family planning, 
of the family members availing themselves of it 31 
Molecular-genetic research 
Up until now no gene defect has been found to be responsible for the 
hereditary type of fronto-temporal dementia. Research is hampered 
because only few families with the hereditary type, with sufficient still-
living family members (or availability of tissues from deceased affected 
family members) have been identified. It is not excluded that, similar to 
Alzheimer's disease, fronto-temporal dementia is clinically heterogeneous. 
Recent molecular biological investigations have already traced gene 
defects, which cause other hereditary brain diseases with an onset in later 
life, sueh as eerebral amyloidosis, Alzheimer's disease, Creutzfeldt-Jakob 
disease and Huntington's disease. Apparently, the familial form of fronto-
temporal dementia is not linked to genes involved in the afore mentioned 
eerebral disorders. 32,33 As far as the amyloid-preeursor-protein (APP)-gene 
is eoneerned this was not to be expeeted, beeause in FTD no or very few 
senile plaques or amyloid deposits in the blood vessel walls are 
encountered, Patients with familial FTD do not have a mutation in the 
prionprotein (PrP)-gene, as deseribed in spongiform eneephalopathies 
whieh bears some resemblanee both clinically and pathologically to 
FTD,34,35 Thus, FTD ean not be regarded as a variant of spongiform 
encephalopathy or Alzheimer's disease. Very recently astrong indication 
for linkage with chromosome 17q21-23 (maximum LOD-score = 3.28 for 
marker GP3A, and recombination fraction (8)=0) was found in the 
mentioned disinhibition-dementia-parkinsonism-amyotrophy complex, 
which also closely resembles FTD clinically and pathologically, 36 For the 
time being it is not clear if linkage to this chromosome is present in 
families with FTD (and if so, in how many families). 
Research 
FTD is an important cause of presenile dementia, but as yet no 
treatment is available. Recently in Rotterdam research involving fronto-
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temporal dementia, subsidized by the Dutch Organization for Scientific 
Research (NWO), has been started. This research i.s aiming at answering 
questions like the prevalence of FTD in the population, and the ratio of 
the familial and sporadic form. In addition, molecular-genetic techniques 
will be used to try to find the gene defect responsib!e for the hereditary 
form. In such a research participation of patients and their relatives is 
necessary, as weil as corporation between several clinicians, geneticists 
and pathologists. If there is an indication for hereditary transmission of 
FTD in a family, this family will be requested to participate in this 
molecular-genetic research. Aspects concerning support, reactions of at 
risk carriers and medical-ethica! problems concerning participation to 
scientific research and, one day, probably predictive diagnostic 
investigations, will be subject to research as weil. By means of molecular-
genetic research more insight will probably be gaim,d in both etiology and 
the mechanisms causing the clinica! heterogeneity of this disease. 
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FAMILIAL AGGREGATION IN 
FRONTO-TEMPORAL DEMENTIA 
INTRODUCTION 
There is an increasing recogmtlOn of non-Alzheimer's dementia 
affecting predominantly the frontal and temporal cortex. I-3 Piek's disease 
characterized by Piek bodies is found in only a minority of these patients. 3 
For the large group of frontotemporal degeneration without Piek bodies, 
various names have come into use: frontal lobe degeneration of non-
Alzheimer type, dementia lacking distinctive histology, frontal lobe 
dementia, and asymmetrie cortical syndrome. I-6 The recently introduced 
term fronto-temporal dementia (FTD) inc1udes most of these conditions, 
and is characterized by specific behavioral changes, frontotemporal 
atrophy on CT or MR!, and the absence of senile plaques and 
neurofibrillary tangles at postmortem examination7 
In families from several countries wilh an autosomal dominant FTD, 
linkage was found to a 2 cM region of chromosome 17q21-228 -16 Because 
FTD overlaps with other dementias showing neurofibrillary tangles, 
amyotrophic lateral sc1erosis and Parkinson's disease, delineation of the 
gene defect of FTD will become crucial in the further diagnostic 
c1assification and research of these conditions. 
Here, a population-based study of FTD in the Dutch population of 15 
million people is presented. Earlier smaller studies in FTD found a 
positive family history for dementia in 40 to 60% of participantsY.4 We 
analyzed the familial aggregation in FTD in the Netherlands and its 
association with other neurodegenerative and cardiovascular diseases, and 
calculated the lifetime risk for dementia among l1rst-degree relatives of 
FTD patients. In view of the association of apolipoprotein E4 (ApoE4) 
genotype with Alzheirner's disease,17 ApoE genotypes were studied in 
FTD patients with and without a family history of dementia. 
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METHOOS 
Design and diagnosis 
A complete ascertainment of patients with FTD in the Netherlands 
was attempted between January 1, 1994 and March 1, 1997. All hospital-
based neurologic and psychiatric practices (n = 164) and physicians in 
psychogeriatrie hospitals or nursing homes (n=251) received a yearly 
postal or telephone enquiry about all suspected FTD cases with onset 
before the age of 65, irrespective of their family history. 
Spouses and first -degree relatives participated in acquiring a detailed 
clinical history on the evolution of the disease using a checklist of frontal 
symptoms, speech and spatial functions as weil as memory problems. All 
patients were investigated by one of the two neurologists and, if possible, 
by a neuropsychologist. Neuroimaging (CT, MRI or single photon 
emission computed tomography [SPECT]), EEG and laboratory tests were 
obtained to support the clinical diagnosis of FTD and to exclude other 
causes of dementia. The severity of dementia varied from mild to severe. 
In patients with severc~ dementia, clinical, neuroimaging (including hard 
copies of CT, MRI or SPECT) and neuropsychological data, al ready 
available, were reviewed. 
A diagnosis of FTD was based on the criteria of Lund and 
Manchester groups,' which include (l) a progressive behavioral disorder 
with insidious onset, (2) affective symptoms, (3) speech disorder, (4) 
preserved spatial orientation and praxis, and (5) selective frontotemporal 
atrophy (CT,MRI) or selective frontotemporal hypoperfusion (SPECT) on 
neuroimaging. All patients had at least one year progression of their 
clinical symptoms. Probable FTD was defined (in the absence of 
international criteria) when clinical symptoms according to the criteria of 
the Lund and Manchester groups (1-4) were supported by characteristic 
neuropsychological findings and frontotemporal atrophy (CT, MRI) or 
hypoperfusion (SPECT) on neuroimaging. The diagnosis FTD was 
definite when postmortem examination in patients who died during follow-
up confirmed the clinical diagnosis. Patients with possible FTD had 
symptorns compatible with FTD without supportive neuroimaging (no or 
normal CT, MRI). All patients with probable FTD had follow-up. 
Two independent neurologists ('NA vG, PS) not involved in clinical 
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data collection validated the clinical diagnosis of FTD by reviewing the 
clinical and neuropsychological data. They had no infonnation about 
family history. In case of disagreement, the diagnosis was established as 
possible FTD. Separate brain imaging evaluation (CT, MRI) was done by 
a neuroradiologist with no knowledge of the patient's history. The frontal 
and temporal atrophy was scored as mild, moderate or severe. 
The study was approved by the Medical Ethical Committee of the 
University Hospital Rotterdam. Infonned consent for participation 
(including DNA studies) was obtained fram the spouse or a first-degree 
relative of each patient. 
F7D patients and control subjects 
Of 126 patients braught to our attention, 74 patients had FTD and 
were included as probands in this study. Fifteen patients with possible 
FTD and 37 patients with other types of dementia (Alzheimer's disease, 
vascular dementia, and undetermined) were excluded. We also excluded 
secondary cases of FTD mentioned in family history to avoid referral bias 
due to fanlilial clustering. Of the 74 patients entering the study, 36 were 
seen to confirm the diagnosis at the outpatient department in our hospital. 
For the other 38 participants, earlier neuropsychological and 
neuroimaging data were available. 
Contral subjects (n=561) matched for age and gender were obtained 
randomly fram a population-based study in the elderly in Rotterdam. IS 
These contral subjects did not show symptorns of dementia at the time of 
the study nor did they score lower than 26 on the Mini-Mental State 
Examination. 19 The education level according to three categories in FTD 
prabands (33 % primary education, 25 % medium level, 42 % higher 
education) was similar to that in contral subjects. 18 Blood for DNA 
isolation was obtained fram 71 patients and 561 contral subjects. ApoE 
genotyping was perfonned according to Reymer et al'" in patients and 
control subjects as described earlier. 17.21 
Family questionnaire 
The family history of dementia was collected for all prabands 
(patients and contral subjects) using a questionnaire, adapted fram the 
Rotterdam Study Y Data were obtained on all first-degree re1atives: 
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gender , current age or age at death, cause of death, occurrenee and age at 
onset of dementia or other neurodegenerative disorders (Parkinson' s 
disease, ALS), history of thyroid disease, hypertension, diabetes mellitus, 
and cardiovascular disorders. The spouse or a first-degree relative 
(usually offspring) provided this information, whieh was checked in a 
telephone interview with a second informant, usually a sibling of the 
patient. After consent, medical records and CT and/or MRI of affected 
relatives, if available, were obtained. 
Statistical analysis 
Risks of developing dementia before age 80 and its age at onset in 
first-degree relatives (siblings and parents) of the FTD-patients (definite 
and probable) were compared with that of control subjects. Children of 
probands and control subjects were excluded because they had neither yet 
reached the at-risk age for FTD nor were there cases of dementia among 
them. Survival analysis of first-degree relatives was used to establish the 
probability of developing dementia before the age of 80 years. The 
censoring age in this analysis was the age at onset of dementia in the 
affected relative and the current age or the age of death of the unaffected 
relatives. Cox proportional hazard analysis was used to estimate the 
hazard ratio (HR), which may be interpreted as a relative risk; that is, the 
risk of developing dementia in one group divided by the risk of dementia 
in another groupY Student's t-test was used when appropriate. 
RESULTS 
FTD patients and con trol subjects 
Ascertainment was made as complete as possible by repeat 
communication with tbe various medical specialists . Tbe patients notified 
were distributed proportionally to the population density of different areas 
of tbe country, except for a probable underreporting from an eastern 
region of tbe country (population of 200.000 habitants). Tbe estimated 
prevalenee of FTD is 1.2 of JO' in age 30 to 40 years, 3.4 of 10' in age 
40 to 50 years, JO.7 of JO' in age 50 to 60 years, and 28.0 of JO' in age 
60 to 70 years. 
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The mean age at ascertainment of the 74 probands was 59.4±9.1 
years (range 37-73 years) and of control subjects was 59.9±2.8 years 
(range 55-64 years). The men-women ratio was 3:5 in the FTD group, 
and 7: 10 in the control group. The mean age at onset of dementia in 
probands was 54.8±8.5 years with a mean duration of 5.9±2.9 years. 
All patients showed frontotemporal atrophy (CT, MRI) or frontotemporal 
hypoperfusion (SPECT) . Frontotemporal atrophy was moderate or severe 
in 55 probands and mild in 19 patients. The clinical diagnosis in patients 
with mild atrophy was supported by !inkage to chromosome 17 in 4 
patients, by pathological verification in 3 patients, and by frontotemporal 
hypoperfusion on SPECT in the remaining 12 patients. Definite FTD was 
established in 11 patients by neuropathological findings (4 patients had 
Piek bodies ). 
Familial aggregation 
A history of dementia before age 80 in first -clegree relatives (parents 
and siblings) was found in 38% (28 of 74) of patients and in 15% (84 of 
561) of control subjects (Tabie 1). Seven (10%) FTD probands had two 
or more first-degree relatives with dementia (see Table 1), but only 5 
(0.9%) of the control subjects had two or more affected first-degree 
relatives. Extensive pedigree research and linkage analysis showed that 9 
FTD probands coming from nuclear families originated from three large 
families (patients related in fourth to the seventh degree), and showed 
!inkage to chromosome 17 (FTD-17 probands)Y The age at onset in FTD 
probands with positive family history (56.5±7.6 years) was similar to 
those with a negative family history of dementia (53.7±8.9 years). 
ApoE genotype 
The ApoE genotype distribution was compared between the total 
group of FTD patients and the control subjects. The frequency of 
ApoE4E4 genotype in the total FTD group was 7.0% versus 2.3% in the 
control group (odds ratio [OR] adjusted for age and gender, 2.2; 95% Cl, 
0.6 to 8.9). The ApoE4E4 genotype in FTD patients with a negative 
family history was 8.9%, and 1.5 % in similar control subjects (adjusted 
OR, 5.2; 95% Cl, 0.9 to 30.8). 
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Table 1. 
History of dementia in first-degree relatives (parents and siblings) 
of patients with FTD and in control subjects. 
Dementia in first-degree relatives 
Total group 
Family history positive 
negative 
Wamen 
Family history positive 
negative 
Men 
Family history positive 
negative 
Number of first-degree relative~. 
with dementia 
o 
2 or more 
FTD patients with unknown linkage 
Pamily history positive 
negative 
Dementia infirst-degree relatives 
Cases Contmls 
n = 74 n = 561 
28 (38%) 84 (15%) 
46 477 
17 (36%) 48 (15%) 
30 271 
11 (41 %) 36 (15%) 
16 206 
46 477 
21 (28%) 79114%) 
7 (10%) 5 (0.9%) 
19 (29%) 84115%) 
46 477 
The age and male-female ratio of first-degree relatives was similar in 
the FTD and the control groups (Tabie 2). A total of 127 patients with 
dementia were identified among 3,345 first-degree relatives of FTD 
patients and control subjects. Two affected parents of control subjects 
were exc1uded by lade of information about age at onseL Dementia before 
age 80 was reported in 38 of 411 first-degree relatives of FTD probands 
and in 87 of 2,934 first-degree relatives of control subjects. The age at 
onset in affected relatives of FTD probands was significantly younger 
than in relatives of controls subjects (60.9±1O.6 years verSus 72.3±8.5 
years). 
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Table 2. 
Dementia before the age of 80 in 411 first-degree relatives (parents/siblings) 
of FTD patients and 2,934 first-degree relatives of control snbjects. 
Mean age in years (SD) 
Gender 
Wamen 
Men 
Relationship 
Parent 
Sibling 
Dementia in affected relatives (%) 
Meall age of onset in years (SD) 
Wamen 
Men 
Parent 
Sibling 
Type of dementia 
FTD linked ta chr. 17 
Probable FTD 
Alzheimer's 1 unknown 
first-degree re!atives 
of FTD patients 
n = 411 
61.3 ± 17.7 
213 
198 
147 
264 
38 (9%) 
60.9 (± 10.6) 
20 (53%) 
18 
25 (66%) 
13 
15 
9 
14 
* differellce statistically significant, p<O.OOl T-test 
NA = infonnation about type of dementia not available 
first-degree relatives 
of contra! subjects 
n = 2934 
63.2 ± 17.0 
1475 
1459 
1082 
1852 
87 (3%) 
72.3 (±S.5)' 
57 (66%) 
30 
77 (89%) 
10 
NA 
NA 
NA 
Dementia among FTD-relatives could be divided into three types: familial 
FTD linked to chromosome 17 in 15 patients (affected FTD-17 relatives), 
probable FTD in 9 patients and dementia of Alzheimer's or unknown type 
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in 14 patients. The dementia in affected relatives of controls could not be 
specified (Tabie 2). 
The cumulative incidence of dementia before age 80 among first-
degree relatives of FTD patients was 22 % compared with 11 % among 
relatives of control subjects (Tab Ie 3, Figure 1). The occurrence of 
dementia in the FTD group was also studied after the exclusion of the 
relatives (n=50) of 9 FTD-17 patients, showing a cumulative incidence of 
18% in this group (see Figure 1), whereas it was 47% for the FTD-17 
group. 
Table 3. 
Hazard ratio of dementia in first-degree relatives (parents/siblillgs) 
of FTD patients and of control subjects. 
First-degree relatives 
of FTD patients 
of control subjects 
female 
male 
parent* 
sibling 
Fm with unknown linkage 
of FTD patients 
of control subjects 
Tatal number 
411 
2934 
1688 
1657 
1129 
2116 
361 
2934 
Affected 
38 
87 
77 
48 
102 
23 
23 
87 
fIR (95% Cr) 
3.5 (2.4·5.2) 
1.3 (0.9·1.8) 
1.8 (1.1·3.0) 
2.4 (1.5-3.7) 
* unaffected parents without information abom current age or age of death were excluded from this 
analysis. 
Proportional hazard analysis for dementia showed an HR of 3.5 (95 % 
Cl, 2.4 to 5.2, Table 3). There was no difference in risk of dementia 
between men and women (HR, 1.3; 95 % Cl, 0.9 to 1.8). Parents were 
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more !ikely 10 develop dementia Ihan siblings (HR, 1.8; 95% Cl, 1.1 10 
3.0). The analysis was repealed for FTD cases with unknown !inkage 10 
chromosome 17, showing an HR of 2.4 (95% Cl, 1.5103.7; Table 3). 
Figure 1. 
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DISCUSSION 
This is the first population-based study of familial occurrence of 
dementia in FTD. The approximate prevalence of FTD varies between 1.2 
of 10' in the age group 30 to 40 years and 28.0 of 10' in the age group of 
60 to 70 years, considering that our ascertainment is as complete as 
possible using the design described. The occurrence of FTD seems less 
uncommon than previously considered. The family history was positive 
for dementia in 38 % of FTD patients. ApoE4 homozygosity is more 
common, although not significantly, in FTD patients with a negative 
family history than in similar control subjects. First-degree relatives of 
FTD patients are at a 3.5 times higher risk of developing dementia before 
the age of 80 than relatives of control subjects. The higher risk for FTD 
relatives remains 2.4 after the exclusion of relatives of chromosome 17-
linked patients. The onset of dementia was significantly earlier (11 years) 
in relatives of FTD patients. 
The strength of Dur study lies in the epidemiological design for 
ascertaining prevalent patients, the stringent criteria for the diagnosis of 
FTD, a structured family history questioIlI1aire (including the use of a 
second infonnant), and evaluation of the diagnosis by two independent 
neurologists blinded to neuroimaging and family history. However, a few 
possible sources of bias may remain. Firstly, the accuracy of the 
diagnosis of FTD in probands is important. FTD is still a relatively 
uncommon type of dementia, and it shares some of its characteristic 
behavioral changes with Alzheimer's disease. For probabJe FTD we 
therefore required neuroimaging evidence for selective frontotemporal 
atrophy or hypoperfusion on SPECT, which has a high correlation with a 
pathological diagnosis of FTD.23 Moreover, the diagnosis of FTD was 
definite by neuropathologic confirmation in 11 patients (including three 
FTD-17 patients), and by linkage to chromosome 17 in another six cases. 
Familial clustering in the selection of patients may be another source 
of bias that was largely prevented by excluding from our study the 
secondary patients from the families notified. All familial probands were 
identified independently from each other and all met the criteria for 
probable FTD in this study. Patients with sporadic FTD might be less 
likely to be referred for neurological examination. However, all cases of 
55 
Chapter 3 
presenile dementia notified by our study had been thoroughly studied (CT 
and MRI or SPECT), irrespective of their family history. This might 
probably be explained by the large impact of the disease on everyday life. 
The frequency of positive family history in FT)) probands was similar 
to that found in Alzheimer's disease,24-26 but lower than the 50% observed 
in small series of patients with FTD. 2.4 
The controls showed a positive family history in 15 %, which was 
comparable with other studiesY The cumulative incidence of dementia in 
the first-degree relatives of FTD probands linked to chromosome 17q21-
22 was 47%, which supports the autosomal dominant inheritance of this 
familial condition. The cumulative incidence curve (Figure I) shows a 
22 % risk for first-degree FTD relatives, who became affected with 
dementia at a significantly younger age (60.9± 10.6 years) than relatives 
of control subjects (72.3±8.5 years). The age in controls seems identical 
to the increasing risk of Alzheimer's disease with age. 
The influence of the probable heterogenous genetic background of 
FT)) was addressed in this study by comparing three families with FTD 
linked to chromosome 17, and familial cases without !inkage information. 
The first-degree relatives from the latter group still are 2.4 times more at 
risk for dementia compared with relatives of control subjects. The future 
gene identification may help to estimate the real proportion of FTD linked 
to chromosome 17q21-22. Other genetic or environmental mechanisms 
may be involved for a proportion of FTD patients. 
The association of ApoE4 homozygosity with FTD confirms our 
earlier results based on a smaller population, and the results of another 
study of autopsy-proved patients with Pick's disease 21 .28 This association 
is less pronounced in the subgroup with a positive family history, which 
might be explained by the fact that familial patients are possibly caused by 
gene mutations with autosomal dominant expression. However, ApoE4 
allelic frequency needs to be investigated in larger samples of FT)) 
patients, because the association between ApoE allelic frequency and FTD 
has not been found in two other studies."·30 Also, a faster progression of 
the disease in FTD patients with the ApoE4 allele as recently found in 
Alzheimer's disease,31·32 has to be studied in our patients at follow-up. 
In conclusion, this study shows an evident familial aggregation in 
FTD that is contributed not onIy to FTD linked to chromosome 17q21-22. 
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The eventual solution of the suggested heterogeneity will be helped by 
identifying the genetic defeets assoeiated with FTD on ehromosome 
17q21-22 and other possible loeations. 
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Chapter 4 
APOLIPOPROTEIN E GENE AND 
SPORADIC FRONTO-TEMPORAL DEMENTIA 
INTRODUCTION 
Fronto-temporal dementia (FTD) is a predominantly presenile type of 
dementia. Although there are a number of families in which the disease 
segregates as an autosomal dominant disorder, in most cases the disease is 
sporadic. FTD is characterized by a progressive change in personality and 
behavior (disinhibition, stereotyped and perseverative behavior), loss of 
initiative, social awareness and insight, and reduced verbal output. The 
E4 allele of the apolipoprotein E gene (APOE) is one of the most 
important risk factors for early- and late-onset Alzheimer's disease (AD) 
and cognitive dec1ine.'·' Although findings have not been as consistent as 
in AD, also other forms of dementia inc1uding vascular dementia/oIO 
Lewy body disease"-15 and Creutzfeldt-Jacob disease'6.17 have been 
associated with the E4 allele of APOE-gene (APOE*4). The relationship 
of apoE with FTD is less c1ear. Two studies failed to show an association 
between APOE*4 and FTD,18.19 one study showed a non-significant 
increase in APOE*4 allele frequency among patients with Pick's disease 
(n=6),20 while one other study reported an earlier onset of FTD in 
APOE*4 allele carriers." However, the statistica] power of previous 
studies has been limited due to the small number of patients studied (n = 8-
27, if restricted to FTD patients without other neurological disorders). We 
examined 34 patients with clinically diagnosed FTD derived from a 
population-based study in the Netherlands. The relation of apoE to the 
risk and onset of the disease was investigated. 
METHODS 
FTD patients were recruited from the Dutch population. The study 
protocol was approved by the Medical Ethical Committee of the 
University Hospital Rotterdam. To obtain a full ascertainment of FTD 
patients, all neurologie, psychiatrie, geriatrie centers and nursing homes 
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were addressed to report their patients twice a year. The study aimed at a 
complete ascertainment of FTD patients diagnosed in the period of 
January I, 1994 and January I, 1996. The study was limited to patients in 
whom the onset was at or before the age of 65 years, as all of these 
patients are likely to be sent in for diagnosis by relatives and/or their 
general practitioner, and therefore can be ascertained population-based by 
addressing the centers as specified above. We did not attempt to ascertain 
late-onset patients, because the possibility of complete ascertainment was 
improbable due to the fact that elderly FTD-patients are often not referred 
to specialized clinics for differential diagnosis. For this study, the clinical 
diagnosis of FTD was independently confirrned by 3 neurologists using a 
standardized protocol according to the criteria of the Lund and 
Manchester study groupS.22 Moreover, imaging studies (CT, MRl or 
SPECT) and neuropsychological testing should support the diagnosis of 
FTD. A total of 34 patients fulfilled our inclusion criteria. Data were 
collected by interviewing at least one next of kin and by reviewing all 
available medical records. If insufficient data were available. additional 
clinical investigations were performed. Age at onset was defined as the 
age at which retrospectively profound personality and behavioral changes 
were first noted. In this study, we only included patients from families in 
which there was no evidence for autosomal dominant transmittance of 
FTD. Autosomal dominant FTD was defined as FTD occurring in at least 
2 generations. In our study we ascertained only 3 patients with a positive 
family history of FTD. The disease occurred in more than 3 generations 
in all three cases. These patients were therefore excluded from the current 
analysis. Subjects with one or more (first-degree) relatives with other 
types of dementia, were considered to have a positive family history of 
other types of dementia. After a written consent, blood was drawn for 
DNA extraction. A sample of control subjects (n=561) was drawn 
randomly from another population-based study conducted in Rotterdam, 
the Rotterdam Study 23 These controls were screened for dementia using 
the Mini Mental State Examination 24 None of the selected controls had a 
score lower than 26 or showed symptoms of dementia at the time of the 
study. 
In cases, apoE genotyping was perforrned according to Reymer et 
al.25 ApoE in controls was genotyped as described earlier26 Allele 
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frequencies for patients and controls were assessed by counting alleles and 
calculating sample proportions. The strength of association between apoE 
and FTD was estimated as the odds ratio. Odds ratios are presented with 
a 95 % confidence interval (CI).27 We used multiple logistic regression 
analysis to take the possible confounding by age, sex and family history 
of dementia into account. The association between apoE and age of onset 
and duration of disease was assessed using multiple linear regres sion 
analysis."' 
RESULTS 
In table 1, baseline characteristics of the study population are given. 
The mean age at onset of our patients was 52.1 years. The mean duration 
of the disease at ascertainment of the patients was 6.6 years. There was 
no statistically significant difference between the patients and controls in 
age or sex distribution. When comparing the APOE allele frequencies, the 
frequency of the APOE*4 allele was significantly higher in patients (25 %) 
than in controls (15%). The odds ratio of FTD was 1.8 (95% Cl 1.0-
3.26) when comparing APOE*4 carriers to non carriers. 
Table 2 shows the apoE genotype distribution in patients and controls. 
Taking the most frequent genotype apoE3E3 as the reference, a significant 
increased odds ratio was found for the apoE4E4 genotype when adjusting 
for age, sex, and family history of other types of dementia. To exclude 
that the association between apoE4E4 and FTD was related to a family 
history of dementia other than FTD in FTD patients, we performed an 
analysis in which patients with such a family history were excluded 
(n=6). The odds ratio remained significantly increased (odds ratio 8.0; 
95% Cl 1.6-40.4; p=O.OOl; not in tabie), suggesting that the association 
is independent of the family history of other types of dementia. A non-
significant increase in odds ratio was found for the apoE3E4 and apoE2E3 
genotypes. The age at onset tended to be lower in patients with the 
APOE*4 allele (p-value trend test = 0.04). The effect was most 
pronounced for subjects homozygote for the APOE*4 allele. There was 
no consistent relationship between the presence of APOE*4 allele and the 
duration of the disease at the time of the study. 
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Tab!e I. 
Baseline characteristics and APOE allele frequencies 
in FTD patients and controls. 
Mean age at onset in years (SD) 
Range 
Duration disease ascertainment in years (SD) 
Range 
Age ascertainment in years (SD) 
Range 
Number of men (%) 
APOE aHele frequency 
(number of alleles) 
APOE*2 
APOE*3 
APOE*4 
.p < 0.05 
Patients 
n=34 
52.1 (9.2) 
35·64 
6.6 (3.7) 
1·13 
58.7 (10.3) 
37·75 
12 (35) 
0.09 (n~6) 
0.66 (n~45) 
0.25 (n~17) 
Controls 
11=561 
59.9 (2.8) 
55-65 
242 (43) 
0.09 (n~ 106) 
0.75 (n~844) 
0.15 (n~l72r 
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Table 2. 
ApoE genotypes in FTD patients and controls. 
Patients Controls 
ApoE genotype 0=34 0=561 
ApoE4E4 3 13 
( 8.8 %) (2.3 %) 
ApoE3E4 11 134 
(32.4 %) (23.9 %) 
ApoE2E4 0 12 
(0 %) (2.1 %) 
ApoE3E3 14 315 
(42.1 %) (56.2 %) 
ApoE2E3 6 80 
(18.9 %) (14.3 %) 
ApoE2E2 0 7 
(0 %) ( 1.2 %) 
°Adjusted for age, sex, family history of dementia 
+No estimarion because of division by 0 
Table 3. 
Odds ratio (95 % Cl) 
Crude 
5.2 
[1.3-20.3J 
1.8 
[O.8-4.2J 
reference 
1.7 
[O.6-4.5J 
Adjusted" 
4.9 
[1.1-20.1J 
1.7 
[O.7-3.8J 
-+ 
reference 
1.5 
[O.5-3.9J 
-+ 
APOE*4 aUele and the age of onset and duration of disease 
at ascertainment in FTD patients. 
Age at ooset in years 
(SD) 
Duration at ascertainment in years 
(SD) 
* One-sided p value 
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Number of APOE*4 alleles 
0 2 
53.7 51.8 43.0 
(8.5) (9.6) (9.6) 
6.4 7.6 3.7 
(3.7) (3.8) (2.5) 
p value 
trend* 
p=O.04 
p=0.35 
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DISCUSSION 
Our population-based study suggests that subjects homozygous for the 
APOE*4 allele are at increased risk of FTD. A problem in the 
interpretation of our findings might be that our study was based on 
clinically diagnosed patients, in whom the disease was not pathologically 
confirmed. Misdiagnosis is unlikely, since the diagnosis in the patients 
was based on very rigid criteria; the clinical diagnosis of FTD was 
supported by neuropsychological confirmation of frontal lobe dysfunction, 
and frontal atrophy on CT or MR!, or hypoperfusion on SPECT scan. To 
have distorted the results of our study, diagnostic misclassification must 
occurred differentially in APOE*4 allele carriers and non-carriers, and 
this was improbable. 
Our findings are compatible with those of one earl ier study of 
pathologically confirmed patients with FTD, which showed a significantly 
carlier onset of the disease in APOE*4 allele carriers and an APOE*4 
allele frequency in patients of 23 % ,21 and one study showing an increased 
frequency of APOE*4 in patients with Pick's disease.20 In contrast, two 
studies failed to show evidence for a relationship between apoE and 
FTD. 18.\9 The largest of these studies was based on a mixture of clinically 
diagnosed (46%) and pathologically (54%) confirmed patients. 19 A 
problem in interpreting our study and earlier ones is the small number of 
patients studied in the individual investigations. Studies had an a priori 
suffident statistical power to determine the effect of the APOE*4 alleie, 
but not for studying the relatively rare apoE4E4 genotype. Yet, our study 
shows astrong relationship between the apoE4E4 genotype and FTD. The 
association remained significant when including only patients without a 
family history of other types of dementia in the analysis, suggesting that 
the association cannot be explained by familial aggregation of FTD and 
other types of familial dementia. 
ApoE has been associated with various types of dementia. '·16 The 
APOE*4 allele frequency in our FTD patients was similar to the allele 
frequency found in sporadic early-onset AD (28%),28 vascular dementia 
(21 % to 46%),'·8 Lewy body disease (35%),12 and Creutzfeldt-Jacob 
disease (33 %) .16 These findings suggest that apoE4 influences the risk of 
dementias that have a very different pathogenesis and clinical expression. 
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AIso, motor neuron disease with bulbar-onset has been associated with 
FTD as well as APOE*4 (frequency in patients 24.2%).29 Uncovering the 
role of apoE in FTD may lead to new insights in the role of apoE in 
dementia and related neurological disorders . Further, our findings may 
have important implications with regard to the use of apoE in the 
diagnosis of AD. Despite the consensus of the working group of the 
American College of Medical Genetics and the American Society of 
Human Genetics stating that apoE testing is not recommended for the use 
as a predictive genetic test,30 Roses suggested that testing for 
homozygosity of APOE*4 may be of use for the differential diagnosis of 
Alzheimer's disease.31 If our finding of astrong association between 
apoE4E4 genotype and FTD is confirmed, the feasibility of diagnosing 
AD based on apoE testing is reduced considerably. 
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Chapter 5 
HEREDITARY FRONTO-TEMPORAL DEMENTIA 
IS LINKED TO CHROMOSOME 17q21-q22: 
A GENETIC AND CLINICOPATHOLOGICAL STUDY 
OF THREE DmCH FAMILIES 
INTRODUCTION 
Hereditary fronto-temporal dementia (HFTD) is the familial form of 
fronto-temporal dementia (FTD), a rare, mostly sporadically occurring 
and predominantly presenile dementia. I·' The characteristic frontal and 
temporal lobar atrophy was originally described by Arnold Pick in 1892.' 
Gans6 in 1923, and later others, reported families with an autosomal 
dominant inheritance pattern.7-10 The diagnosis of Pick's disease, the best 
known type of FTD, is now set aside for cases with so-called Piek 
bodies,11.12 and several authors introduced diagnostic descriptions for new 
entities of frontal atrophy without Pick bodies. 15-17 The main clinical 
features of FTD are personality changes, a disinhibited and inappropriate 
behavior, hyperorality, stereotyped and perseverative behavior, emotional 
and social indifference, aspontaneity, loss of judgement and insight, and 
speech reduction. I.13 
Molecular genetic studies of HFTD failed to find mutations in !he 
genes implicated in Alzheimer's disease or the mutation in the prion 
protein gene involved in Creutzfeldt-Jacob disease."-20 More recently, 
!inkage to chromosome 17 has been reported in a family with 
disinhibition-dementia-parkinsonism-amyotrophy complex (DDPAC), 2 
families with progressive subcortieal gliosis (PSG) and a family with 
pallido-ponto-nigral degeneration (PPND).21-23 The disease in these 
families shows a strong clinical and pathologieal resemblance to HFTD, 
as reported in this study. 24-26 
To investigate whether HFTD could also be !inked to the same reg ion on 
chromosome 17q21-q22, we performed a linkage study with 3 large 
families with HFTD that were ascertained in the Netherlands_ Here, we 
report evidence for !inkage of HFTD to chromosome 17q21-q22, the 
same chromosomal region were DDPAC, PPND and PSG have 
previously been loca!ized. 
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MATERIAL AND METHODS 
Family studies 
In a genetic-epidemiologic study of FTD in the Netherlands, we 
aimed to obtain a full ascertainment of FTD patients by addressing all 
neurologic, psychiatric, geriatric, and nursing homes to report their 
patients twice a year. In this study, 2 large families (Families land III) 
with dementia were identified, whereas a third one (Family II) was 
reexamined. These families were selected for linkage analysis because of 
their strong clinical and pathological similarities. The second family has 
been c1escribed before as hereditary Pick's disease, despite the absence of 
Pick bodies . 24 Dementia is transmitted as an autosomal dominant disorder 
in all 3 families4 (Figure la and b). The clinical picture in affected 
individuals meets the criteria for FTD 1 The age at which behavioral 
changes were reported by more than 1 relative was considered as age of 
onset. Diagnosis of living patients was established using extensive 
neuropsychological testing and brain computed tomographic (CT) 
scanning and/or magnetic resonance imaging (MRI); diagnosis of 
deceased patients was established either on pathology findings or on 
available medical records and family interviews. 
Family I 
The first family consists of 2 sisters with dementia in the first 
generation and 49 of 160 offspring (28 men and 21 women) of these 2 
sisters in the subsequent five generations (see Figure la). The c1iagnosis of 
FTD was establishec1 in 8 living patients. Sufficient clinical information 
and family history were available on 18 affected relatives to allow 
establishing age of onset and diagnosis of HFTD, whereas the type of 
dementia could not be specified by lack of detailed information in the 
remaining affected family members. A neuropsychological assessment was 
performed in 15 of 18 patients. Ten patients had CT scanning; 3 cases 
had a single-photon emission computed tomographic (SPECT) scan and 3 
an MRI scan. Neuropathological examination in all 14 autopsied cases 
confirmed HFTD. 
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Family II 
This family with HFTD was previously documeuted by Schenk and 
others 2 -4 There are seven generations with 34 affected relatives (14 men 
and 20 women). CT scans were performed in 6 patients and SPECT 
scanning in I patient. Neuropathological examination in IS patients 
confirmed the clinical diagnosis of HFTD. After the last report another 2 
affected cases were identified (V 14 and V21) 4 
Family III 
Dementia was first recognized in 1 male, and subsequently another 29 
affected relatives were identified (see Figure lb). Relevant clinical data 
are available on 10 patients, CT scanning and neuropsychological 
assessment in 7 patients, and SPECT scanning in 2 patients. 
Neuropathological studies in 1 patient confirmed the diagnosis of HFTD. 
Af ter written consent, DNA was isolated from peripheral blood 
leukocytes as described by Miller and colleagl).es.2' Blood was taken from 
5 patients from Family I, 2 patients from Family II, and 5 patients from 
Family Hl. DNA samples were also obtained from 62 healthy relatives 
with 50 % risk for developing dementia (31, 15 and 16 individuals 
respectively) . 
This study was approved by the Medical Ethics Comrnittee of the 
University Hospital Rotterdam. 
Pathology 
Brain specimens of different cortical regions , basal ganglia, anel pons 
from 11 cases (5 [rom Families I and II each, and 1 from Family III), 
were reexamined for Pick bodies, ballooned cells, and 
imrnunohisrochemical features. Imrnunohistochemistry included the 
following antibodies: ubiquitin (1: 125; Novocastra), tau (1 :400; Dako, 
no. A 024), an antibody against paired heli cal filaments (PFHs)( I : 100; 
ICN), an anti body against somatodentritic microtubule-associated protein 
(MAP-2)(l: 170; Zymed), and Jl-amyloid antibody (1:600; Novocastra). 
Staining with a conventional peroxidase anti-peroxidase method was done. 
Age- and sex-matched controls (normal and with Alzheimer's disease) 
were used for comparison. 
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Pedigree of family 1. As lhe disorder shows dear autosomal domin3Jl.t Îil.t1crita11CC, sex dcsignation of family 
members has been omilled for privacy reasons. 0 = unaffected; 0* = two different spouses; <8> = 
possibly affeeted; (> = affeeted (dementia); clinica! information insufficient to establish diagnosis FTD; • 
= affeeted (fronto-tempora! dementia); suffieient clinica! information and/or pathoJogieally eonfirmed. 
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DNA studies 
Simple sequence length polymorphisms (SSLPs) from chromosome 
17q21-q22 were amplified from 50ng of genomic DNA. One primer from 
each pair was end labeled with gamma 32p-ATP using T4 polynucleotide 
kinase. The amplification was performed essentially as described28 except 
for markers D17S946 and D17S932 for which 7.5% dimethyl sulfoxide 
was added to the reaction mix. Analysis of SSLPs was performed on a 
denaturing 6 % acrylamide gel. 
Chromosome 17 markers were obtained from the CEPH/Genethon 
linkage map.29 Marker order was obtained by combining data from the 
CEPH/Genethon linkage map and the Whitehead physical map30 and is 
shown in Figure 2. 
Linkage analysis 
Pairwise lod scores were calculated for each family by using the 
MLINK program of the LINKAGE programs package (vers ion 5.1),31 
assuming HFTD to be an autosomal dominant disease with a gene 
frequency of 0.0001. The mean age of onset in the available families was 
51 years (range 43-75 years). The late age of onset was accounted for by 
defining 4 liability classes with different penetrance values (Tabie I). 
Phenocopy rate was estimated to be 0.1 % for individuals older than 50 
years of age and 0.01 % for individuals younger than 50 years of age. 
Mutation rate was set at zero and equal recombination rates for males and 
females were assumed because of the variabie recombination ratio 
between males and fema1es in this region.29.30 Marker allele frequencies 
were kept equal because allele frequencies from the Dutch population 
were not available. Ca1culation of pair-wise lod scores with allele 
frequencies calculated from individuals marrying in into the HFTD 
kindreds did not substantially alter results « 10%). 
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Figure 2. 
Schematic map of the hereditary fronto-temporal dementia (HFTD-linked region 
on chromosome 17q2l-q22 with sex-averaged distanees based on the 
CEPH/Geneton linkage map." For each family, the number of recombinational 
events in affected individuals is indicated with an arrow accompanied by the 
number of recombinations observed. The double-sided arrow indicates the 
minimal critical region for HFTD. 
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Table I. 
Liability classes used iu the Iinkage analysis. 
Liability c1ass Penetrance 
Class 1 1.00 < married in or affected 
Class 2 0.95 < unaffected, at risk> 50 yr 
Class 3 0.75 < unaffected. at risk, between 40 and 50 yr 
Class 4 0.10 < unaffected, at risk < 40 yr 
RESULTS 
Demographic data and clinical features 
The age of onset was comparable in Families land II (mean 50.4 and 
46.5 years respectively); all but one patient developed symptoms before 
the age of fifty-seven. In Family III the mean age of onset was 63.4 years 
(range from 57 to 75), which is significantiy different (p < 0.(01). The 
mean duration of illness was similar for the three families (8.2-8.7 
years )(range between 4 and 16 years). The mean age of death in Family 
III (71.9, range 63-81 years) again differed significantly (p < 0.001) from 
that in Family I and Il (58.6 and 54.7 years respectively). The mean age 
of onset and of death was constant over consecutive generations . The 
male to female ratio of patients in Family 11 was 2 to 5, but equal to 1 in 
Families I and lIl. There was a remarkable unifonnity in clinical 
symptoms and progression of the disease within each family. 
Disinhibition, including aggressive behavior, stealing, jocularity 
and/or obsessional behavior, was the presenting symptom in all patients of 
Family land Family II. Loss of initiative was !he prominent presenting 
feature in Family 111, and developed later in Families land Il. 
Hyperorality, roaming behavior, restlessness and stereotyped behavior 
developed often during the course of the illness. Spontaneous speech 
became gradually reduced in all, resulting in a state of mutism. Mild 
memory problems were common. 
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Neurological examination was always normal in the early phase of the 
disease, except sometimes for frontal release reflexes. The progression of 
the disease was quite similar in these families. Pyramidal and 
extrapyramidal signs occurred in several patients in the late phase of the 
disease (see Table 2). Neuropsychological assessment showed frontal 
dysfunction in all patients of the three families. Perseveration, impaired 
attention, decreased mental shifting, impaired execmive skills and speech 
reduction reflecting frontal lobe dysfunction were found in combination 
with intact orientation and memory functions at neuropsychological 
assessment. 
EEG, serum levels of vitamins, lues reactions, andfor thyroid 
functions tests, performed in most patients, were always normal. CT 
scanning af ter a mean duration of illness of 2.5 years (range 1 to 5 years) 
showed frontal atrophy (mild in 6, moderate to severe in 9 patients) in 15 
cases from the three families, whereas CT scan was normal in 4 patients. 
Increased signal intensities in the subcortical white matter of the frontal 
lobe on T2-weighted MRI images were found in two patients of Family I. 
Frontotemporal hypoperfusion on SPECT was found in all six investigated 
patients. 
The brain weights at autopsy from Families land II were strongly 
reduced (mean 1035 and 920 g respectively); one case of Family Hl was 
1170 g. Moderate to severe atrophy of the frontal lobe was present in all 
cases of Families I to lIl, as weil as atrophy of the anterior part of the 
temporal lobe. The caudate nucleus was atrophied in 9 cases of Family I 
and 11 each, and in one patient of Family 111. Neuronalloss, gliosis and 
spongiosis were found in the frontal and temporal cortex, in the absence 
of senile plaques and neurofibrillary tangles. The substantia nigra was 
degenerated in 4 brains of Family land II each, and in one patient of 
Family 111. Neuronalloss in the olivary nuclei was found in 3 brains. 
Some cases of Families land 11 showed white matter changes 
(demyelination andfor gliosis). Ballooned cells in the cortex andfor basal 
ganglia were found in a number of cases of the Families land 11, whereas 
these cells were absent in one case of Family 111. Piek bodies were 
lacking in brains of the three families, except sporadieally in one brain 
from Family 11. At re-examination of 10 available brain specimens no 
Pick bodies were found at all. 
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Table 2. 
Comparison of clinical and pathological features between three 
chromosome-17 linked neurological disorders and three families witb HFTD. 
PPND DDPAC PSG IIFTD 
Number of patients 26 12 8 49 
Mean age of onset (yr) 43 45 46 51 
Presenting symptoms 
Personality and behavioral changes 10 12 6 ':;,9 
Dementia 5 
Parkinsonism 14 
Subsequent manifestations 
Dementia 26 12 8 '·9 
Supranuclear palsy 15 
Extrapyramidal signs 25 11 7 10 
Pyramidal signs 16 3 7 
Amyotrophy 1 
Neuropathology n=4 n = 6 n = 7 n = 30 
Macroscopy 
Prontal atrophy 4' 6 7 30 
Microscopical involvement 
Frontal cortex +/- ++ ++ ++ 
Temporal cortex +/- ++ ++ ++ 
Caudate nucleus + run +/- +-
Substantia nigra 4 6 4 9 
Hippocampus +/- +/- + 
Amygdala +/- ++ run -"/-
Thalarnus +/- run +/- +/-
Spinal cord nm +/- +/-
Ballooned eeUs nm + 
Piek badies nm run 
run = not mentioned; - = not affected; +/- = not generally affected; + = generally affected; -1--1-
= prominently affected; * = mild generalized atrophy described. PPND = pallido-pomo-nigra! 
degeneration; DDPAC = disinhibition-dementia-parkinsonism amyotrophy complex; PSG = 
progressive subcortical gliosis; HFTD = hereditary fronto-tempora! dementia. 
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Immunohistochemical studies were negative for tau or ubiquitin. In two 
patients scattered mild diffuse and granular staining for MAP-2 was 
visible in both neurons and glia. 
Linkage 
Three linkage reports21.23 of variabie forms of fronta! lobe dementia 
prompted us to investigate whether the families with HFTO described in 
this study were linked to the same region on chromosome 17q21-q22. We 
selected twelve 55LPs from the CEPH/Genethon linkage map. There was 
a discrepancy in marker order between the CEPH/Genethon linkage map 
and the Whitehead physical map for markers 0175932 and 0175934.29•30 
In our study we used the marker order obtained by physical mapping data 
from the Whitehead map. 
Positive lod scores were obtained for a number of markers in the 
region for all three families. Table 3a/b summarizes the pairwise lod 
scores between HFTO and the twelve chromosome 17q markers. None of 
the individual families was powerful enough to provide significant 
evidence for linkage by itself, but with the combined data of the three 
families significant lod scores were obtained for the marker 0175932 
(Z=4.70 at 8=0.05) and D175934 (Z=4.28 at 8=0.00). 
A substantial part of the information that contributed to these lod 
scores in these families comes from unaffected individuals that are at risk 
for the disease. We therefore re-analyzed 0175932 and 0175934 giving 
all the unaffected individuals a diagnosis unknown. The maximum lod 
score obtained with this analysis for marker 0175932 was 2.99 at 
8=0.00. For marker 0175934 the maximum lod score obtained was 3.46 
at 8=0.00. 
The marker order and inter-marker distances of the available 
genetic and physical maps do not always coneur. Therefore multi-
point linkage analysis can generate a confidenee interval that later 
would prove to be inaccurate. To strengthen our findings we 
performed haplotype analysis for all 12 markers positioned 
according to the physical map. In a number of cases the haplotype 
of the markers for the affected individuals eould not be determined 
because of the unavailability of first degree relatives (data not 
shown). As aresult it could not be determined whether marker 
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Table 3a. 
Two-point lod scores for chromosome 17 markers 
and hereditary fronto-temporal dementia. 
Recombination fraction (9) 
Marker Family 0.000 0.010 0.050 0.100 0.200 0.300 0.400 
D17S953 1 -3.96 -1.31 -0.59 -0.29 -0.04 0.02 0.08 
II -1.29 -1.14 -0.77 -0.52 -0.25 -0.10 -0.02 
III -2.18 -1.96 -1.35 -0.87 -0.36 -0.12 -0.02 
Total -7.43 -4.41 -2.71 -1.68 -0.65 -0.20 -0.04 
D17S925 -0.43 -0.37 -0.19 -0.05 0.07 0.08 0.05 
II -8.16 -1.21 -0.54 -0.29 -0.10 -0.03 -0.01 
III -1.89 -1.70 -1.17 -0.76 -0.30 -0.08 0.01 
Total -10.48 -3.28 -1.90 -1.10 -0.33 -0.03 0.05 
017S933 -3.55 -1.33 -0.63 -0.34 -0.14 -0.06 -(LOl 
II -8.14 -0.63 -0.02 0.16 0.20 0.11 0.03 
III -0.96 -0.83 -0.46 -0.21 0.00 0.04 0.01 
Total -12.65 -2.79 -1.11 -0.41 0.06 0.09 0.03 
017S946 1.88 1.84 1.67 1.43 0.95 0.48 0.12 
II 0.34 0.33 0.29 0.24 0.17 0.10 0.04 
III -2.30 -1.96 -1.20 -0.71 -0.24 -0.06 -0.01 
Total -0.08 0.21 0.76 0.96 0.88 0.52 11.15 
D17S800 1 -0.35 -0.32 -0.23 0.14 -0.04 0.00 0.01 
II -0.18 -0.18 -0.15 -0.12 -0.07 -0.03 ~).01 
III 0.92 0.94 0.98 0.96 0.77 0.47 0.15 
Total 0.39 0.52 0.60 0.70 0.66 0.44 11.15 
017S934 2.76 2.71 2.50 2.22 1.58 0.91 0.32 
II 1.35 1.33 1.23 1.10 0.82 0.49 0.16 
III 0.17 0.20 0.27 0.26 0.16 0.05 -0.02 
Total 4.28 4.24 4.00 3.58 2.56 1.45 0.46 
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Table 3b. 
Two-point lod scores for chromosome 17 markers 
and hereditary fronto-temporal dementia. 
Recombination fraction (6) 
Marker Farnily 0.000 0.010 0.050 0.100 0.200 0.300 0.400 
D17S932 2.64 2.59 2.38 2.10 1.49 0.86 0.29 
][ 1.61 1.57 1.44 1.27 0.90 0.50 0.14 
Hl -3.98 0.36 0.89 0.96 0.79 0.47 0.14 
Tatal 0.27 4.52 4.71 4.33 3.18 1.83 0.57 
D17S951 2.07 2.05 1.93 1.74 1.26 0.71 0.21 
][ 0.68 0.67 0.61 0.53 0.37 0.21 0,07 
Hl -0.45 -0.29 0.08 0.27 0.34 0.22 0,07 
Total 2.30 2.43 2.62 2.54 1.97 1.14 0.35 
D17S791 1 1.55 1.54 1.42 1.25 0.85 0.46 0.16 
][ 0.80 0.77 0.68 0.57 0.38 0.21 0,07 
Hl -5.12 -0.70 0.05 0.31 0.38 0.25 0.08 
Total -2.77 1.61 2.15 2.13 1.61 0.91 0.31 
D17S788 -2.81 -0.79 -0.17 0.03 0.12 0.08 0.02 
][ _ 00 
-0.42 0.17 0.34 0.36 0.23 0,07 
][] 
-13.03 -2.86 -1.35 -0.72 -0.19 -0.02 0.01 
Total - 00 -3.27 -1.35 -0.35 0.29 0.29 0.10 
D17S79O 1 -1.82 -0.02 0.60 0.77 0.73 0.48 0.18 
][ 
- 00 
-0.20 0.38 0.53 0.50 0.33 0.12 
Hl -5.62 -1.43 -0.74 -0.45 -0.19 -0.09 -0.03 
Tatal - 00 -1.65 0.24 0.85 1.04 0.72 0.27 
D17S787 2.60 2.57 2.43 2.20 1.65 1.02 0.39 
][ - 00 
-0.41 0.18 0.35 0.37 0.24 0.08 
Hl -8.40 -2.46 -1.47 -0.92 -0.35 -0.11 -0.03 
Tatal _ 00 -0.30 1.14 1.63 1.67 1.15 0.44 
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family I 
0178953 22 a2 24 24 33 
017$925 4a a4 44 a5 a4 
0178933 66 26 65 56 sa 
0178946 • 47 57 72 • 45 .4a 
017$800 
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2 
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0178934 18 101 1 8 1 8 1 8 
0178932 21 12 2a 27 26 
017$951 2a 62 21 21 25 
017$791 2a 82 27 211 25 
0178788 24 52 2a 25 25 
017$790 • 56 65' • 55 1 4 • sa 
017S787 68 66 6a 47 47 
Figure 3a. 
Marker data far ehromasame 17q21-q22 markers far all available patients in the 
three families with hereditary franta-temparal dementia. Markers are ariented 
fram the eentramerie side ta the telamerie side. The hatehed baxes indieate the 
maximum regian of allele sharing between patients. "Alleles that are shared anly 
by same patients in the family. Only relatives leading ta a eamman ancestor are 
indieated. Family I. 
Filled symbals represent affected individuaIs, question marks in symbals indicate 
that insuffieient data were available ta determine diagnosis, open symbals indieate 
unaffeeted individuaIs. 
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family 11 family 111 
0 
r 0178953 33 33 33 33 13 
0175953 14 1 2 0178925 22 32 32 42 42 
0175925 45 41 0178933 53 53 33 13 13 
0175933 51 54 0178946 43 43 63 43 43 
0175946 34 31 0178600 12 1 2 22 22 22 
0178800 42 44 D178934 12 1 2 52 52 52 
0175934 105 102 0175932 32 32 32 0175932 42 42 22 22 0178951 23 13 33 33 33 0175951 44 44 0178791 37 * 37 * 47 * 52 52 D175791 14 14 
0175788 47 46 0178788 33 11 11 33 33 
0175790 25 26 0178790 12 12 24 21 21 
0175787 14 1 7 0178787 45 61 46 54 54 
Figure 3b. 
Marker data for ehromosome 17q21-q22 markers for all available patients in the 
three families with hereditary fronto-temporal dementia. Markers are oriented 
from the eentromerie side to the telomerie side. The hatched boxes indicate the 
maximum region of allele sharing between patients. *Alleles that are shared oniy 
by some patients in the family. Only relatives leading to a common ancestor are 
indicated. Family 11 and Family 111. 
Filled symbols represent affected individuals, question marks in symbols indicate 
that insufficient data were available to determine diagnosis, open symbols indicate 
unaffected individuaIs. 
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alleles were identical by descent (IBD) or just identical by state (IBS). In 
order to determine the size of the critical region far the gene respansible 
far HFTD we therefare compared marker data far affected individuals 
anly (Figure 3 a/b). 
The 5 patients from Family I share a camman allele far 6 of the 
markers tested (Figure 3a). On the centromeric side no sharing was found 
far D17S953, D17S925, D17S933 and D17S946. On the telameric side 
na sharing was abtained far D17S790 and D17S787. The twa patients in 
Family II (Figure 3b) share a cammon allele far all 12 markers that were 
tested and no recombination event could be detected by comparing 
inherited alleles. The !inkage analysis, however, revealed recombination 
events in this family for markers D17S788, D17S790 and D17S787 
(Tabie 3). In Family III (Figure 3b) the patients share at least one allele 
for almost all markerS except far markers D17S791, DI7S788, and 
D 17S787. At least two recombination events must have taken place in this 
family since only 3 out of 5 patients share a common allele for 017S79l. 
These data places the HFTO locus telomeric from D17S946 and 
centromeric from 017S791. The distance between both markers is 5 cM 
on the sex average !inkage map (Figure 2).29 
A common ancestor for the three families could not be traeed 
genealogically. The patients from the th ree families do not share a 
common disease haplotype. This indicates that HFTD in the three families 
is caused by independent mutational events. 
DISCUSSION 
The three families with HFTD described in this study show strong 
clinical and pathological similarities. All patients presented with 
behavioral changes followed by mutism, and sometimes by pyramidal 
and/or extrapyramidal signs in the final phase. Selective atrophy of the 
frontal and temporal lobe is the characteristic feature on CT/MRI and at 
neuropathological examination in all three families. Anterior 
hypoperfusion on SPECT was a common finding . The unifying 
pathological feature in all three families was the selective frontotemporal 
atrophy with aspecific features. Although ballooned cells were present in 
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some cases, Pick bodies were lacking in all. 
There are also some clinical differences between the three families. 
The mean age of onset in Family III was significantly higher than in the 
other two families. Disinhibition was the presenting clinical symptom in 
Families land I1, but loss of initiative in patients of Family lIl. Caudate 
atrophy, degeneration of the substantia nigra and white matter 
involvement found in some brains of the three families might reflect intra-
familial phenotypical variation. Similar observatians are reported in 
hereditary dysphasic dementia and other conditions with a descriptive 
diagnosis.'6.24.26 Ballooned cells were present in same brains of Families I 
and II. The fact that they were lacking in the only autopsied case of 
Family III does not indicate a pathological distinctian from Families land 
I1, since ballooned cells were not found in several brains from these 
families either. 
Family II has been cited as hereditary Pick's disease (HPD) in 
McKusick Mendelian Inheritance of Man. 32 However, if Piek bodies are 
essential for diagnosis Piek's disease then, according to the criteria, this 
family should not be considered as having Pick's disease, since Pick 
bodies were lacking in all cases. It is even doubtful if other earlier 
reported families did have HPD, since most of these families did not 
show Pick bodies 7·IQ Taking into account the contribution of Arnold Pick 
to the recognition of this type of dementia,' one might also re-define and 
re-introduce the diagnosis Piek's disease for all cases with frontotemporal 
atrophy. In that case, frontal atrophy with Pick bodies should be 
considered as a subtype. 
We report linkage of HFTD in three Dutch families to chromosome 
17q21-q22. All families generated positive lod scores with several 
markers from this chromosomal region. None of the families is 
informative enough to generate a significant lod score by itself but 
combining the data from all families gives significant evidence for 
linkage. The clinical heterogeneity of Family III compared with FanlÎlies I 
and II is not reflected in the linkage results. Family III also generated 
positive lod scores for a number of markers (Tabie 3). Two unaffected 
individuals in this family share part of the haplotype that is found in 
patients (data not shown). These individuals are 70 and 75 years of age 
respectively and in the linkage analysis we assumed 95 % penetrance of 
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the disease phenotype at that age. For this reason these individuals are 
regarded by the linkage program as likely recombinant cases, resulting in 
low lod scores curves that had their peak at a considerable recombination 
value from markers. Considering the later onset of the disease in this 
family, the linkage parameters that were used are probably to conservative 
for this specific family. It is still unclear whether these individuals will 
still develop the disease phenotype. Further support that Family III is 
indeed linked to chromosome 17q21 comes from the fact that all five 
patients share a common allele for more then 20 cM on chromosome 
17q21-q22 (Figure 2 and 3b). 
Comparison of marker alleles revealed recombination events in 
affected individuals with a number of markers. Recombinatioll events with 
the markers D 17S946 and D 17S791 define the boundaries of the critical 
region. According to the CEPH/Genethon linkage map these markers are 
separated by a genetic distance of approximately 5 cM. The three families 
do not share a common "disease" haplotype suggesting that independent 
mutations are responsible for the onset of the disease in these families. 
For a number of markers it could not be determined whether the 
shared alleles were IBD or IBS. We are currently constmcting hybrid cell 
lines of all available patients in order to separate the "disease" 
chromosome and the "healthy" chromosome. This will enable us to 
determine whether shared alleles are IBD or IBS. These data could reduce 
the critical region further. 
A large number of genes have been localized on chromosome 17q. 
Several of them are involved in neurological functions or diseases and 
could be regarded as candidate genes for HFTD. Glial fibrillary acidic 
protein (GFAP) is an intermediate-filament protein that is highly specific 
for cells of astroglial lineage (glial fibrillary tangles ). The level of protein 
expression is elevated in patients with Alzheimer disease, Down syndrome 
and scrapie infection'3.35 The exact localization of this gene on 
chromosame 17q is unclear." The nerve growth factor receptor (NGFR) 
is able to bind nerve growth factors and is an essential component in the 
survival and maintenance of sympathetic and sensory neurons"·38 NGFR 
was located on a single restriction fragment of 500 kb with the HOX2B 
gene. 39 According to the mapping data in the Human Genome Database40 
the HOX2B gene is localized within the critical region for HFTD. 
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The microtubule associated protein tau that was localized on the long 
ann of chromosome 17 appears to be involved in the maintenance of 
axonal cytoskeletal structure. The gene is expressed in neurons and its 
transcripi is subject to alternative splicing and post-transcriptional 
modifications. These modifieations can lead to the formation of the paired 
helical filament, which is a major component of neurofibrillary tangles. 
Neurofibrillary tangles in Alzheimer disease41 .42 anel neurofilaments in 
Piek bodies, as observed in sporadic patients with Pick's disease, stain 
intensively with antibodies against phosphorylated tau.43 However, in 
brain tissue of cases of HFTD from this study no Pick bodies were found; 
ballooned cells were observed but they did not stain with antibodies 
against tau. 
Genetic mapping on radiation hybrids places tau between markers 
D17S190 and D17S409.44 These markers are not part of the 
CEPH/Genethon map that was used for this study and it is difficult to 
determine whether tau or one of the other genes mentioned above are 
localized within the critical region. We are currently in the process of 
mapping these genes into the CEPH/Genethon linkage map by using the 
GeneBridge 4 radiation hybrid mapping panel 45 
This study demonstrates linkage in three families with HFTD to 
chromosome 17q21-q22. Rcccntly, linkage was reported to the same 
region of three hereditary neurological disorders with a very strong 
clinical and pathologieal resemblance: disinhibition-dementia-
parkinsonism-amyotrophy complex (DDPAC) ,21 familial progressive 
subcortical gliosis (PSG)22 and autosomal dominant parkinsonism and 
dementia with pallido-ponto-nigral degeneration (PPND).23 Now an 
important question is whether these chromosome 17q21-q22 disorders are 
caused by mutations in the same gene, or whether there are different 
genes in this region that are responsible for these disorders. 
The three conditions show considerable clinical and pathologieal 
overlap with HFTD in age of onset, presenting and subsequent symptoms, 
and most affected brain regions24-26 (Tabie 2). All four conditions share a 
presenile age at onset and most patients show personality and behavioral 
changes as an initial manifestation. The mean age of onset between 
families varies , but this difference is smaller than the intra-familiar 
differences in age of onsel. Brain tissue reveals only general features of 
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degeneration like neuronal cell loss and gliosis. Pick inclusion bodies are 
absent in all cases. Varying degrees of frontal lobe atrophy was present in 
all cases of DDPAC, PSG, and HFTD. In the PPND-family mild 
generalized atrophy with mild neuronalloss and gliosis was found. 
Degeneration of subcortical structures (caudate nucleus, hippocampus and 
substantia nigra) showed a rather similar pattern in all families. 
There are, however, also some differences within the 'chromosome 
17-families'. Firstly, parkinsonism was the only presenting symptom in 
14 out of 26 affected family members of the PPND-family, but only in 
one out of 69 patients of the other families. During the course of the 
disease parkinsonism is also observed in the majority of the patients with 
DDPAC and PSG and in 10 out of 49 patients with HFTD. The absence 
of parkinsonism in the majority of HFTD patients must be interpreted 
with caution because most patients had their neurological examination in 
an early phase of the illness. The actual frequency of parkinsonism might 
have been higher in later phase of the illness. 
Secondly, 5 patients from the PPND-family had dementia as the 
presenting symptom whereas in the other families these were personality 
and behavioral changes. To determine if these manifestations show 
overlap requires a detailed comparison of clinical data. Finally, there was 
a significant difference in age of onset between the first two families and 
third family of the present study. Even if there are some clinical and 
pathological differences between the phenotypes of HFTD, DDPAC and 
PSG these are no basis for a sharp differentiation into separate entities. 
Also the presentation of parkinsonism in PPND seems different from the 
other families, but it needs additional study to establish if this is 
phenotypic variation or locus heterogeneity. 
At this moment it is unknown if these four conditions are genetically 
related. The published data do not allow definition of an overlapping 
critical region for the four disorders. The critical reg ion for the 
responsible genees) for PSG and DDPAC has not yet been determined; 
multi-point linkage analysis for DDPAC suggested a localization between 
D17S800 and D17S787 but these borders are based on healthy "at risk" 
individuals and must be interpreted cautiously. The critical region for 
PPND was determined based on recombination events in affected 
individuals. This region, between markers D17S250 and D17S943 partly 
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overlaps with the critical region for HFTD reported in this paper. 
The currently available data suggest that all four disorders might very 
weil be caused by different mutations in the same gene or even by variant 
expressions of a single mutation. Another explanation might be different 
genes, localized in close proximity of each other, being responsible for 
the four linked neurologieal diseases. The answer to this question requires 
nuther dissection of this region and the identification of its genes. 
In conclusion HFTD is part of a group of neurodegenerative diseases 
with striking clinical and pathological similarities. The critical regions for 
all four disorders show considerable overlap on chromosome 17q21. The 
available clinical and genetical data suggest that this group of disorders 
might be considered as phenotypic variants of the same disorder. The 
discussion whether the group of "chromosome 17 linked neurological 
diseases" should be considered as separate entities, as subtypes of HFTD, 
or even hereditary Pick's disease, wil! only be resolved after the 
identification of the responsible genedefect for these disorders. 
REFERENCES 
1. The Lund and Manchester Groups. Clinical and neuropathological criteria 
for frolltotemporal dementia. J Neurol Neurosurg Psychiatry 1994;57:416-
418. 
2. Sanders J, Schenk VWD, Van Veen P. A family with Pick's disease. 
Verhandelingen der Koninklijke Nederlandsche Akademie van 
Wetenschappen 1939; Section 2, Part 38, No 3, pp 1-124. 
3. Schenk VWD. Re-examination of a family with Pick's disease. Arm Hum 
Gen 1959;23:325-333. 
4. Groen .IJ, Endtz U. Hereditary Piek's disease. Seeond re-examination of a 
large family and discussion of other hereditary cases, with partieular 
referenee !O electroencephalography and computerized tomography. Brain 
1982; 105 :443-459. 
5. Piek A. Über die Beziehungen der senilen Hirnatrophie zur Aphasie. Prag 
med Wochensehr 1892;17:165-167. 
6. Gans A. Betrachtungen über Art und Ausbreitung des krankhaften Prozesses 
in einem Fan von Piekscher Atrophie des Stirnhirns. Z Ges Neurol 
Psychiatr 1923;80:10-28. 
7. Thorpe FT. Piek's disease (eireumscribed senile atrophy) and Alzheimer's 
94 
Hereditary Franto-Temporal Dementia is linked ta chramosame 17 
disease. J Mental Science 1932;78:302-314. 
8. Löwenberg K, Boyd DA, Salon DD. Case reports; occurrenee of Pick's 
disease in early adult years. Arch Neurol Psychiat 1939;41:1004-1020. 
9. Malamud N, Waggoner W. Genealogie and clinicopathologic study of 
Pick's disease. Arch Neurol Psychiatr 1943;50:288-303. 
10. Van Mansvelt J. Pick's disease. A syndrome of lobar cerebral atrophy, its 
clinico-anatomieal and histopathological types. Thesis 1954; Enschede: Van 
der Loeff. 
11. Brun A. Frontal lobe degeneration of non-Alzheimer type. Neuropathology. 
Arch Gerontol Geriatr 1987;6: 193-208. 
12. Tissot R, Constantinidis J, Richard J. Pick's disease. In: Vinken and Bruyn, 
eds: Handbook of Clinical Neurology 1985, North-Holland Publishing 
Company, Amsterdam;46:233-246. 
13. Neary D, Snowden JS, Northen B, Goulding P. Dementia of frontal lobe 
type. J Neurol Neurosurg Psychiatry 1988;51:353-361. 
14. Knopman OS, Mastri AR, Frey WH, Sung JH, Rustan T. Dementia lacking 
distinctive histologie features: a common non-Alzheimer degenerative 
dementia. Neurology 1990;40:251-256. 
15. Miller BL, Cummings JL, Villanueva-Meyer J, Boone k, Mehringer CM, 
Lesser IM, Mena I. Frontal lobe degeneration: clinical, neuropsychological 
aud SPECT characteristics. Neurology 1991;41:1374-1382. 
16. Morris JC, Cole M, Banker BQ, Wright D. Hereditary dysphasic dementia 
aud the Piek-Alzheimer spectrum. Ann Neurol 1984;16:455-466. 
17. Passant U, Gustafson L, Brun A. Spectrum of frontal lobe dementia in a 
Swedish family. Dementia 1993;4:160-162. 
18. Neary D, Pickering-Brown S, Roberts D, Owen P. Apolipoprotein E4 
alleles and non-A1zheimer's disease forms of dementia. Letter. 
Neurodegeneratiou 1993;2:300-1. 
19. Owen F, Cooper PN, Pickering-Brown S, McAndrew C, Mann DMA, 
Neary D. The lobar atrophies are not prion encephalopathies. 
Neurodegeneration 1993 ;2: 195-199. 
20. Collinge J, Palmer MS, Sidle KCL, Mahal SP, Campbell T, Brown J. 
Familial Pick's disease and dementia in frontal lobe degeneration of non-
Alzheimer type are not variants of prion disease. J Neuro1 Neurosurg 
Psychiatr 1994;57:762. 
21. Wilhelmsen KC, Lynch T, Pavlou E, Higgins M, Nygaard TG. Localisation 
of disinhibition-dementia-parkinsonism-amyotrophy complex to 17q21-22. 
Am J Hum Gen 1994;55:1159-1165. 
22. Petersen RB, Tabaton M, Chen SG, Monari L, Richardson SL, Lynches T, 
95 
Chapter 5 
Manetto v, Lanska DJ, Markesbery WR, Currier RD, Autilio-Gambetti L, 
Wilhelmsen KC, Gambetti P. Familial progressive subcortical gliosis: 
presence of prions and linkage to chromosome 17. Neurology 
1995;45: 1062-1067. 
23. Wijker M, Wszolek ZK, Wolters ECH, Rooimans MA, Pals G, Pfeiffer 
RF, Lynch T, Rodnitzky RL, Wilhelmsen KC, Arwert F. Localization of 
the gene for rapidly progressive autosomal dominant parkinsonism and 
dementia with pallido-ponto-nigral degeneration to chromosome 17q21. 
Hum Molec Gen 1996;5:151-154. 
24. Lanska DJ, Currier RD, Cohen M, Gambetti P, Smith EE, Bebin J, 
Jackson JF, Whitehouse PJ, Markesbery WR. Familial progressive subcorti-
cal gliosis. Neurology 1994;44:1633-1643. 
25. Wszolek ZK, Pfeiffer RF, Bhatt MH, Schelper RL, Cordes M, Snow BJ, 
Rodnirzky RL, Wolters EC, Arwert F, Calne DB. Rapidly progressive 
autosomal dominant parkinsonism and dementia with pallido-ponto-nigral 
degeneration. Arm Neurol 1992;32:312-320. 
26. Lynch T, Sano M, Marder KS, BeH KL, Foster NL, Defendini RF, Sima 
AAF, Keohane C, Nygaard TG, Fahn S, Mayeux R, Rowland LP, 
Wilhelmsen KC. Clinical characteristics of a family with chromosome 17-
linked disinhibition-dementia-parkinsonism-amyotrophy complex. Neurology 
1994;44: 1878-1884. 
27. Miller SA, Dykcs DD, Polesky HF. A simple saJting out procedure for 
extracting DNA from human nucleated ceHs. Nucleic Acids Res 
1988;16:1215. 
28. Weber JL, May PE. Abundant class of human DNA polymorphisms which 
can be typed using the polymerase chain reaction. Am J Hum Genet 
1989;44:388-396. 
29. Weissenbach J, Gyapay G, Dib C, Vignal A, Morissette J, MilIasseau P, 
Vaysseix G, Latrop M. A second generation linkage map of the human 
genome based on highly informative microsatellite loci. Nature 
1992;359:794-801. 
30. Information available through the Whitehead Institute World Wide Web site 
(http://www-genome.wi.mit.edu/). 
31. Lathrop GM, Lalouel JM. Easy calculations of lodscores and genetic risks 
on a small computer. Am J Hum Genet 1984;36:460-465. 
32. Online Mendelian Inheritance in Man. Catalogs of autosomal dominant, 
autosomal recessive, and X-linked phenotypes, available through World 
Wide Web (http://www3.ncbi.nlm.nih.gov/Omimi). 
33. Duguid JR, Bohmont CW, Uu N, TourteHotte WW. Changes in brain gene 
96 
Hereditary Franta-Temparal Dementia is linked ta chramasame 17 
expression shared by scrapie and Alzheimer disease Proc Natl Acad Sci 
USA 1989;86:7260-7264. 
34. Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot U, White 
CL, Araoz C. Brain Interleukin 1 and S-100 immunoreactivity are elevated 
in Down syndrome and Alzheimer disease. Proc Nat! Acad Sci USA 
1989;86:7611-7615. 
35. Wietgrefe S, Zupancic M, Haase A, Chesebro B, Race R, Frey W, Rustan 
T, Friedman RL. Cloning of a gene whose expression is increased in 
scrapie and senile plaques in human brain. Science 1985;230:1177-1179. 
36. Brownell E, Lee AS, Pekar SK, Pravtcheva D, Ruddle FH, Bayney RM. 
Glial fibriUary acid protein, an astrocytic-specific marker maps to human 
chromosome 17. Genomics 1991;10:1087-1089. 
37. Chao MV, BothweU MA, Ross AH, Koprowski H, Lanahan AA, Buck CR, 
Sehgal A. Gene transfer and molecular cloning of the human NGF receptor. 
Science 1986;232:518-521. 
38. Johnson D, Lanahan A, Buck CR, Sehgal A, Morgan C, Mercer E, 
Brothwell M, Chao M. Expression and structure of the humau NGF 
receptor. CeU 1986;47:545-554. 
39. Bentley KL, Ferguson-Smith AC, Miki T. Physicallinkage of Hox 2.1 and 
nerve growth factor receptor. Cytogenet CeU Genet 1989;51:961. 
40. Human Genome DataBase, available through World Wide Web 
(hup:/ /gdbwww.gdb.org/) 
41. Goedert M, Wischik CM, Crowther RA, Walker JE, Klug A. Cloning and 
sequencing of the cDNA encoding a core protein of the p,tired helical 
filament of Alzheimer disease: identification as the microtubule-associated 
protein tau. Proc Nat Acad Sci USA 1988;85:4051-4055. 
42. Kosik KS. Tau protein and neurodegeneration. Mol Neurobiol 1990;4:171-
179. 
43. Murayama S, Mori H, !hara Y, Tomonaga M. Immunocytochemical and 
ultrastructural studies of Pick's disease. Ann Neurol 1990;27:394-405. 
44. Abel KJ, Boehnke M, Prahalad M, Ho P, Flejter WL, Watkins M, 
Vanderstoep J, Chandrasekharappa SC, Collins FS, Glover TW. Aradiation 
hybrid map of the BRCA1 region of chromosome 17qI2-q21. Genomics 
1993; 17:632-641. 
45. Gyapay G, Schmitt K, Fizames C, Jones H, Vega-Czamy N, Spillett D, 
Muselet D, Prud'Homme JF, Dib C, Auffray C, Morisette J, Weissenbach 
J, GoodfeUow PN. Aradiation hybrid map of the human genome. Hum 
Molec Genet 1996;5:339-346. 
97 

Chapter 6 
CIiinical heterogeneity 
• m 
Fronto-Temporal Dementia 
linked to chromosome 17 
(submitted for publication) 
Chapter 6 
CLINICAL HETEROGENEITY 
IN FRONTO-TEMPORAL DEMENTIA 
LINKED TO CHROMOSOME 17 
INTRODliCTION 
Fronto-temporal dementia (FTD) is a common non-Alzheimer type of 
preseniIe dementia with frontal and temporal involvement, and behavioral 
rather than memory problems. ,-4 Among FTD cases a familialor genetic 
form is suggested by the family history in 20-50% of cases.'" An 
autosomal dominant inheritance is documented in Northem European 
families and different designations are known, such as hereditary Pick's 
disease .'·14 
Genetic and clinical heterogeneity among the familial fronto-temporal 
dementias became recently documented. Disinhibition-dementia-
parkinsonism-amyotrophy complex linked to chromosome 17q21-q22 was 
the first disorder localized to this chromosomal area. 15 It was followed by 
about 10 families with hereditary FTD, including three from The 
Netherlands." The descriptive diagnoses included familial progressive 
subcortical gliosis, presenile dementia with psychosis and dementia with 
pallido-ponto-nigral degeneration. 17' 22 
This study reports three Dutch FTD families, genetically linked to 
chromosome 17q2-q22; the intra- and inter-familial differences in 
presenting symptomatology and age of onset and their ApoE genotype as 
a possible approach to risk differentiation. 
METHODS 
A nation-wide, three years (1994-1997) genetic-epidemiological study 
of fronto-temporal dementia in the N etherlands identified three large 
families in the Netherlands. These families were apparently unlinked, as 
demonstrared by genealogical studies up to 1800, showing no interfamilial 
connections . Dementia was transmitted as an autosomal dominant disorder 
in all three families. 
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Clinical infoffi1ation on affected cases was obtained by proxy 
interviews with first degree relatives and spouses, and infoffi1ation from 
clinicians and medical records. The age of onset was established from the 
ages at which behavioral changes developed as remembered by more than 
one relative. Early (first two years) and subsequent (from 2 years after 
onset) symptoms were obtained using a checklist of frontal features. 
Complete clinical infoffi1ation was available on 18 cases (8 alive) in 
family I, and 21 cases (2 alive) in family II and 10 cases (3 alive) in 
family lIL'·JO Partial neuropsychological data were available on 12 cases 
in family I, 16 cases from family Il and 5 cases from family HI. 
Complete data were present on 3, 1 and 1 cases respectively. 
CT scans were available in 23 cases (10 in family I, 6 in family Il, 
and 7 in family HI). 15/23 CT scans were reviewed by RT. MRI was 
available on three patients in family 1. Six SPECT analyses were 
performed (3 in family I, 1 in family Il and 2 in family HI). 
DNA studies were done on peripheral 1eukocytes after infoffi1ed 
consent by proxy. ApoE genotyping was perfoffi1ed according to Reymer 
et al. 23 
A neuropathological diagnosis of FTD was available in 14 cases in 
family I (6 of these with a documented clinical history), in 15 cases from 
family II (11 of these fully clinically documented) and one case in family 
HI. Neuropathological review of brain tissues (JMK, WK) was done on 5 
cases (family I), 5 cases (family lI) and 1 case (family HI). Sections of 
different cortieal regions, basal ganglia and pons were re-stained 
(hematoxylin-eosin and Bodian) and analyzed for Piek bodies and 
ballooned eells. Immunohistochemistry was done using antibodies against 
ubiquitin (1: 125; Novoeastra), 7 (1:400; Dako, no. A 024), paired helical 
filaments (PRF)(1:100; ICN), somatodendritic mierotubules assoeiated 
protein (MAP-2)(1: 170; Zymed), and Il-amyloid (1:600; Novoeastra). A 
conventional peroxidase- anti-peroxidase method was used for staining. 
Age and sex matched controls (noffi1al and with Alzheimer's disease) 
were used for eomparison. 
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RESULTS 
Clinical features 
A relative early (TabIe I) mean age of onset (50.4 years, family land 
46.5 years, family U) was seen in family I and U. The majority of 
affected cases manifested before 57 years. A significantly later onset 
(mean 63.4 years) was found in family III (p < 0.001) (Figure I). 
However, the mean duration of illness was similar in the three families 
(8.2-8.7 years, range 4 to 16 years). The mean age of death differed from 
early (58.6 and 54.7 years) in families I and U to 71.9 years in fanüly III 
(p < 0.001). The clinical evolution, the mean age of onset and of death 
remained stabIe over consecutive generations in the different families. The 
sex ratio of affected men and women was 2 to 5 in family U, and I to 1 
in families I and UI. 
Progressive behavioural changes and speech reduction during the 
disease were found in all cases (TabIe I). Disinhibition was the presenting 
symptom in 17 (94%) of family I-cases and 18 (86%) of family U-cases. 
However, loss of initiative was the major presenting symptom in family 
III (80%), with disinhibition developing only later. Hyperorality (76-
90%), restlessness (60-83%) and stereotypic behavior (89-95%) occurred 
as an early or late symptom in all patients, sinlilarly as a reduction of 
spontaneous speech (100%), and word finding difficulties (10-28%). 
Delusions (10-22%) were less frequent. Neurological evaluation early in 
the disease was normal, except for frontal release reflexes in some cases. 
Later, pyramidal (10-19%) and extrapyramidal signs (14-28%) occurred. 
The neuropsychological profile, based on 5 cases with complete 
evaluation, showed associative and perseverative conduct, and decreased 
attention, concentration and initiative, and impaired abstraction, planning, 
and menta1 shifting. Visuoconstruction, orientation and praxis remained 
normal. In the remaining cases with partial data perseveration (88 %), 
impaired executive skills (38 %), decreased verbal fluency and speech 
reduction (54 %) were frequently found. Orientation and memory 
functions were usually normal or only nlildly impaired. 
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Table 1. 
Demograplnic and clinical characteristics in three families 
with chromosome 17 linked hereditary fronto-temporal dementia. 
Age of onset (range) 
Duration (range) 
Age of death (range) 
Restles~mess 
Disinhihition 
Hyperorality 
Stereotyped behavior 
Loss of initiative 
Delusions 
Decreased speech 
Imaging (CT) 
Atrophy: 
frontal ~ temporal 
temporal > frootat 
na abnonnalities 
asymmetry 
Family I 
n = 18 
50.4 (44-65) 
8.2 (4-15) 
58.6 (53-67) 
early' 
(%) 
44 
94 
39 
33 
61 
28 
22 
n = 10 
8 
1 
1 
2 
late" 
(%) 
83 
100 
89 
89 
100 
39 
100 
Family II 
n = 21 
46.5 (40-53) 
8.3 (5-15) 
54.7 (49-62) 
early 
(%) 
43 
86 
48 
67 
62 
10 
19 
0=6 
6 
o 
o 
o 
late 
(%) 
67 
95 
76 
95 
86 
19 
100 
* 
** 
# 
## 
Meao age of onsel in patients from family m significantly higher (p<O.OOl). 
Meao age of death in patients from family III significantly higher (p <0.001), 
Early: manifesting during firsuwo years after disease onsel. 
Late: manifesting ~ 2 years after disease onset. 
Family III 
n = 10 
63.4 (57-75)* 
8.7 (6-16) 
71.9 (63-81)** 
early 
(%) 
40 
30 
20 
10 
80 
20 
10 
0=7 
5 
1 
2 
late 
(%) 
60 
100 
90 
90 
100 
30 
100 
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Figure 1. 
Mean age of onset in three families with 
chromosome 17 linked 
hereditary fronto-tem poral dementia 
* = Mean age of onsel in family III (63.4 years) is significantly higher lhan 
in family I (50.4 years) and family II (46.5 years). 
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lmaging studies 
On brain CT, 1 to 5 years after onset of the disease (TabIe 1) 
frontotemporal atrophy was seen in 21/23 cases. Temporal involvement 
was usually limited to the anterior pole. Two CT scans were normal. The 
severity of frontal atrophy usually (19/21) exceeded or was similar to 
temporal atrophy; temporal atrophy was predominant in 2/21 cases. The 
frontotemporal atrophy was symmetrical in 19/21 cases. Mild asymmetrie 
ventricular dilatation was seen in 4 cases. The atrophy in families I-III 
was similar in degree and distribution. Jncreased signal intensities in the 
frontal subcortical white matter were seen on T2-weighted MRJ images in 
two of three cases (see Figure 2). Frontotemporal hypoperfusion was 
found on 6/6 cases analyzed by SPECT (Figure 3); two of these had a 
normal CT scan. Anterior cerebral hypoperfusion increased during yearly, 
serial SPECT observations in one patient. 
ApoE genotypes 
ApoE genotyping was obtained in 7 cases (family I), 2 cases (family 
II), and 5 cases (family II1)(Table 3). The frequency of ApoE2E2 was 
7%, of ApoE2E3 36%, and of ApoE3E3 57%, and the ApoE4 allele was 
absent in all cases. 
Pathology 
The mean brain weight was 1035 g (n= 14; range 855-1230 g) in 
family J, 920 g (n=15; range 730-1250 g) in family II, and 1170 g in the 
case from family lIl. Frontal atrophy was a consistent feature and anterior 
temporal atrophy was nearly constant (TabIe 2). Asymmetrieal, 
predominant left frontotemporal, atrophy was found in 3 brains from 
family I. Degeneration of the caudate nucleus was found in 19 cases (in 
family I 9/14, in family II 9/15, and in family III 1/1). Neuronalloss, 
gliosis and spongiosis in the frontal and temporal cortex were constant 
findings. Substantia nigra degeneration was seen in 4/14 brains from 
family land 4/15 in family 11, and in the single case of family lIl. White 
matter demyelination and gliosis were found in 6/14 cases (family I), 5/15 
cases (family II) and 1/1 case (family III). Sporadic neurofibrillary tangles 
were seen in !he hippocampus in one case from family I and vague seniIe 
plaques were seen in the temporal lobe in another case from family I. 
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Figure 2. MRI scan of a patient from family I showing increased signa! 
intensities in the subcortica! white matter of the fronta! lobe on T2-weighted 
images. 
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Figure 3. SPEeT scans of a patient from family I showing marked 
frontotemporal hypoperfusion. 
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Table 2. 
l'athology in three families with chromosome 17 Iinked 
hereditary fronto-temporal dementia. 
Family I Family 11 Farnily III 
n = 14 n = 15 n = 1 
Macroscopical atrophy 
- frontal 14 15 
- temporal IO 14 
- caudale nucleus 9 9 
Microscopical changes 
- white matter 6 5 
- nigral degeneration 4 4 
- ballooned eells 7 5 0 
- Piek badies 0 0 0 
Table 3. 
ApoE genotypes in three families with chromosome 17 Iinked 
hereditary fronto-temporal dementia. 
Family patient ApoE genotype Age of onset Duration (at death) 
E2E2 65 
2 E2E3 45 8 
3 E2E3 44 
4 E2E3 53 
5 E3E3 54 
6 E3E3 56 11 
7 E3E3 57 
11 1 E3E3 50 
11 2 E3E3 44 
1lI E2E3 75 
1lI 2 E2E3 57 
1lI 3 E3E3 70 
1lI 4 E3E3 57 IO 
1lI 5 E3E3 64 
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Pick bodies were observed neither initially nor on revision but for one 
case in family Il. Ballooned neurons in cortex and/or basal ganglia were 
present in 7/14 cases (family I), 5/15 cases (family 11), and 0/1 case 
(family HI). No paired helical filaments, Jl-amyloid, T or ubiquitin were 
observed by immunohistochemistry (see Methods for antibodies used). 
Scattered and granular staining for MAP-2 was seen in neurons and glia 
in two cases. 
DISCUSSION 
Clinical heterogeneity for age of onset and presenting symptoms is 
observed in three Dutch families with FTD linked to chromosome 17. 
Brain atrophy is generally symmetrical as is shown by imaging and 
pathological studies. The ApoE4 allele was absent among cases tested and 
this suggests that ApoE4 does not influence the phenotype in familial 
cases with FTD as also recently reported by US.2'.25 
The age at onset in families land 11 is quite constant over the 
generations (between 45 and 57 years); anticipation through an expanding 
trinucleotide repeat mechanism is thus very unlikely. The relatives at risk 
consider reaching the age of 55 as coming into the safety zone for 
developing dementia. A significantly higher mean age of onset (63.4 
years; range 57-75 years) is present in family III. Other families with 
fronto-temporal dementia linked to chromosome 17 (FTD-17) show even 
a wider range between 27 and 74 years.,2.26 The mean duration of illness 
in the present families (8.2-8.7 years) is similar as seen in most other 
FTD-17 families; however, shorter duration and a few longer disease 
courses up to 26 years were reported 22.26.27 The variation in age of onset 
within the Dutch families could not be explained by the distribution of the 
ApoE genotype, as has also been shown in presenilin families." 
Further clinical variability in FTD-17 is shown by the frequent 
disinhibition in families land 11, and other reported families'2.".l9.26.27.2', 
while loss of initiative as prominent feature in family HI might lead to an 
erroneous clinical diagnosis of Alzheimer's disease. Speech impairments 
developed gradually in all cases in this study. The early occurrenee of 
dysphasia (reduction of spontaneous speech and of fluency), dysnomia and 
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impaired comprehension is characteristic for hereditary dysphasic 
dementia, in which linkage to chromosome 17 also was established."·30 In 
that family. the temporal area might be affected early on in the disease as 
an enlarged temporal hom on CT has been found in one case. 12 
Psychiatric symptoms, as delusions and paranoid ideas, were rarely seen 
in our study, but were frequent in familial presenile dementia with 
psychosis27. and an initial diagnosis of schizophrenia was often made as in 
a few other patients from other FTD-17 families. 26.27 
Parkinsonism is another variabIe feature of FTD-17. It was seen 
during the course of FTD in some cases in this study, but is the 
presenting sign in more than half of cases with pallido-ponto-nigral 
degeneration with parkinsonian signs. 18 Reduced striatal tracer uptake was 
seen in 4 patients with this disorder 18 The nigrostriatal dopaminergic 
pathway needs to be analysed in other FTD-17 families as weIl. 
Degeneration of substantia nigra, a rather constant feature of FTD-17, 
was cJearly present in 9/30 cases in our study; however detailed 
neuropathological reports did not routinely mention the aspect of the 
substantia nigra. 
A symmetrical frontotemporal atrophy on CT was found in all but 
four Dutch cases, the latter having asymmetric ventricular enlargement. 
Such an asymmetric pattem is also found in hereditary dysphasic dementia 
and the Swedish FTD-17 family."·22 Frontal atrophy on CT was absent in 
two early FTD-17 cases, but frontal hypoperfusion was shown by SPECT 
in these cases. Absence of frontal atrophy has been found in other 
(familial) FTD cases.'·I'.'1 The frontotemporal atrophy was severe in all 
cases in our families, as contrasting to mild in disinhibition-dementia-
parkinsonism-amyotrophy complex and pallido-ponto-nigral 
degeneration. 18.19 White matter gliosis induces increased signal intensity 
on T2-weighted MRI images as seen in 2 patients (Figure 2), which is 
also documented in neuropathological studies, and shows similarities to 
familial subcortical gliosis. I' 
Tau abnormalities were absent as studied by conventional 
immunocytochemistry in our families. Abnormal tau positive neuronal and 
glial incJusions (hyperphosphorylated sites) have been described in some 
FTD-17 families, using anti-tau antibodies (AT 8, AT 270, AT 100, AT 
180, PHFl).27."'" Studies with identical antibodies in the Dutch and other 
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families may be helpfui to see if there is an FTD subgroup with a 'tau-o-
pathy'; and whatever role tau has as a primary or secondary phenomenon 
in the disease. 
Interfamilial phenotypical variation might be caused by different 
mutations in the same gene or in different genes. The patients from the 
three families do not have a common haplotype for the locus of the 
disease-gene. The disorder in these three families may be caused by 
independent mutational events. 16 The identification of an FTD gene and its 
mutational heterogeneity may give further insight into the causes of the 
clinical variability in these families. 
REFERENCES 
1. Van Mansvelt J. Pick's disease. A syndrome of lobar cerebral atrophy, its 
clinico-anatomical and histopathological types. Thesis University Utrecht 
1954;Enschede:van der Loeff. 
2. Tissot R, Constantinidis J, Richard 1. Piek's disease. In: Vinken and Bruyn, 
eds: Handbook of Clinical Neurology 1985, North-Holland Publishing 
Company, Amsterdarn;46:233-246. 
3. Cummings JL, Benson DF. Cortical dementias: Alzheimer's disease and 
other cortical degenerations. Ch III in Dementia: a clinical approach. 
Butterworths-Heinemann, Boston, 1992, pp 75-93. 
4. Mendez MF, Selwood A, Mastri AR, Frey WH. Pick's disease versus 
Alzheimer's disease: a comparison of clinical characteristics. Neurology 
1993;43:289-292. 
5. Giannakopoulos P, Hof PR, Bouras C. Dementia lacking distinctive 
histopathology: clinicopathological evaluation of 32 cases. Acta Neuropathol 
1995;89:346-355. 
6. Gustafson L. Frontal lobe degeneration of non-Alzheimer type. Clinical 
picture and differential diagnosis. Arch Gerontol Geriatr 1987;6:209-223. 
7. Gustafson L. Clinical picture of frontal lobe degeneration of non-Alzheimer 
type. Dementia 1993;4: 143-148. 
8. Neary D, Snowden JS, Northen B, Goulding P. Dementia of frontal lobe 
type. J Neurol Neurosurg Psychiatry 1988;51:353-361. 
9. Schenk VWD. Re-exarnination of a farnily with Pick's disease. Ann Hum 
Gen 1959;23:325-333. 
10. Groen 11, Endtz U. Hereditary Pick's disease. Second re-exarnination of a 
111 
Chapter 6 
large family and discussion of other hereditary cases, with particular 
reference to electroencephalography and computerized tomography. Brain 
1982; 105 :443-459. 
IJ. McKusick VA. Mendelian inheritance in man. Catalogs of autosomal 
dominant, autosomal recessive, and X-linked phenotypes. The John 
HopkiI1S University Press, Baltimore and Londen 1990, 9th edition. 
12. Morris JC, Cole M, Banker BQ, Wright D. Hereditary dysphasic dementia 
and the Piek-Alzheimer spectrum. Ann Neurol 1984; 16:455-466. 
13. Passant U, Gustafson L, Brun A. Spectrum of frontal lobe dementia in a 
Swedish famil y. Dementia 1993; 4: 160-162. 
14. Kim RC, Collins GH, Parisi JE, Wright AW, Chu YB. Familial dementia 
of adult onset with pathological findings of a 'non-specific' nature. Brain 
1981; 104:61-78. 
15. Wilhelmsen KC, Lynch T, Pavlou E, Higgins M, Nygaard TG. Localization 
of disinhibition-dementia-parkinsonism-amyotrophy complex to 17q21-22. 
Am J Hum Gen 1994;55: 1159-1165. 
16. Heutink P, Stevens M, Rizzu P, Bakker E, Kros JM, Tibben A, Niermeijer 
MF, Duijn CM van, Oostra BA, Van Swieten JC. Hereditary 
frontotemporal dementia is linked to chromosome 17q21-q22: A genetic and 
clinicopathological study of three Dutch families. Arm Neurol 1997;41: 150-
159. 
17. Wijker M, Wszolek ZK, Wolters ECR. Rooimans MA, Pals G, Pfeiffer 
RF, Lynch T, Rodnitzky RL, Wilhelmsen KC, Arwert F. Localization of 
the gene for rapidly progressive autosomal dominant parkinsonism and 
dementia with pallido-ponto-nigral degeneration to chromosome 17q2J. 
Hum Molec Gen 1996;5:151-154 
18. Wszolek ZK, Pfeiffer RF, Bhatt MH, Schelper RL, Cordes M, Snow BJ, 
Rodnitzky RL, Wolters EC, Arwert F, Calne DB. Rapidly progressive 
auosomal dominant parkinsonism and dementia with pallido-ponti-nigral 
degeneration. Arm Neurol 1992;32:312-320. 
19. Lanska DJ, Currier RD, Cohen M, Gambetti P, Smith EE, Bebin J, 
Jackson JF, Whitehouse PJ, Markesbery WR. Familial progressive 
subcortical gliosis. Neurology 1994;44: 1633-1643. 
20. Petersen RB, Tabaton M, Chen SG, Monari L, Richardson SL, Lynches T, 
Manetto V, Lanska DJ, Markesbery WR, Currier RD, Autilio-Gambetti L, 
Wilhelmsen KC, Gambetti P. Familial progressive subcortical gliosis: 
presence of prions and linkage to chromosome 17. Neurology 
1995 ;45: 1062-1067. 
2J. Bird TD, Wijsman EM, Nochlin D, Leehey M, Sumi SM, Payami H, 
112 
Clinical heterogeneity in Fronto-Temporal Dementia 
Poorkaj P, Nemens E, Rafkind M, Schellenberg GD. Chromosome 17 and 
hereditary dementia: linkage studies in three non-Alzheimer families and 
kindreds with late-onset FAD. Neurology 1997;48:949-954. 
22. Basun H, Almkvist 0, Axelman K, Brun A, Campbell TA, Collinge J, 
ForselI C, Froelich S, Wahlund L, Wetterberg L, Lannfelt L. Clinical 
characteristics of a chromosome 17-linked rapidly progressive familial 
frontotemporal dementia. Arch Neurol 1997;54:539-544. 
23. Reymer PWA, Groenemeyer BE, Burg R van de, Kastelein JJP. 
Apolipoprotein E genotyping on agarose gels. Clinical Chemistry 
1995;41: 1046-1047. 
24. Stevens M, Van Duijn CM, De Knijff P, Van Broeckhoven C, Heutink P, 
Oostra BA, Niermeijer MF, Van Swieten JC. Apolipoprotein E gene and 
sporadic frontallobe dementia. Neurology 1997;48:1526-1529. 
25. Stevens M, Van Duijn CM, Kamphorst W, De Knijff P, Helltink P, Van 
Gooi WA, Scheltens P, Ravid R, Oostra BA, Niermeijer MF, Van Swieten 
Je. Familial aggregation in fronto-temporal dementia. Neurology 1998 in 
press. 
26. Lynch T, Sano M, Marder KS, Bell KL, Foster NL, Defendini RF, Sima 
AAF, Keohane C, Nygaard TG, Fahn S, Mayeux R, Rowland LP, 
Wilhelmsen KC. Clinical characteristics of a family with chromosome 17-
linked disinhibition-dementia-parkinsonism-amyotrophy complex. Neurology 
1994;44:1878-1884. 
27. Sumi SM, Bird TD, Nochlin D, Raskind MA. Familial presenile dementia 
with psychosis associated with cortical neurofibrillary tangles and 
degeneration of the amygdala. Neurology 1992;42: 120-127. 
28. Bird TH, Levy-Lahad E, Poorkaj P, Sharma V, Nemens E, Lahad A, 
Lampe TH, Schellenberg GD. Wide range in age of onset for chromosome 
I-related familial Alzheimer's disease. Ann Neurol 1996;40:932-936. 
29. Yamaoka LH, Welsh-Bohmer KA, Hulette C, Gaskell G, Murray M, 
RimmJer JL, Helms BR, Guerra M, Roses AD, Schmechel DE, Pericak-
Vance MA. Linkage of frontotemporal dementia to chromosome 17: clinical 
and neuropathological characterization of phenotype. Am J Hum Genet 
1996;59: 1306-1312. 
30. Lendon CL, Shears S, Busfield F, Talbot CJ, Renner J, Morris JC, Goate 
AM. Molecular genetics of hereditary dysphasic dementia. Neurobiol Aging 
1994; 15:S128. 
31. Knopman DS, Mastri AR, Frey WH, Sung JH, Rustan T. Dementia lacking 
distinctive histologie features: a common non-Alzheimer degenerative 
dementia. Neurology 1990;40:251-256. 
113 
Chapter 6 
32. Spillantini MG, Crowther RA, Goedert M. Comparison of the 
neurofibrillary pathology in Alzheimer's disease and familial presenile 
dementia with tangles. Acta Neuropathol 1996;92:42-48. 
33. Spillantini MG, Goedert M, Crowther RA, Murrell JR, Farlow MR, Ghetti 
B. Farnilial multiple system tauopathy with presenile dementia: a disease 
with abundant neuronal and glial tau filaments. Proc Natl Acad Sci 
1997;94:4113-4118. 
34. MUITell JR, Koller D, Foroud T, Goedert M, Spillantini MG, Edenberg HJ, 
Farlow MR, Ghetti B. Familial multiple-system tauopathy with presenile 
dementia is localized to chromosome 17. Am J Hum Genet 1997;61:1131-
1138. 
35. Foster NL, Wilhelmsen K, Sima AAF, Jones MZ, D' Amato CJ, Gilman S 
and conference participants. Frontotemporal dementia and parkinsonism 
linked to chromosome 17: a consensus conference. Arm Neurol 
1997;41 :706-715. 
114 
Chapter 7 
Once revealed, no more to be 
concealed: 
piitfaHs in genetic research 
on neurodegenerative disease: 
the case of 
Fronto-Temporal Dementia 
(subrnitted for publicatiou) 
Chapter 7 
ONCE REVEALED, NO MORE TO BE CONCEALED: 
PITFALLS IN GENETIC RESEARCH 
ON NEURODEGENERATIVE DlSEASE: 
THE CASE OF FRONTO-TEMPORAL DEMENTIA 
INTRODUCTION 
General introduction 
An increasing number of neurodegenerative diseases is becoming 
defined at the molecular level since the last decade, enabling improved 
diagnosis and presymptomatic testing in late-onset disorders . Examples 
are Huntington disease, hereditary cerebral hemorrhage with amyloid-
Dutch type, inherited cerebral ataxia, myotonic dystrophy, Alzheimer 
disease and many others. I.6 The rate of detection of defects is increasing, 
especially in dominant disorders. Finding mutations in a gene often leads 
to fundamental insight into the normal and pathological functions of this 
gene. However translation of this knowledge into effective 
pharmacological or gene therapy for late onset neurodegenerative 
disorders is not expected in the immediate future. 
Although gene loca!ization and identification are obviously necessary 
steps to understand the etiology and molecular-genetic aspects of early 
and late-onset dementias , pedigree and !inkage studies may be an 
underestimated burden for participants in families with a hereditary 
disease. Relatives may leam about their own risk for the first time 
through participation. 7 Facing the threat of an appalling disease can cause 
a variety of psychologieal, legal, and ethical problems for individuals at 
risk, which problems are of ten unfamiliar to clinicians and scientists. '·13 
Psychosocial effects of predictive DNA -testing have been extensively 
studied in Huntington families.'·12·14.16 Little attention has been given to 
the effects of conducting family studies for establishing !inkage and gene 
identification. 
In a neurogenetic study on early-onset fronto-temporal dementia,17·I' a 
careful study design attempted to prevent psychological distress when 
participams might become aware of their personal risks. The present 
paper describes several medical-ethical dilemmas not foreseen in the study 
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protocol, which required ad hoc decisions. This experience may 
contribute to improvement of genetic research protocols . 
Fronto-temporal dementia 
Fronto-temporal dementia (FTD), including Pick's disease, is a 
degenerative type of dementia, with onset usually in the fOUlth to sixth 
decade and with a duration of illness of 5-10 years. FT)) is of ten 
sporadic, but a familial type is present in 20-40 % . ]9·22 The personality and 
behavioral changes (especially disinhibition), restlessness, stereotyped and 
perseverative behavior, emotional insensitivity with loss of insight and 
impaired judgement have a great impact on care givers and relatives. No 
specific treatment is available, but paIliative interventions for behavioral 
disturbances are now being explored. Most patients are admitted 111 a 
nursing home when they become mute and severely demented. 
METf-IODS 
The Research Program 
In a collaborative program on neurogenetics, patients with FTD 
(either sporadic or familia!) were recruited from the Dutch population. 
This study included clinical, genetic-epidemiological and pathological 
aspects. Participation was asked from all neurological, psychiatric and 
geriatric centers to report data on patients with FTD, with the consent of 
the patient or his/her legal representative. Three large families were 
identified, showing an autosomal dominant transmission of FTD over 5 to 
7 generations, and genetic linkage study allowed gene localization to 
chromosome 17 q21-q22. 17.18 
A family study implies that the investigators bear legal and ethical 
responsibilities to inform their subjects adequately. 23 All referred patients 
and their spouses or close relatives were requested to participate in the 
study through a letter handed out by the referring clinician. 
At the interview (often held at the homes of patients/relatives) patients 
and their representatives were informed about the disease, its genetics, 
and the aims of the genetic study. A clear distinction was made between 
the research phase of the study: no information on the personal genetic 
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status would be disclosed. Later on, those wishing personal information, 
when linkage or a mutation would be established, could make an 
individual request at that time, for personal risk assessment and 
counseling after taking another blood sample. We did not want to harm 
individuals who only wanted to participate for scientific research. When 
the family history suggested more FTD cases, we asked the first 
participant to inforrn his/her relatives of this study and request, by means 
of an information letter, for participation as weIl. 24 
After giving adequate information, and establishing that this was 
understood, written consent was obtained. 
The patient's medical records were reviewed, and the medical history 
was completed with information from the patient, the spouse or close 
relatives. The family history was obtained and checked for similar or 
related diseases in the first and other degree relatives. Genealogical 
searches using population registration data from 1800 onwards allowed 
linkage of pedigrees. 
Clinical data on patients, obtained in our or other hospitaIs, included 
a general medical examination, neurological examination, 
neuropsychological testing, brain imaging (Computerized tomography 
(CT)/Magnetic Resonance Imaging (MRI) or Single Photon Emission 
Computerized Tomography (SPECT». A blood sample was taken for 
DNA isolation. 
Participating relatives at risk contributed a DNA sample. To prevent 
dissemination of unwanted information, doctors seeing the families were 
kept unaware of the distribution of the 'disease' haplotype in the pedigree. 
It was mentioned that localization or identification of the gene might 
enable predictive testing. Participants who asked for defining their 
personal risk status were referred to the clinical genetics department for 
genetic counseling and psychological support. 25 
The study protocol was approved by the Medical Ethics Cornrnittee of 
the University Hospital Dijkzigt, Rotterdam. 
The ethical background of the research protocol 
The protocol was based upon two moral key principles for involving 
individuals as subjects of research: respect for autonomy, and 
beneficence. Respect for autonomy implies that the inforrned consent of 
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the potential research partIcIpant must precede involvement in the 
research." The information must be adequate and allow comprehension 
and 'informed decisions' by the research subject. Subjects should be told, 
amongst others, about the purpose, limitations, and possible outcomes of 
the study. Possible benefits and risks should be communicated in a 
balanced way. The consent component of informed consent refers to a 
voluntary decision on the part of a competent person. In case of 
incompetence of a candidate research subject, proxy consent of a 
representative should be obtained. The principle of beneficence c.q. 'do 
not harm' obliges the researcher to protect the best interests of research 
subjects. The relationship of risks to benefits should be assessed 
independently, and based on available data. 
It was decided that personal results from the linkage or mutation 
research would not be communicated without an independent request for 
personal risk assessment and genetic counseling. Reasons for this 
approach are: (1) consent for a family study should not imply automatic 
identification of the at risk status for a late onset disorder, (2) there is 
often a long delay (> 2 years) before practical linkage or mutation 
analysis becomes possible, (3) an independent blood sample handled in a 
diagnostic laboratory is always needed to obtain areliabie personal risk 
assessment. 
CASE-REPORTS 
Case 1.' the issue of beneficence.' clinical versus research roles 
The medical specialist who is also involved in research programs has 
the potential conflict of approaching the patient as a doctor (what is good 
medical practice?) or as a researcher (how will research benefit from this 
patient?).25.27 It can be a dilemma to balance between on the one hand the 
importance of participation of a patient for the ongoing research in FTD, 
and on the other hand the necessity to avoid possible harm to patient and 
family. Another dilemma concerns the timing of asking consent. In the 
next case the dilemmas regarding the issue of beneficence, and balancing 
between clinical care and research interests are discussed. 
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Clinical course 
A 47 year-old woman (married, three adolescent children) was 
referred to our clinic with a two year history of progressive changes in 
her behavior. Previously an efficient, serious and hard-working person 
she became slowly and progressively absent-minded, and neglected her 
domestic responsibilities. Her conduct became impulsive and restless. She 
was easily irritated and exhibited a rigid inflexibility in thinking. She 
walked an identical route every day regardless the weather. She lost 
emotional concern for her family. Obsessive economizing developed as 
she stopped buying groceries and new clothes. She nearly lacked any 
insight in her altered behavior and relations. 
Neuropsychological and neurological examination, and imaging 
studies confirmed the clinical diagnosis FTD. Her mother died in a 
nursing home at the age of 62 with adementing illness. Mother's father 
died in psychiatrie hospital at the age of 70. Despite this family history 
the spouse and children were not aware that adementing illness could be 
running in the family. 
The clinician, who was member of the research team, recognized the 
name of the patient's grandfather as potentially belonging to a large 
kind red already known with hereditary FTD. Genealogical research, 
performed with the family' s consent - as part of the diagnostic process -
showed thaI this family was indeed related to the large FTD kindred. 
Outcome of this cas e 
The outcome of the genealogical research was not immediately 
communicated as the spouse and children were very upset about the 
diagnosis and perspectives of the patient, and needed time to cope with 
the situation. After one month, the clinician estimated that the spouse 
could be informed on the heredity of his wife's disease and the 
consequences for the children. The spouse had great difficulties in 
grasping the far-reaching impact of the genetic aspects of his wife's 
disease for his children. He discussed his confusion and anxieties about 
the burdening information with the psychoiogist of the team. Later 
another member of the research team informed the spouse and children on 
the study on FTD. After weighing the pros and cons they consented for 
participatioll, and expressed interests in further genetic counseling. 
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Case 2: the dilemma of the unexpected finding 
ResuIts from an autopsy are generally communicated to the spouse or 
children to confirm or refute a diagnosis. In this study, non-disclosure of 
personal results of the !inkage study was agreed upon." However, does 
this exclude the need 10 inform a family on the unexpected post-mortem 
change of a diagnosis in the deceased index patient? 
Clinical course 
A 55-year-old man was referred with a four year history of 
progressive changes in behavior. He had been admitted to a nursing home 
since a year. 
Problems started at age 51, af ter the death of his wife. He left his 
work too early, he quarreled about irrelevant matters, showed 
inappropriate behavior and Jack of emotional concern for his children. He 
was unaware of these problems. The family physician observed impulsive, 
disinhibited, and stereotyped behavior, hyperora!ity, and memory 
problems. He first diagnosed the problems as belonging to a severe 
mourning process. Six months later he referred the patient to an out-
patient neurologie clinic. He had a weight gain of more than 20 kg. 
Speech, judgement and anticipation were severely reduced. Neurological 
examination and routine laboratory tests were norma!. Neuropsychological 
tests indicated organie fronta! dysfunction and CT-scanning demonstrated 
frontotemporal atrophy. The family history was negative. 
A possible diagnosis of sporadic FTD was made. The children 
consented to partieipate in the study and a blood sample of the index 
patient for DNA analysis was obtained. 
The patient died at age 57 after a progressive course into akinesia and 
near mutism. The autopsy showed macroscopically severe frontal atrophy 
and a degenerated caudate nucleus. Microscopically neuronal cell loss was 
notieed in the caudate nucleus, putamen and nigral substance. The 
neuropathologieal results could not confirrn the clinical diagnosis FTD but 
provided strong indications for the autosomal dominant Huntington's 
disease, wilh the consequence of a 50% risk for the children to develop 
the disease. DNA-testing for confirmation of diagnosis or prediction in 
individuals at 50 % risk is possible since 1987. ' 
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Outcome of this case 
The children were inforrned on the possible diagnosis of HD and 
brieflyon the heredity of the disease by a member of the research team. 
They were referred to the department of clinical genetics for counseling 
and discussing the option of confirming diagnosis of HD in their father. 
In individual sessions the consequences were considered. All children and 
their partners wished to have diagnosis of HD in their father confirmed by 
the DNA-test. After confirmation of diagnosis they were counseled on the 
presymptomatic test for themselves. Initially, they all wished to have 
certainty, but after follow-up counseling (by the psychoiogist) they fully 
realized the implications of becoming identified as a gene carrier and 
reacted wilh shock and fear. All children expressed that they thought that 
they could not deal with a future that wil! inevitably be overshadowed by 
HD. One of them became pregnant and decided not to have the pregnancy 
tested on HD. The availability for additional support and/or counseling 
when needed was offered. They were informed on the Dutch patient 
organization. Only one (a year later) opted for presymptomatic testing. 
Although the confirmation had also consequences for the siblings of 
the patient, and for their offspring, the children decided not to inform 
these relatives. They argued that they had underestimated the appalling 
impact for themselves and wished not to burden their relatives. 
Case 3. 171e dilemma of safeguarding autonomy: individual versus joint 
sessions 
In genetic research families are usually approached through a key 
relative who is willing to inforrn the other family members. Such 
information may have a far-reaching psychological influence in the family 
communication patterns. Therefore, as a rule, potential participants are 
individually approached, inforrned on the study, and asked for consent by 
the research team. This is done to proteet the individual privacy and 
enable answering individual questions and needs. However, for reasons of 
convenience, researchers or families may ask for joint sessions to inforrn 
an entire family, ask their consent and sample the blood. In the next case 
the need and value of individual sessions are demonstrated. 
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Clinical course 
A 57 years old man became progressively restless and aggressive after 
showing declining initiative in the previous years. He had difficulties in 
doing his work and gave up leisure activities. He wandered in town and 
drove around aimlessly without losing his way. He had no insight into his 
illness. His spontaneous speech diminished, he became completely 
apathie, mute and incontinent for urine. He died in a nursing-home at the 
age of 67. Neuropathological results revealed strong evidence for FTD. 
The spouse and children knew that a form of early onset dementia 
was segregating for many generations in the family. Some children had 
been aware of their personal risks for developing the disease without 
knowing the precise magnitude of their risk. There was little 
communication about their father's disease and its possible genetic nature. 
After referral by the physician of the psycho geriatrie hospital the spouse 
and one of her twelve children (age ranged from 20 to 45 years) allowed 
the research team to inform the other children about the study. They 
indicated that a joint information session at the mother's house would be 
the only option to obtain participation of all children. 
Outcome of the case 
The investigators insisted to have separate sessions with all individuals 
and four children decided to refrain from participation. The spouse was 
eager to learn more about her husbands diagnosis, but was also reluctant 
because of the possible consequences for her children. Of the 12 children 
at risk, some of the older had completed their families and approached the 
age of onset, which increased their uncertainty. Moreover , [hey had to 
face the problem how and when to communicate this knowledge to their 
children. The younger children were in the process of forming 
relationships and starting a family, and the sudden genetic information 
confronted them with their risks to pass the gene on to their future 
offspring. 
Different problems were experienced. Some children at risk had 
supportive partners, others feIt abandoned by their partners. Two 
daughters had greater experience with the disease through their years of 
involvement in care giving to their father , but that caused reactivation of 
those painful early memories. Lack of support by other siblings was 
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resented by them. The disease of the father and the different degree of 
involvemem in care giving had caused anguish and family secrets 
influencing the inter-sibling relationships. The investigators were initially 
unaware üf these perspectives when the children asked different questions. 
Some children said that certain questions could not have been asked in 
presence of their siblings or mother. Guilt feelings and resentments played 
an important role in their mutual communication. A son stated for 
example that it had been better when his father was admitted to a nursing 
home in an earlier stage. 
DISCUSSION 
The role antagonism of clinician - investigator, the problem of 
unexpected findings, and the impossibility of giving adequate pre-consent 
information during a family session are recurring themes in genetic family 
studies. Their frequency is only to increase as the power and speed of 
positional c10ning of disease related genes through family studies 
increases, and clinicians and geneticists adapt more readily to the 
requirements of that 'trade' . However, every separate family and their 
individuals mcmbers will have a similar set of problems to be expected 
when confronted with an usually interested and eager clinician who wants 
to catch the familial disease in the network of modern genetics. 
In the present study, the 'clinician - investigator' dilemma, the 
'unexpected finding' , and the 'personal versus group' concept of 
information of research subjects in a family study are addressed. 
The 'c!inician - investigator' dilemnw 
The 'Aha-Erlebnis' to hear a name of one of the ancestors in a 
kindred known to a clinician because of an inherited disease, is a classical 
'clinical instrument', but not to be applied without great discretion and 
prudence. The clinician has the eventual responsibility to explain a 
diagnosis, and - if present - its heredity, as part of the diagnostic process. 
However, timing of information, and utilization of family and pedigree 
data for the diagnosis might consider the family's ability to comply with 
the speed and consequences of clinical thinking and wisdom. When the 
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family is entangled in a domestic crisis because of the diagnosis of the 
disease, the research involved clinician must use restraint before asking 
consent to proceed with agenetic study and to involve at risk individuals 
in research leading to future predictive testing. Asking participation and 
consent at a stage when shock and emotional imbalance predominate is 
inappropriate as the family members can not oversee all the ramifications 
of participation. The competence to consent is a necessary condition of 
infonned consent. The notion of competence refers to a precondition of 
acting voluntarily and understanding infonnation. Psychological 
conditions like shock and emotional disturbance may temporarily limit 
competence, rendering a possible consent invalid. 
A second dilenuna is the interaction of a clinical and research role of 
the doctor involved. It could be argued that a physician, who has also 
research interests, can not adequately safeguard the patient's process of 
making an independent decision. The researcher - clinician might be 
tempted to talk the family 'into' participating to research. However, if the 
family is interested in knowing about the disease and its heredity, they 
may be referred to a clinician not involved in the research team, or a 
clinical geneticist to secure the independent information about the clinical 
responsibility and research interests . 12 
Unexpected findings during clinical work-up or as a sequela of research 
interests 
The post-mortem diagnosis in the second case was an unexpected 
finding which gave rise to a series of dilemmas. The suggestion of 
Huntington's disease could be confirmed with the use of DNA-mutation 
analysis. The first question is whether the team could ignore the 
unexpected finding, because information on this issue could possibly 
burden the children and secondly was beyond the purpose of the study on 
FTD. Given the relevance of excluding or confirming the diagnosis for 
the children the team considered this option to be unjustified. 
The second question, thus, was when should children be informed? A 
first option is to test the paternal blood on HD by means of the patient's 
DNA without discussing this issue with the family. If HD is excluded the 
problem regarding HD is solved, confinnation of HD leads to infonning 
the family. However, the golden rule - that nothing shall be done without 
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permis sion and consent of the participants - should not be violated. This 
leaves the second option to first inform the children about the hypothesis 
of HD and discuss with them to have it confirmed/excluded or nOI. 25 •28 
The third question is who should inform the children? Should this be 
the research team, the general practitioner or referring medical specialist? 
In our opinion, the researcher should be cautious in taking this role. He 
has a professional responsibility that the consequences of his research 
efforts are adequately dealt with in the interests of the participants. 
However, with full awareness of the pitfalls the researcher may be the 
most appropriate person to inforrn and provide support, not in the least 
due to his professional relationship with the family. In addition, providing 
good medical care implies also a profound exchange and discussion with 
the participants' physicians. 25.27 
The fourth question is what should be told and how comprehensive 
should the provided information be? One alternative is to proceed with the 
paternal DNA testing for the specific disorder as part of the post-mortem 
diagnosis. The focus of the inforrnation at that stage is the relevance of 
the diagnosis and not the consequences for !he children. If, in this case, 
HD is confirmed, the implications may be discussed with the children 
individually, including the option of predictive testing. Alternatively, 
information on the disease may be given in individual sessions with the 
emphasis on the risks for children of affected persons. However, 
discussing personal risks might cause uncertainties and preoccupation with 
early symptoms ('symptom search') which may prove unnecessary when 
HD is excluded. In our view this last alternative however does inforrned 
consent justice most adequately. 
The subject of unexpected findings, with unexpected consequences for 
relatives of a research subject to be at risk for a different disorder as from 
one originally tested for, underscores the importance of 'preventive 
ethics', i.e. clinical ethics which is anticipatory and proactive, rather than 
only reactive, which has been advocated in this case. Preventive ethics, 
ideally, allows physicians and researchers to avert ethical dilemrnas or at 
least identify potential moral confliets earlier , when management may he 
simpier and more effective. 29 To prevent dilemrnas in the second case, the 
possibility of unexpected findings should be discussed during the consent 
process 30 It should be documented under which circumstances research 
subjects wish to he informed of such unexpected findings in the future. 
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Personal versus group setting 
Concerning the dilemma raised in the third case, lessons from 
previous experience with Huntington disease have learned how the burden 
of a genetic disease can overshadow the entire family7,16,31,32 Collective 
denial and myths can accompany the segregation of the disease over more 
than two generations ' Familial bonds can be severed due to the appalling 
disease, and marital discord is not seldom the result of the incapacity to 
adequately cope with the distress as a result of the disease.33 These 
psychological effects may have profound intluence on the current family 
communication and interaction patterns. An important reason for an 
individual approach in family studies is that the individual's participation 
must be based on free choice (the issue of autonomy), unimpeded by 
family pressure and divergent expectations. AIso, there are individual 
differences in the need and capacity to receive information. The dosage of 
information might be tailored to the individual ability to work through the 
threatening perspective, and on the availability of emotional support by 
spouses.34 The differences in age and the structure of the family (having 
or not having children) may result in different agendas that must be 
addressed lO Moreover, some individuals may wish to become extensively 
informed about the disease and personal risks (the novelty seekers), 
whereas others wish to remain ignorant (the deniers-avoiders). All these 
aspects of privacy of individual relatives cannot be safeguarded in joint 
sessions. AIso, in the group setting individual questions and answers may 
induce adverse reactions in relatives such as rejection of thoughts about 
prenatal testing or suicide. 
The investment of any research team or genetic counselor to provide 
information on a per-personlcouple basis wil! be widely reimbursed by 
better understanding of individuals . The individual approach is most fit 
for implementing the subjective standard for disclosure of information, 
which takes account of the individual informational needs of pers ons in 
the process of making difficult decisions. It is this standard alone that can 
assure that persons are receiving the sort of information needed for valid 
informed consent. 35 Furthermore, the individual approach allows for a 
better ability of relatives to share or not share emotions or decisions. In 
conclusion, an individuallcouple approach in genetic studies is a 
fundamental prerequisite. 
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ConclusiofiS and ethical evaluatiolZ 
What are the lessons from the cases described in this article? First, 
the clinicianJresearcher must be aware of the temptations of role reversal 
and act according to good medical practice. His first interest is the care 
for the patient; the scientific excitement ought not to interfere with good 
patient care. Requests for participation in research should be discussed at 
an appropriate moment. Second, informed consent, which is obviously a 
prerequisite for conducting genetic research, should account for 
unexpected findings in genera!. Even though it is an iIlusion that adequate 
informed consent can cover all specific unexpected findings or 
psychological ramifications, at least some of the dilemmas concerning 
unexpected findings can be prevented or more adequately dealt with. 
Third, the individual approach of participants safeguards all individual 
interests. Pragmatic reasons (practical availability of time and manpower) 
and the risk of loosing participants should be considered as subordinate to 
the individual interests. 
Genetic research may result in predictive testing programs with the 
inclusion of psychological evaluation.'·36 We emphasize that full and 
continuous attention should also be given in the stage of genetic research. 
This requires that members of the research team who have contacts with 
families must be knowledgeable about the psychosocial aspects. Although 
researchers may be optimal sensitive for the psychosocial impact of their 
research etforts on participants, there may be moments that they become 
blinded for the effects of their acting. Therefore, genetic research would 
ideally include systematic psychological and ethical evaluation in order to 
safeguard the needs of participants. 7 
We have observed that many participants have not made use of the 
availability of additional genetic counseling and psychological support 
while the research has raised many questions and uncertainties in them.37 
Weneed more insight into their coping strategies, i. e. how they come to 
terms with the burden of their personal risks. Also, observations in this 
group may increase the knowledge of how genet ic research affects the 
communication within extended families. 
Our presentation of three cases may contribute to the development of 
sound research protocols. In the final section of our paper we want to 
focus on what we consider to be a primary moral issue with regard to 
128 
Once revealed, na mare ta be cancealed 
genetic research, both chronologically and materially: the recruitment of 
participants among relatives of the index person. This issue is especially 
relevant in the context of genetic research on late onset, untreatable, 
disorclers. 
A key principle of research involving human subjects, namely that 
concern for the interests of participants must always prevail over the 
interests of science and society, should, of course, also apply to relatives 
who are approached for participation in genetic research. Can the 
recruitment of relatives be justified in view of this principle? An 
affirmative answer can only be given if the (possible) benefits of 
participation outweigh the (possible) risks. 
During the study we gradually discovered that a larger than expected 
number of relatives did not suspect that the condition of the index person 
may be genetic, and that they themselves carry an increased risk of 
getting the disease 7 If they do suspect this, they may underestimate the 
magnitude of their risk. In view of this, asking reIatives to participate in 
genetic research may imply an unsolicited message that they (and their 
children) are at high risk of carrying harmful genes. This message is 
particularly burdensome if the condition under study is untreatable, and 
effective preventive measures are absent. The ethics of genetic research 
primarily focusses on possible risks of participation in research. The 
psychological risks involved in the recruitment of possible participants 
among relatives should, we think, be given due attention in the 'risk-
benefit' analysis. 
The latter risk can be considered acceptable from a moral point of 
view if they are being outweighed by possible benefits for participants in 
genetic research. One should, however, not take for granted that this is 
the case. Benefits of ten mentioned in the literature include that such 
research wil! provide options for predictive testing, that it will allow for 
better preparation on the future (especially planning career and family), 
and that research wil! ultimately give an outlook on prevention and 
(better) treatment of the disease under study. One should, however, 
acknowledge that these benefits are uncertain, if not speculative, and 
probably not eminent. Indeed, the time scale for the development of 
preventive or therapeutic treatment for dementia will probably be 
measured in decades, rather than years. 38 Furthermore, in many cases the 
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informatioI! that relatives are (or may be) at high risk wil! not contribute 
to their informed reproductive decision making. After all, some of the 
candidate participants wil! have completed their families, and if not, it is 
uncertain whether they wil! consider the infoffilation relevant for future 
reproductive choices. Finally, from the experience with presymptomatic 
testing for Huntington's disease it can be extrapolated that only a minority 
of the persons at risk wil! ultimately ask for presymptomatic diagnosis (if 
available) of late onset, untreatable, disorders when preventive options are 
absent. 
In view of this, we suggest that recruiting relatives, who may not 
suspect that they are 'at risk', for participation in genetic research on late 
onset, untreatable disorders, may be more difficult to justify than is often 
assumed. In any case, this preliminary issue deserves a prominent place 
on the agenda for the ethics of genetic research. 
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PREPAIRING FOR PRESYMPTOMATIC DNA TESTING 
FOR EARLY ONSET ALZHEIMER'S DISEASEI 
CEREBRAL HAEMORRHAGE AND 
HEREDITARY FRONTO-TEMPORAL DEMENTIA 
INTRODUCTION 
An increasing number of neurodegenerative diseases have been 
defined at the molecular level in recent years, making it possible to 
determine the genotype precisely before the onset of symptoms. 
Presymptomatic testing programs are available for Huntington's disease 
(HO), hereditary cerebral haemorrhage with amyloid-Dutch type, 
inherited cerebral ataxia, myotonic dystrophy, and Alzheimer's disease. 1.6 
For other autosomal dominant disorders, the genetic cause will be 
detected in the near, foreseeable future. Significant progress has been 
made in unravelling the dynamics of genes and their products.' However, 
effective pharmacological or gene therapy for late onset neurodegenerative 
disorders is not expected to be available in the immediate future. 
In a collaborative programme on neurogenetics in Rotterdam, two 
studies on early onset dementia are currently being carried out. The first 
study concerns a family with presenile Alzheimer's dementia and cerebral 
haemorrhage (FAO-CH). FAD-CH is caused by a mutation in codon 692 
of the gene for Jl-amyloid precursor protein (JlAPP) on chromosome 21. 8 
Extracellular amyloid plaques, intra-neuronal neurofibriIlar tangles, and 
amyloid angiopathy were found in the brains of two FAO-CH patients. 
Mutations in the JlAPP-gene account for less than 3 % of disease onset 
before 65 years of age. 8 
In a second study, early onset fronto-temporal dementia was found in 
three Outch families with an autosomal dominant transmission pattern 
over 5 to 7 generations. The typical clinical features in the patients with 
hereditary fronto-temporal dementia (HFTD) were disinhibition, 
stereotyped behavior, roaming, and hyperorality. Frontal and temporal 
atrophy on CT scan supported the clinical diagnosis in eight, two, and 
five living patients in the three families, respectively. The diagnosis of 
HFTO was confirmed in each family by pathological examination of the 
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brain in one, 14, and 15 patients, respectively. Macroscopie examinations 
showed selective atrophy of the frontal cortex, non-specil1c changes 
(neuronalloss, spongiosis, gliosis), and ballooned cells. Evidence was 
found in these three families for linkage of HFTD to chromosome 17.27 
HFTD and FAD-CH are primary degenerative diseases of the brain, 
with onset usually in the fourth to sixth decades of life. ,.]2 Both conditions 
have an average age of onset between 40 and 60 years of age. The course 
in both disorders is variabie, with the development of profound dementia 
ranging from two to 10 years af ter diagnosis. No specific (reatment is 
available, but the use of p'a1liative treatments is now being explored. 
Misdiagnosis of HFTD or F AD-CH, such as depression (FAD-CH) or 
manie states (HFTD), may occur in the early stages of the disease and has 
often led to unsuccessful psychotherapy of couples . The diagnosis of 
FAD-CH and HFTD is psychologieally devastating to the partner and 
his/her offspring, who have seen the patient's parent, sib, or another close 
relative become progressively disabled. People sometimes incorrectly 
believe themselves to be at risk because of symptom searching or 
preoccupation with early signs. Often, "soft" signs, whieh are not specific 
for FAD-CH or HFTD, are perceived as a precursor of the disease. 
Genetie mutational or linkage analysis may confirm the diagnosis in 
patients with HFTD or FAD-CH and could provide presymptomatic 
testing for at risk subjects. Presymptomatic testing for Huntington's 
disease is considered as the paradigm for prediction programmes for other 
late oaset neurodegenerative diseases and cancers 13 and should provide the 
experience necessary to improve pretest and post-test counselling. Before 
the introduction of lhe predictive test, attitudinal studies among those at 
risk for Huntington's disease have shown that the commonly cited reasons 
to take the predictive test were the unbearable uncertainty, anticipating the 
future, and planning a family, but that an unfavorable result might also 
lead to depressive feelings and suicidal behavior. 14-16 These surveys 
indieated that the majority would make use of a predictive test if it were 
available. With careful consideration of the ethical, clinieal, and legal 
implications of presymptomatic testing for an incurabie late onset 
disease, iJ. 17· " guidelines were carefully developed and testing was carried 
out cautiously in research settings.20 To date, requests for the test have 
been far below the expected rate, although in The Netherlands 150 people 
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apply for it yearly, and about 15 % of the estimated cohort at 50% risk 
has receivecl test results. 21 •22 Only a small amount of experience has been 
reported on testing for preseniIe dementia. In Sweden, one out of three 
people tested at 50% risk for the APP 670/671 mutation was identified as 
a mutation carrier. After a one year period with depressive feelings and 
suicidal thoughts, this subject could eventually handle his situation. 
Intensive attention and care at the genetics clinic was needed. The non-
carriers had expressed their relief. 23 Although the potential benefits of 
predictive testing may include relieving uncertainty and planning the 
future, the acceptability of, and need for, presymptomatic testing for early 
onset dementia has not yet been established 4 .25 
This study adclresses the impact of approaching families with a 
hereditary preseniIe dementia for genetic research with the aim of 
establishing a predictive testing programme, as was done for Huntington's 
disease. We studied the ability to cope with being at risk for HFTD or 
FAD-CH, the influence of the disease upon a variety of areas of life, and 
the attitude towards presymptomatic testing. Guided by our clinical 
experience with these neurodegenerative disorders, we expected similar 
attitudes as were found in people at risk for Huntington's disease in the 
Dutch presymptomatic testing programme 26 The results could be helpfui 
for the medical-ethical evaluation of this and other genetic research 
programmes, to establish a suitable, disease specific testing protocol, and 
to develop support strategies when testing does become available. 
SUBJECTS AND METHODS 
Clinical, genetic-epidemiological, and pathological research was 
conducted on FAD-CH and HFTD in a collaborative programme in 
Rotterdam, The Netherlands. DNA linkage and mutation studies were 
done in one family with familial early onset FAO-CH' and three families 
with HFTD.27•28 Participants were at 50% risk for HFTO (n=43) or 
FAO-CH (n=21) and cooperated after fully informed consent. 
Participants had a general medical examination, neurological examination, 
neuropsychological testing, brain imaging (MRI-scan), blood sampling, 
and were asked to participate in a clinical psychological assessment and 
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an attitudinal survey. The Medical Ethics Connnittee of the University 
Hospital Dijkzigt, Rotterdam, approved the protocols. Participants were 
informed about the disease (MS, CMvD, JCvS), and received information 
about the genetic pattern of the familial FAD-CH or HFTD. They were 
referred, when needed, to the Clinical Genetics Department for further 
genetic counselling (MFN) or psychological support (AT). 
Forty-three out of 50 people at risk for HFTD (86%) and 21 out of 
26 people at risk for FAD-CH (81 %) gave consent for the clinical 
psychological study which consisted of an in depth interview and 
administering psychologkal questionnaires that were completed at home. 
Questionnaires were returned within a week after the interview. 
Demographic data (gender, age, marital status, employment status, 
number of children, number of sibs, and level of education) were 
collected. An Attitude Questionnaire (AQ) was administered that consisted 
of questions on the following areas: experience with the disorder, the age 
at which the person \earned about the heredity of HFTD or FfI.D-CH, the 
subject's attitudes towards taking the presymptomatic test, the expected 
outcome of the test, attitudes toward prenatal testing and terminating a 
pregnancy in different circumstances. Most questions had the response 
categories yes/agree, don't know, no/not agree. Questions on experience 
with the disease, impact on personal life, and reasons for and against 
predictive testing were open ended, for which response categories were 
compiled to suit the connnon themes emerging from the answers. The 
estimated risk of inheriting the gene or developing the disease was 
assessed using a visual analogue scale. People who considered taking a 
future predictive test when it became clinically availab1e answered 
questions about the anticipated impact of either test results. The AQ was 
adapted from the Dutch Huntington Presymptomatic Progrannne.26 
The data were analyzed with vers ion 6.0 of SPSS for Windows and 
the software Confidence Interval Analysis (CIA) 29 The data are presented 
as the 95 % confidence intervals (95 % Cl) of proportions. For 
camparisons between groups, 95 % confidence intervals for differences of 
proportions were used; a confidence interval that did not inc1ude zero 
indicated statistical significance. Chi-square analyses (for categorical 
variables) and t tests (for continuous variables) were used to determine 
whether there were any differences in demographic variables between 
groups. 
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RESULTS 
Demographic information 
The demographic information on the participants is given in table 1. 
Table 1. 
Charac!eristics of people at risk for hereditary fronto-tempoml dementia 
(HFTD) and familial Alzheimer's disease/cerehral haemorrhage (FAD-CH). 
HFTD (n ~ 43) FAD-CH (n ~ 21) 
Mean age 
Years 38.7 (21-61) 38.1 (22-60) 
SD 9.7 10.4 
Time lag* 
Years 5.4 (0-37) 6.6 (0-40) 
SD 8.9 6.9 
No of affecled relatives** 
Range 3.0 (1-7) 1.0 
Male/female ratio 21/22 12/9 
No(%) No (%l 
Marital status 
Single 10 (23) 2 (10) 
Married 26 (61) 14 (67) 
Common law 6 (14) 2 (10) 
Widow 1 (2) 
Divorced 3 (14) 
Children 
o Children 17 (40) 9 (43) 
1 Child 4 (9) 3 (14) 
~ 2 Cllildren 22 (51) 9 (43) 
Highest level of education 
Elementary/lower vocational school 14 (33) 9 (43) 
?:: High school 29 (67) 12 (57) 
* Period that elapsed since participant leamed about personal risk for FAD·CHIHFTD. 
** First or secOlId degree. 
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Thirty-four subjects at 50% risk for HFTO and 21 for FAO-CH 
participated in the study on gene localization, and all except three from 
the HFTO group completed the psychological questionnaires. The latter 
three individuals withdrew from the study because they feIt too anxious 
about their risk after having undergone the entire procedure. No 
significant differences were found between the HFTO and FAO-CH 
groups. The majority had a stabIe relationship and fewer than half had no 
children. Participants with children (60%) had a mean of two children. 
Learning about HFTD or FAD-eH and personal risk 
The average period that had elapsed (time lag) since participants first 
learned about their personal risks was about six years in both groups 
(TabIe 1). However, 24% of the group at risk for FAO-CH and 45% of 
the HFTO group first heard about their personal risks during this study. 
Eighty percent of both groups at risk learned about their own risk af ter 
the age of 18 years, at a mean age of 25.9 years (SD 8.6) and 26.5 years 
(SD 11.3). In the interviews, some people reported severe reactions, such 
as depressive feelings, guilt towards spouse and children, sleeping 
disturbances, phobic reactions, and marital problems. For others, 
participation in the genetic study meant relief because the scientific 
attention had given them some hope for the future. 
Uptake of presymptomatic testing 
Twenty-seven people at risk for HFTD (68 %) and 12 at risk for 
FAD-CH (57%) would take the presymptomatic test when it became 
clinically available, whereas five (13%) and three (14%) people in either 
group were still uncertain about it. Nineteen (49 %) out of the total group 
of 39 individuals who would take the test indicated that they would use it 
as soon as it became available. The others did not feel prepared to learn 
about precise risks at this stage. Eight people at risk for HFTD (20 %) and 
six at risk for FAD-CH (26 %) would not take the test. 
Those who would not take the presymptomatic test were also against 
testing minors « 18 years). Half of the group that considered predictive 
testing had the opinion that children under 18 should be allo wed to have 
the test. No differences were found between !he HFTD and the FAD-CH 
groups. 
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Reasons for or against presymptomatic testing 
For people who would take or consider taking a future 
presymptomatic test, the major reasons for uptake are presented in table 
2. Generally , those at risk for either FAO-CH or HFTO cited similar 
reasons. Almost half of the participants declared their reasons as: helping 
research, informing their children, general planning for the future, and 
relieving uncertainty. Planning a family was only a minor reason for 
uptake. Two people would take the test for reasons of insurance. 
Considerations against presymptomatic testing were expressed by 28 
people out of the group that considered predictive testing (60 %). Fear of 
adverse effects such as anxiety and depression after an unfavorable result 
was mentioned by 24 of them (51 %). Seven (15%) emphasized that an 
unfavorable result would overshadow their life entirely. One person 
feared that an unfavorable test result might lead to being refused 
insurance. 
Table 2. 
Reasons* for taking the presymptomatic DNA test 
for hereditary fronto-temporat dementia (HFI'D) 
or familial Alzheimer's diseaseJcerebraI haemorrhage (FAD~CH). 
HFTD' (n ~ 32) FAD-CH' (n ~ 15) 
No (%) No(%) 
(1) FOT the sake of the childrenJ 
clarify risk to children 16 (50) 7 (47) 
(2) Ta help research! 
ta stop the disease 13 (42) 7 (47) 
(3) General planning for the future 9 (29) 7 (47) 
(4) Ta relieve uncertainty 15 (46) 4 (27) 
(5) Ta plan a family 3 (8) 3 (20) 
(6) Ta prepare for Ehe furure 
(anticipating the disease) 4 (13) 3 (20) 
(7) Insurance 2 (13) 
* This was an open ended question; more than ane reason could be given. 
S Answered by those who would consider taking the presymptomatic [cst. 
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for differences 
(-27; 34) 
(-37; 24) 
(-48; 11) 
(-08;49) 
(-33; 12) 
(-31; 16) 
(-31; 04) 
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Fourteen subjects who would not take the test (eight at risk for HFTO 
(20%) and six at risk for FAO-CH (26%)) cited as the main reasons 
against testing the fear of unfavorable test results and the inability to cape 
with such an outcome, preoccupation with signs of the onset of the 
disease, and expected distortion of the current course of life. One person 
feared possible misuse by insurance companies. In this group only few 
reasons for testing were given: the responsibility to inform children 
(n=2), family planning (n=2), and to help research (n=2). No 
differences were found between the HFTO group and the FAO-CH 
group. 
Impact of HFTD/FAD-CH on personallife 
The impact of the disease on personal life is presented in table 3. 
Subjects at risk for HFTO reported significantly more preoccupation with 
symptoms than the FAO-CH-group. More than half (60%) of the HFTO-
group said that the disease in their relatives had affeeted their mood 
(anxiety, depression) and had led to feelings of uncertainty. 
(1) 
(2) 
(3) 
(4) 
(5) 
(6) 
Table 3. 
bnpact of hereditary fronto-temporal dementia (HFfJ)) 
or familial Alzheimer's disease/cerebral haemorrhage (F AlO-CH) 
on life of people at 50% risk. 
HFTD (n ~ 40) FAD-CH (n ~ 21) 
No(%) No (%) 95% Cl 
for differences 
Preoccupation with symplOms 24 (60) 3 (14) (24; 67) 
Restriction in planning the future 21 (53) 7 (33) (-06; 45) 
Anxiety, depression, uncertainty 24 (60) 6 (29) (07; 56) 
Disturbanees of family life 5 (13) 2 (10) (-13; 19) 
Positive influence 4 (20) (-36;-02) 
No influence 8 (20) 11 (52) (-57;-08) 
More than half (53 %) of the HFTO group felt restricted in making plans 
for the future. Four had previously undergone sterilization to prevent 
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transmission of the gene to their offspring. For FAD-CH, more than half 
of those at risk (52 %) said that the disease had not influenced their 
personal lile. 
Comparison of the most significant symptoms of HFTD/PAD-CH in 
affected relatives as perceived by the participants (Tabie 4) showed that 
more than two-thirds (70 %) of the HPTD group mentioned the 
disinhibition and restlessness as the most significant symptoms. In some 
cases, specific changes in oral/dietary behavior and sexual disinhibition 
was mentioned. In the PAD-CH group at risk, the most significant 
symptoms were dysmnesia and personality changes. 
Table 4. 
Most significant symptoms* of hereditary fronto-temporal dementia (HFlrD) 
or familial Alzheimer's disease/cerebral haemorrhage (F AD-CH) 
as perceived and experienced by people at risk. 
(1) 
(2) 
(3) 
Change of personality 
DisinhibitionJrestlessness 
Loss of insight and judgement 
EmotionaI lability/euphoria 
Lack of spontaneityl 
emmional unconcem 
Depressive episodes 
Aggression 
Stereotyped behavior 
Cognitive delerioration 
Dysmnesia 
Disoriemation 
Dysphasia 
Dyspraxia 
HFTD (n ~ 40) 
No(%) 
12 (30) 
28 (70) 
12 (30) 
9 (23) 
4 (10) 
9 (23) 
4 (10) 
17 (40) 
4 (10) 
3 (7) 
12 (30) 
* In first or second degree affected relatives. 
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No(%) 
6 (29) 
1 (5) 
4 (19) 
2 (10) 
1 (5) 
3 (14) 
1 (5) 
2 (10) 
7 (33) 
6 (29) 
1 (5) 
2 (10) 
95% Cl 
fOT differences 
(-23; 25) 
(48; 82) 
(-11;33) 
(-22; 03) 
( 02; 34) 
(-22; 13) 
( 02; 34) 
(-15; 16) 
(-19; 32) 
(-40; 03) 
(-09; 15) 
( 02; 39) 
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Expected effects of risk for HF7D/FAD-CH 
Previaus feelings abaut getting the disease or not were assessed with a 
visual analague scale. Twenty-seven peaple at risk far HFTD (68%) and 
15 at risk far FAD-CH (71 %) thaught that their persanal risk was equal 
ta or less than 50 %. Eighteen percent in the HFTD graup and 10 % in the 
FAD-CH group estimated their risk as higher than 70 %. Anticipatian of 
the effects of being identified as a gene carrier did not differ between the 
graups and shawed a high awareness of the increased burden far the 
spause (Tabie 5). 
Table 5. 
The expected inflnence af ter receiving an increased risk 
of presymptomatic testing for hereditary fronto-temporal dementia (HFTD) 
or familial Alzheimer's disease/cerebral hacmorrhage (FAD-CII). 
An incrcased risk HFTD (n ~ 40') FAD-CH (n ~ 21) 
No(%) 
Wilt increase the problems of my partner 22 (55) 
Will increase tbe problems of my children 17 (43) 
Will allow me ta plan 
my own furure better 
Will allow me ta plan 
the future of my family better 
Will increase my problems 
Will cause me ta become depressed 
Will adversely affect my marriagel 
16 (40) 
14 (35) 
16 (40) 
9 (23) 
relationship 4 (10) 
Win decrease tbe qualiry of m)' life 7 (18) 
No(%) 
16 (76) 
12 (57) 
!1 (52) 
!1 (52) 
7 (33) 
3 (14) 
5 (24) 
2 (10) 
'" Participants who considered uptake of presymptomatic testing. 
95% Cl 
for differences 
(-45; 03) 
(-41; 12) 
(-39; 14) 
(-44; 09) 
(-19; 32) 
(12; 28) 
(..34; 07) 
(09; 25) 
Participants vividly cammented on haw their affected parent was not 
aware of the deteriaratian in the later stages of the disease, but that the 
healthy parent became extremely burdened by the devastatian caused by 
the disease and the difficult decisians ta be made regarding the patient. 
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Twenty-three percent of the HFTD/FAD-CH group were afraid of 
becoming depressed. Forty-nine percent of the HFTD/FAD-CH groups 
had confidence that they could cope with an unfavorable test outcome, 
whereas 12 % stated that such aresuit would ruin their life. 
Two out of 39 subjects at risk for HFTD/FAD-CH (5%), who would 
undergo presymptomatic testing, indicated in the questionnaire that they 
might corrunit suicide after an unfavorable result and nine (23 %) stated 
that they had not resolved this question. All but two indicated that they 
would seek professional help after an unfavorable test result. 
The most comrnonly cited effect of receiving a decreased risk was a 
reduction in problems for spouses (70%) and children (54%) and 
improved planning for their personal fulUre (51 %) and the family's future 
(49 %). Only 13 % agreed that a decreased risk would improve the 
marriage/reJationship. 
Expected impact on family planning 
Among the 26 childless people (41 % ), six persons wished to have 
children, another seven were uncertain. Three people with offspring 
would have more children. Six of the nine who wished to have (more) 
children would take the presymptomatic test. In case of an unfavorable 
result, one of them would refrain from having children, three were 
uncertain about prenatal diagnosis, one would opt for pregnancy 
termination of a felUs with an increased risk for the disease, and one 
would not use prenatal testing. Two people were uncertain about taking 
the presymptomatic test and did not agree with prenatal diagnosis . One 
did not wish to leam of his or her personal status, but would opt for 
excJusion testing, that is, excJuding whether or not a felUs has received a 
chromosome from the affected grandparent. 
Some participants would encourage their offspring to take the test 
before starting a relationship (35%), or before planning a family (42%). 
If an increased risk was found in their adult child, 31 % of the respondents 
would encourage this child to opt for prenatal diagnosis . 
The majority of respondents (59 %) were against the availability of 
prenatal testing for HFTD or F AD-CH. When asked whether pregnancy 
termination was acceptable in a variety of situations (Tabie 6), a minority 
of all respondents found abortion acceptable in the case of prenatal 
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detection of an increased risk for HFTO or FAO-CH (20 % and 29 % , 
respectively). Among those who found the availability of prenatal testing 
acceptable as a clinical service (n=25, 41 %), 19 would actually use it in 
the event of a pregnancy in their own family, whereas nine of this 
subgroup would terminate the pregnancy if the fetus showed an increased 
risk for HFTO of FAO-CH. 
Table 6. 
Attitudes of people at risk for hereditary fronto-temporal dementia (HFTD) 
or familial Alzheimer's disease/cerebral haemorrhage (FAJ[)-CH) 
towards abortion in different circumstances. 
I think abortion is acceptable if HFTD (n ~ 40) 
Nu(%) 
Health of mother is in danger 
because of pregnancy 31 (78) 
Prenatal diagnosis shows a serious disease 25 (63) 
Prenatal diagnosis shows Down syndrome 18 (45) 
Prenatal diagnosis shows increased risk 
for HFTD/FAD-CH 8 (20) 
The baby is unwanted 
(for other than medical reasons) 12 (30) 
Presymptornatic testing and additional support 
FAD·CH (n ~ 21) 
No (%) 
20 (95) 
16 (76) 
10 (48) 
6 (29) 
6 (29) 
95% Cl 
for differences 
(-34;-02) 
(-37; 10) 
(-29; 24) 
(-32; 14) 
(-23; 25) 
Almost all participants (90 %) emphasized that extensive pretest 
genetic counselling is a necessity when presymptomatic testing becomes 
available. Counselling should include exploration of all pros and cons of 
testing, with the inclusion of the emotional ramifications and the impact 
on marital and family interactions . In addition, 82 % found that 
psychological assessment is necessary to assess whether test candidates 
can cope with the test outcome. Half of the participants (49 %) held the 
opinion that the test should not be offered if the test candidate intends to 
comrnit suicide after an unfavorable result. Thirty-one percent stated that 
the test should not be offered unless the disease can be cured. Twenty-one 
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percent feli: that the test results should not be added to the medical 
records. 
DISCUSSION 
Participation in pedigree linkage studies 
Gene loca!ization and identification are obviously necessary for 
obtaining information about the aetiology and molecular genetic aspects of 
early and late onset dementia. Common interests in the insight into the 
hereditary nature of dementia may contribute to future therapeutic 
interventions. Half of those at risk in this study mentioned "to help 
research" as an important motive for participation. Yet the potential 
burden of participation in pedigree and !inkage studies is often 
underestimated by researchers and medical specialists. Facing the threat of 
an appalling disease can cause a variety of psychological, legal, and 
ethical problems for people at risk. In addition, family members may 
learn about their own risk for the first time through participation. This 
problem was often the case for the groups at risk for HFTD or FAD-CH. 
In the information sessions, many people did not fully understand all the 
ramifications of being at risk. Ideas about the heredity were only vague 
and infoffilation previously obtained from professionals (neurologist, 
general practitioner) were often similarly unclear. Most of the participants 
were accordingly shocked by the information about their own risks. Is it 
acceptable 10 recruit relatives for participation in research who may not 
even suspect that the disease under investigation is genetic, and that they 
may carry genes potentially harmful to them or their offspring? For some 
relatives the request for participation was not ominous news because they 
suspected that the disease was hereditary. Other relatives may have a 
positive attitude towards research because genetic information may be 
relevant, for example, for reproductive decisions or informing their 
children. Refraining from conducting family studies leaves a family 
ignorant and might prevent members from knowing the potential threat of 
personal risks. The moral price of such a policy is that family members 
are denied the possibility of anticipating their future and making general 
decisions. Obtaining consent, protecting privacy and confidentiality, and 
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safeguarding divergent and conflicting intrafamilial and intergenerational 
interests present moral challenges to the conduct of sound research 30 Our 
experience emphasizes that strong collaboration of all disciplines 
(molecular and clinical geneticist, neuroiogist, psychoiogist, medical 
ethicist, general practitioner) involved is a requirement for conducting 
genetic studies. 
Many people at risk for HFTD were preoccupied with early 
symptoms in themselves which reflected anxiety and great concern about 
their future, which was different for the FAD-eH group. The 
disinhibitionlrestlessness in the affected parent and other affected relatives 
was often experienced as frightening and overshadowed the lives of many 
of those at risk for HFTD. This fear affected their self-esteem, future 
prospects, and their relationship with spouses and relatives. Therefore, in 
the programming and institutional ethical review of pedigree and !inkage 
studies, attention must be paid to the provision of genetic and 
psychological counselling. AIso, familiarity with genetic concepts in all 
medical disciplines becomes essential and medical curricula must meet 
such requirements. 
Localization or finding of the gene often results in the clinical 
application of predictive testing programmes, given the experience with 
Huntington's disease, polyposis coli, and breast and ovarian cancer. The 
predictive programme for Huntington's disease was embedded in careful 
genetic counselling following the international guidelines, and 
psychological follow-up.'O,31.32 Although the medical-ethical issues and 
benefits of predictive testing are still under debate, the widespread 
application of such testing as a clinical service proceeds for untreatable 
genetic disorders . It is not known whether alternatives for solving the 
emotional and decision problems in people at risk are offered and can be 
sufficiently met in health care. Predictive programmes may be too easily 
established as a result of finding a linkage or mutation, without proper 
ethical reflection or contairunent in a follow up research experimental 
condition. 
Although genetic counselling often implies being the devil's advocate 
by discouraging people at risk from undergoing the test for diseases that 
have no outlook on treattnent, the Huntington experience shows that 
applicants for the test are very determined to have test results, even in 
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those cases where other options of dealing with the threat might be 
preferabie. Weighing the pros and cons of testing is eventually a personal 
responsibility. 
Acceptance of presymptomatic testing programmes 
Both FAD-CH and HFTD are rare, devastating diseases, yet the 
majority of participants in this study would take a presymptomatic test if 
it became available. As with results found in those at risl( for 
Huntington's disease, many denied the potential untoward effects of 
becoming identified as a gene carrier. 26.33.34 Preparation for the future and 
worry about the spouse were the main reasons for taking the test, in 
contrast to the HD group, where family planning was paramount. 26 
Because for the HFTD/FAD-CH groups the age of onset is usually much 
later and the risk increases dramatically as age advances, people at risk 
for HFTD/FAD-CH might consider testing for general planning such as 
retirement, medical directives, and early diagnosis and appropriate 
treatment. 24 
The purpose of counselling is to safeguard considerable deliberation. 
Half of the group that considered predictive testing found that testing 
should also be accessible for minors under 18 years, which is similar to 
the opinions of test candidates for Huntington's disease.26 Yet the request 
of parents to test their children who are minors should be rejected as this 
would violate the child's right "not to know". It should be safeguarded 
that the child can make an autonomous decision when he/she reaches the 
age of majority 35 
Twenty-eight percent of those who considered predictive testing 
would either commit or consider committing suicide after becoming 
identified as a gene carrier, although they would seek professional 
support. This is similar to attitudinal studies in HD. 16 Half of the 
participants thought that those who considered committing suicide after an 
unfavorable result should not be given the test. This raises the question of 
what is good clinical practice. Applicants for the predictive test who are 
in a shock or who are depressive, and who are consequently not able to 
make a weIl considered, autonomous choice, should not be given access 
to the test or testing should be postponed. In all cases, extensive pretest 
counselling is a prerequisite, in which the pros and cons of testing are 
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explored and weighed. It should be investigated whether [he suicidal 
intention is an indication of either a depressive state of mind or of rational 
considerations. In addition, the counsellor can actively raise the issue of 
possible adverse reactions to unfavorable test results , with the inclusion of 
suicide intentions. It should be noted that the experience with testing for 
Huntington's disease has shown that people at risk who are not able to 
cope with unfavorable test results exclude themselves from testing (self-
exclusion). What if a competent applicant expresses his intentions to 
commit suicide after unfavorable results? Should access to the test be 
refused in such cases? Such a policy has certain objections. First, 
prohibition of testing those considering suicide would lead to the 
concealment of suicidal intentions , as was experienced in the HO 
presymptomatic testing programme. Second, unconditional refusal of 
access to testing would be a violation of the principle of autonomy. This 
principle imp lies the professional respect for the applicant' s considerations 
regarding the eonsequences of either test result. MoreovcL rcfusal of 
access to the test has its moral price because this woulel force test 
candidates to remain uncertain about their genetic status. Suicide is not 
immoral and the intention to commit suicide in certain circumstances not 
unreasonable. Hence, suicide in case of an unfavorable test result is not a 
priori irrational. Consequently, it is, in our opinion, a priori morally 
tenable to allow access to a future predictive test if an applicant expresses 
his intention to commit suicide after unfavorable test results. In 
conclusion, we recommend that anxieties and expectancies regarding one's 
fate be openly discussed. Testing may be postponed and additional 
support offered when needed. It should also be noted that, as clinical 
experience with Huntington's disease has shown, suicide may become an 
option in the final stages of the disease, and not as a reaction to an 
increased risk test result or after onset of the first signs of the disorder. 
People who are the first in a family to participate in genetic studies 
and presymptomatic testing programmmes may assume the responsibility 
for informing their offspring and relatives about the new information. In 
the families studied, the key person was often the patient's spouse with 
whom the heredity of the disease was first discussed and who consented 
by proxy to testing the affected patient. Sueh proxy consent is acceptable 
given the potential interests of children and other relatives with regard to 
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certainty about personal risks, or the relevance of differential diagnosis. 
In addition, confirmation of diagnosis using DNA testing does not conflict 
with the demented patient's interests. lt may be objected, however, that 
the potential interests of children and other relatives disqualify them as 
proxy. Therefore, good medical and ethical practice requires close 
consideration and discus sion whether personal interests interfere with 
being a proxy. 
Information on genetic studies may cause emotional upheaval in 
relatives who are informed and resentment against the inforrnants . 
Informing and supporting people with this specific mission about these 
family issues, which are usually unexpected, may stimulate other relatives 
to appreciate the value of family studies. 
The intended uptake of testing among the HFTD/FAD-CH groups is 
similar to the intended uptake in the HD groups at risk. The actual uptake 
may be much lower given the HD experience,36 which is illustrated by the 
finding that only a minority wishes testing immediately upon availability. 
As in the HD studies, participants at risk for HFTD/FAD-CH emphasized 
the need for extensive pretest counselling and psychological assessment. 
Again, the group that requires predictive testing should also be inforrned 
about alternative ways of dealing with the issues that led to uptake of the 
test. Psychotherapy or behavioral therapy might help people to cope better 
with their anxieties. Couples could be supported in exploring other ways 
of dealing with their wish to have children. Predictive testing programrnes 
seem to be subject to the "technological imperative". Therefore, the 
counsellor should approach applicants wilh full respect for their opinions 
but must also play the role of the devil's advocate when trying to discuss 
the pros and cons of testing and consideration of alternative coping 
strategies. However, this requires a closer collaboration of clinical 
genetics services and institutions of mental health. 
Predictive testing for preseniIe dementia, such as Alzheimer's disease, 
should be undertaken only in the context of research protocols, using 
careful neurological and psychological assessments-'" Testing should not 
run unnoticed in a widespread clinical application without proper previous 
evaluation of such a service. However, predictive testing is generally 
considered, by both professionals and potential users, as a clinical service 
and not as a research protocol, with the consequence of a lack of follow 
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up data, which hampers a thorough medical-ethical evaluation. Obviously, 
the relevance of mandatory research assessments for the evaluation of 
predictive testing should be c1arified. Consequently, the contribution to 
the improvement of the clinical service must be convincing. If these 
requirements are met, people should be encouraged to participate in 
research assessments, and to adhere to the provisions of a research 
protocol. This may be an appropriate expectation by those offering 
presymptomatic testing for HFTD or FAD-CH and HFTD. 
One special issue that was not addressed by the Alzheimer' s study 
group,24 but which needs ·attention, concerns those at 25 % risk, who are 
asymptomatic grandchildren of affected subjects. Identification of a person 
at 25 % risk as a gene carrier identifies the unaffected, intervening, parent 
as a carrier of the disease mutation. Moreover , sibs would see their risks 
increase to 50 % . Af ter the identification of the HD gene, 
recommendations for presymptomatic testing included a statement 
regarding those at 25 % risk. These reconunendations stated r.hat extreme 
care should be exercised when testing a person at risk would inadvertently 
provide information about another pers on who has not requested the test. 
In such cases, every effort should be made by the counselJors and the 
subjects concerned to provide a satisfactory resolution of this conflict. 20 
The majority of representatives from lay organizations favored the opinion 
that if no consensus could be reached, the right of the pers on at 25 % risk 
should have priority over the right of the parent not to know. An 
important argument is that planning a family may be the main reason for 
young adults to take the test, whereas their unaffected parents see their 
chances of ever developing HD dramatically decrease after the age of 50. 
Those at risk for presenile dementia are approaching the mean age of 
onset after 50 years of age, at a time when their children may start a 
family (three-quarters of the grandchildren in the study group are older 
than 18 years). Thus, we expect more conflict of interests compared with 
HD and, in line with the HD guidelines, every effort must be made to 
solve such controversies both at an individual and a family level. The 
serious dilemma for the counsellor is whose rights and interests should 
prevail. Should the counsellor give priority to the applicant's right to 
knowor should he deny testing in order to proteet an invasion of the 
relatives' right not to know? Exclusion testing in a pers on at 25 % risk 
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may be a solution, that is, excluding whether or not one has received a 
chromosome of the affected grandparent. Such an outcome does not 
change the risk of the parent at 50 % risk. However, the initial conflict 
arises again if the applicant's risk has increased to 50% and he/she wishes 
full certainty. Obviously, an unequivocal guideline is not compatible with 
the individual interests of all parties involved. The counsellor's 
responsibility is to safeguard that all advantages and disadvantages are 
discussed and weighed, with the inclusion of the impact of testing for 
relatives. Eventually, the test candidate should decide and have the 
responsibility for his decisions. lt is obvious that inherited late onset 
disorders should be considered as a problem that may have affected the 
whole family for more than two generations . The family is therefore a 
relevant clinical frame of reference for the genetic counsellor and other 
health care professionals. 18.37,38 
Prenatal testing 
When using the Dutch HD testing programmme, one of the main aims 
was to obtain information useful for family planning, 26 Family planning 
was found to be less important in the present survey of people at risk for 
HFTD/FAD-CH, The majority were against the availability of prenatal 
diagnosis as a clinical service. Little more than half of those who 
supported such provision would use it personally and even in this group 
half of the respondents rejected pregnancy termination if an increased risk 
in the fetus was found. The eventual demand for HD prenatal testing was 
lower than was expected from pretest attitudes, but was constant over 
time (unpublished data presented at the 16th International Meeting of the 
World Federation of Neurology Research Group on Huntington's Disease, 
1995). The expected use of prenatal diagnosis in HFTD/FAD-CH might 
be even lower. This expected uptake might reflect feelings in the latter 
group that onset of the disease is generally later9 ," These attitudes reflect 
the painful and thoughtful handling of options by those at risk and make 
c1ear the need for human compassion for people who have experienced 
the tragedy of the disease in their families, Hence, the individual request 
for prenatal diagnosis ought to be appreciated. However, access to 
prenatal diagnosis for untreatable late onset disorders should be denied to 
couples who would consider a selective pregnancy termination, in order to 
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prevent the violation of the future child's right not to know. In the present 
study, 10 out of 19 couples would opt for prenatal testing but not for 
selective abortion. This requires prudent counselling of couples before 
conception, if possible. This may be a task for the general practitioner 
followed by referral to a clinical genetics department. 
Preimplantation genetic diagnosis may become an alternative in the 
near future. Recently, it has been suggested that preimplantation genetic 
diagnosis could be used as a method to achieve prevention of untreatable, 
autosomal dominant late onset disorders in offspring without disclosure of 
parental genotype. 4O The couple would be told only that their embryos 
were tested, and that only apparently disease free embryos were replaced. 
No information would be given which might provide a basis for inferring 
whether or not any embryos with the mutation were identified. Hence, 
parents would derive no direct or indirect information about their own 
genetic risk, while preimplantation diagnosis could reduce the fetal risk to 
zero. This option could be valuable for parents at risk who prefer not to 
know their genetic status. It remains to be seen, however, whether this is 
arealistic alternative. First, the burdens and risks of in vitro fertilization 
should not be underestimated. Furthermore, a condition would be to 
separate those involved in the testing procedure and the counsellor , 
otherwise it may become impossible to protect the parent's right not to 
know adequately. 
Genetics and discrimination 
Both employers and the health, life, pension or disability insurance 
companies may discriminate against people known to have an increased 
risk for cancer or neurodegenerative diseases. 41 The Dutch debate on the 
person's duty to reveal genetic information to insurance companies, and 
on exclusion from life insurance of those at risk for HD and myotonic 
dystrophy, leads us to emphasize the potential harm to carriers of genes 
for untreatable genetic disorders with delayed onse!. Our clinical 
experience has taught us that most people at risk for a variety of inherited 
late onset disorders are not aware of the risk of insurance and 
employment discrimination or tend to underestimate these issues. Some 
people have requested predictive testing in order to get access to life 
insurance. This experience underlines the need for further discussion 
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regarding the use of genetic information by insurance companies and 
employers. We advocate that participants in genetic studies must be 
extensively inforrned of the potential hazards, which may lead to 
withdrawal from the protocol, or to delay testing until arrangements have 
been made. At the time of our study, much media attention was paid to 
the discrimination based on genetic risks, which might explain that 20 % 
of the participants held the opinion that test results should not be added to 
the medical records. Local legislation should protect people with a genetic 
susceptibility so that those at risk feel free to use the options of genetic 
testing, and scientists can proceed with research." Although legal, ethical, 
biomedical, and psychosocial issues must be extensively addressed in pre-
and post-test counselling sessions, we are aware that the informed consent 
remains unsatisfactory and has much limitations with regard to these 
issues. 
Genetic research and health care 
The increasing number of diseases that can be predicted by genetic 
testing (with far reaching consequences) raises the question of how 
genetics services and other medical disciplines can meet the need for 
careful pre and post-test counselling and additional support. Although the 
need is acknowledged and emphasized in every study, the planning and 
resources required are rarely considered in most countries. This leaves the 
human aspect of genetics, such as psychological support and evaluation 
studies, dependent upon external, temporary financial support. Such lack 
of continuity in patient care and research and dissemination of clinical 
research findings may greatly endanger the quality of genetic medicine in 
the future. 
Follow up care must provide proper and consistent information and 
support about the effects of test results on partner relationships and 
families. General practitioners must be properly informed about the 
impact of being at high risk on psychological weil being. Health care 
providers must consider the complex psychological, ethical and social 
issues in the application of presymptomatic testing. They should be aware 
of their own feelings of helplessness,'244 and be careful not to consider 
the test as the only option. They must be educated on these issues in order 
to establish adequate support provisions. 
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Conclusions 
The major limitation of this study was the relatively small number of 
participants. Another bias may be caused by a number of sibs in the study 
as four different families were involved. Therefore, the results must be 
considered wilh caution. The group studied may not be representative of 
the entire population at risk for presenile dementia. Moreover , the resulls, 
with the inclusion of the intention to have predictive testing when 
available, may have been biased by the extensive psychologieal attention 
of the researchers that the participants received. An important limitation is 
that the data were obtained by means of self-report. The disadvantages of 
self-report data are weU known and include possible social desirability 
bias. Therefore, qualitative studies using observation and interview 
techniques and case studies conducted by people who are able to observe 
people at risk and their families objectively can improve the understanding 
of the observations which will consequently increase the clinical 
significanee. 
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GENERAL DISCUSSION AND CONCLUSIONS 
9.1 INTRODUCTION 
The familial and genetic aspects of fronto-temporal dementia (FTD) 
are the central theme in this study. The update and extension of earl ier 
work on familial FTD in our country'·2 allowed, also through a nation-
wide inventory, the analysis of family material that enabled localization of 
the gene (see chapter 5). 
Simultaneously, the first, three-years prospective case-finding study in 
this country, allowed an estimation of the prevalence of this disease (see 
chapter 3). 
The genetic-epidemiological comparison of familial and non-familial 
FTD was addressed, and the differentiation of the disease from 
Alzheimer's disease: in familial FTD no association for disease risk or 
other parameter was found for apolipoprotein E4 (ApoE4)(see chapter 3 
and 4). 
The psychological burden and ethical implications for relatives to 
become involved in a genetic study of an untreatable disease in their 
family may reinforce the genetic threat of that disease and bring people 
closer to the fear of losing their own personality, strength and 
characteristics. These aspects are rarely addressed in family studies in late 
onset genetic disease (see chapter 7 and 8). 
9.2 METHODOLOGICAL CONSIDERATIONS 
The studies on familial aggregation of dementia in FTD (chapter 3) 
and the association with the apolipoprotein E 4 allele in FTD (chapter 3 
and 4) were the first population based studies, allowing ascertainment of 
cases as complete as possible. Misdiagnosis and selection bias of cases 
could still have influenced the data on prevalence and familial 
aggregation. Diagnostic accuracy might be impaired in two ways. Firstly, 
FTD might eventually (at autopsy) be proven as Alzheimer's disease (AD) 
or another non-FTD disorder. In our study (n=74) the diagnosis FTD 
was probable in 55 cases and definite in 19 cases using autopsy and/or 
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linkage to chromosome 17 as criteria. In 43 out of these 55 cases the 
clinical diagnosis was supported by severe frontotemporal atrophy on CT, 
which corre1ates strongly with the pathological diagnosisJ'7 , and by 
frontotemporal hypoperfusion on SPECT in the remaining 12 cases with 
mild atrophy on CT. It seems very unlikely that the probable diagnosis in 
our patients will proven to be wrong, due to the strict supportive 
neuroimaging criteria. Many spouses and first degree relatives of living 
FTD patients are willing to give informed consent for post-mortem 
studies, whieh will enable us to verify the diagnosis in the near future. 
This will inerease retrospective diagnostic accuracy in the future. 
AIso, an erroneous diagnosis of AD might, in fact, be FTD. Early 
FTD cases may easily beeome mislabelled as AD when FTD still shows 
normal findings on CT or MRI 8 The distinct nature of FTD usually 
beeomes evident soon by the its prominent frontal symptomatology, 
selective frontotemporal atrophy, and by the relative preservation of 
spatial orientation, praxis and memory functions . 
9.3 GENETIC-EPIDEMIOLOGICAL DATA 
The genetic-epidemiological study (chapter 3), the first nation-wide 
study of this disease, shows a prevalence of FTD in the Netherlands 
ranging from 1.2110' (age group 30-40 years), 3.4/10' (age group 40-50 
years), 10.7110' (age group 50-6- years) to 28.0110' (age group 60-70 
years). These data are eomparable to other observations 9 Familial 
aggregation of dementia as evidenced by a positive family history for 
dementia in first degree relatives was found in 38% of FTD in our series. 
If one takes the total of FTD cases (n=74) in our epidemiological 
survey, their first degree relatives have a 3.5 fold e1evated risk for 
developing dementia as gender and age matched controls. Even after 
excluding the FTD cases with known linkage to chromosome 17, the 
hazard ratio of dementia in first degree relatives of FTD patients with 
unknown linkage remains significantly elevated (HR=2.4; 95 % Cl: l.5-
3.7)(chapter 3). 
The families with FTD in the Netherlands allowed gene localization 
of a gene for FTD to the ehromosome 17q21-q22 area (chapter 5); this 
result was possible by extensive analysis of the original family from the 
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Netherlands,I.2·IO and two newly identified families. Haplotype studies 
(chapter 5) on the chromosomal area containing the mutation gave 
evidence for independent mutations in these families as no shared 
haplotypes were found, indicating possible allelic heterogeneity; the age 
of onset (earlier in families land 11, later in family III) supports this 
evidence for genetic heterogeneity (chapter 6). 
Recent gene localization studies on the various forms of FTD have 
given an expanding spectrum of clinical designations and eponyms (see 
Table I in chapter I) of diseases linked to an apparently identical area on 
chromosome 17 q21-q22, resulting in the questions: 
are there so many genes in this rather narrow chromosomal region? 
are there so many different mutations in a single gene in that area, 
and is the 7-gene a possible candidate? The absence of haplotype 
sharing among the three Dutch FTD families suggests rather 
heterogeneous mutations in this area. 
which molecular mechanism will eventually be found as a unifying 
concept for FTD-17 diseases, that broadly share important clinical 
characteristics? 
As ± 60% of Dutch FTD cases had a negative family history for 
dementia, it remains to be clarified if the disease mechanism is similar as 
in the genetic forms, or if other errors-like somatic mutations, 
transcriptional or translational errors occurred. The similarity arises with 
the debate on the different causes of 'sporadic' Alzheimer's disease 
(possible transcriptional error)1l and early onset familial Alzheimer's 
disease (mutations in genes located on chromosomes 1, 14 and 21). 
9.4 APO E4 GENOTYPE IN FTD 
The occurrence of the apolipoprotein E4 allele in homozygous and 
heterozygous state was found to be a risk indicator especially for non-
familial Alzheimer's disease."·14 The ApoE4 genotype in FTD was 
analyzed in our population based study in a subgroup of 34 FTD cases 
without clear evidence of autosomal dominant inheritance (chapter 4) and 
showed a significant association with FTD (OR=4.9; 95% Cl: 1.1-20.1). 
A decreased age of onset was found as the number of ApoE4 alleles 
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increased, suggesting a similar mechanism as the ApoE effect in 
Alzheimer's disease D ,15,17 A re-analysis of ApoE4 in a larger set of FTD 
patients also showed (see chapter 3) a higher frequency of the ApoE4E4 
genotype in cases, most pronounced in those without a famiI)' history of 
dementia, compared to controls . 
The predictive value of ApoE4 status for risk identification is clearly 
absent in familial FTD (none of the tested patients with linkage to 
chromosome 17 had an ApoE4 alleie), and only contributory in sporadic 
FTD. These results also imply that ApoE4 status is probabi)' useless in 
the differential diagnosis between AD and FTD. Since the different Apo E 
alleles may be related to the format ion of hyperphosphory lated 7, 7-
pathology has to be further investigated in FTD,18,19 
The analysis of families at the level of clinical phenotype, ApoE4 
association and chromosomal linkage has greatly contributed to our 
understanding of the complexities of fronto-temporal dementias , in their 
course to become identifJed at the IIIolecular level. The clinical diversity 
of disorders mapped to the candidate area wil! give a further insight into 
the tremendous variability between a gene mutation and the phenotype in 
major brain disease, 
9.5 PSYCHOSOCIAL AND ETHICAL ASPECTS OF GENETIC 
FAMILY STUDIES ON NEURODEGENERATIVE DISEASE 
The participation of families is inevitable in molecular-genetic studies, 
Neurologists and scientists working with them have a long tradition of 
taking family participation, also of healthy but at risk relatives, for 
granted: are not the researcher's endeavors for the benefit of the family? 
However, in disorders associated with early onset dementia (ol:her than in 
the better studied and better informed Huntington's chorea families) there 
is a lack of information, and also fear, suppression and denial of obvious 
autosomal dominant transmission, This renders these families quite 
unprepared for the confrontation with potentially high genetic risk of the 
disease, when they are asked (as healthy sib or offspring of a FTD 
patient) to donate blood for a DNA-linkage study, or to participate in a 
family, genetic or ps)'chological study, where questionnaires or interview 
questions mal' inform them about their own, often unexpected risk for 
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dementia. 
Another specific aspect in familial FTD is the threatening impact of 
the personality changes during an extended period in the index patients. It 
is generally experienced as worse than in Alzheimer's disease (where 
personality and mood changes are less threatening) and in Huntington's 
disease (where changes in character and mood may extend for a longer 
period, bUI: the contact with the patient may be preserved) where these 
aspects are generally better recognized by the family, also because there is 
easily available information. 
This study gives the first observations and problems perceived by 
FTD relatives in participating in and consenting to a family study (see 
chapter 7 and 8). 
We address a weil known but generally under-reported problem of 
role-interchange of the c1inician and the researcher, and the potential 
sources of conflict, even if 'written informed consent after full 
information' was obtained. The purpose of inc1uding these obsen'ations 
on the psychological and ethical implications of family studies is three-
fold: 
(I) Family studies on late-onset diseases are 'classical tools of the 
trade' in neurology and their ramifications became only recently 
recognized, with the introduction of presymptomatic testing for 
Huntington's disease. 
(2) Clinical specialists in university hospital practices have often 
multiple rol es subsequent or simultaneously to patients, relatives and 
others. Reflection on the different status of each role remains 
essential. 
(3) Perceptions and acceptance of emotions and reactions of 
individual relatives in a family study are necessary to remain aware 
of the relatives' grief, concern about the index cases and their own 
anxiety and despair about the future. 
Also the group approach for counseling or informing relatives gives 
problems. Different relatives have different needs and capacities to learn 
about their personal risk for adementing disease without treatment or 
prevention. Individual sessions are better suitable to give information and 
obtain consent. 
AIso, the need for additional support may be established. The 
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potential outcome, including unexpected findings, may become explored. 
9.6 ATTITUDES TOWARDS FUTURE PRESYMPTOMATIC 
TESTING 
As expected from other attitudinal studies on late onset genetic 
diseases, two-third of relatives at risk generally expect to utilize a future 
presymptomatic test (see chapter 8), but if this possibility becomes real, 
the experience with Huntington's disease learns that only 10-15 % of risk 
carriers wilI actually apply for it during its first years.20·2J The previous 
data fully explain how painful this process is of handling anticipation, 
expectation, hope, fear and uncertainty. 
9.7 FUTURE STUDIES 
The next years wilI probably bring answers to the question of the 
'dementia burdened locus on chromosome 17q21-q22' with more than ten 
c1inically and pathologically generally similar disorders (FTD-17), but 
with widely different names, clinical presentations and age of onset (see 
also chapter 1).22 
Tau pathology has to be investigated more closely with 
phosphorylation-dependent antibodies like PHF1, AT8, ATlOO, ATl80 
and AT270. Tau-positive lesions in neurons and glial cells will be studied 
in Dutch FTD-17 cases in the next months and immunoblotting of 7 
protein enables comparison with other FTD-17 families and Alzheimer's 
disease.23 •24 
After gene identification the preva1ence of familial FTD linked to 
chromosome 17q21-22 may be estimated and a presymptomatic testing 
programme enabling genetic counseling in people at risk may be 
developed. 
The eventual question wilI become the disease mechanism, reliable 
famiI)' information, and understanding the possible interventions in the 
molecular wrong doings. 
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10.1 SUMMARY 
INTROQUCTION 
Fronto-temporal dementia (FTD), its clinical, genetic and 
epidemiological aspects were assessed in a study aiming at complete 
ascertainment of FTD in the Netherlands. We analysed in depth since 
1994 more than hundred patients, their spouses and families, including 28 
families with two or more relatives with dementia and three large multi 
generation kindreds. 
Fronto-temporal dementia and Pick's disease have a long history, 
reviewed briefly in chapter 1. FTD, as it became recently defined by the 
Lund and Manchester groups may be differentiated from Piek' s disease by 
the absence of specific neuropathological findings like Pick cells and Piek 
bodies. FTD is a primary degenerative disease of the brain. It starts 
usually from age 40-60 years. Progressive behavioral changes occur early 
in the disease. Three forms of FTD are known (chapter 2): frontal lobe 
dementia, frontal lobe dementia with motor neuron disease, and 
progressive aphasia with behavioral disorders . Lobar atrophy of the 
frontal and temporal cortex is seen by imaging and at autopsy. 
Mieroscopically, there are aspecific neuronalloss, gliosis and spongiosis 
in several cortical layers. FTD is a rare disease, but epidemiologieal data 
are lacking. A few families show an autosomal dominant inheritance. The 
autosomal dominant form of FTD in the Netherlands is studied including 
a family previously studied by Schenk. This review (chapter 2) of the 
clinical, pathological and imaging aspects formed the starting point of an 
over three years nation wide case finding study. 
EPIDEMIOLOGIC AND GENETIC ASPECTS 
Our study is the first prospective population based study (15 million 
inhabitants) of FTD (chapter 3) showing a prevalence ranging from 
1.21106 (age group 30-40 years), 3.4/106 (age group 40-50 years), 
10.7/106 (age group 50-60 years) to 28.01106 (age group 60-70 years). 
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The family history of dementia was analysed in 74 FTD patients and 561 
age- and gender-matched control subjects. Dementia befare the age of 80 
years in at least one relative was found in 38% (28/74) of cases but only 
in 15 % (84/561) of controls. Also. dementia in at least two first-degree 
relatives was significantly more common among FTD patients (10 %) than 
in the controls (0.9 %). The first -degree relatives of FTD had a risk of 
22 % for dementia befare 80 years, as compared with 11 % in relatives of 
contrals . The age of onset of dementia in affected first -degree relatives of 
FTD cases (60.9± 10.6 yrs) was significantly lower than among affected 
relatives of controls (72.3±8.5 yrs). The risk of dementia among first-
degree relatives of FTD patients was 3.5 times (95% Cl 2.4-5.2) higher 
than among relatives of controls. The hazard ratio in the subgroup with 
unknown linkage to cllfomosome 17 was 2.4 (95% Cl 1.5-3.7). 
The risk for dementia in first -degree relatives shows suggestive 
evidence for genetic heterogeneity. In first -degree relatives of FTD cases 
linked to chromosome 17, this is 47% (suggestive for autosomal dominant 
inheritance). It is 18 % in relatives of FTD cases with unknown linkage 
and 11 % in relatives of controls. 
LINKAGE ANAL YSIS 
Three multi-generation Dutch kindreds with FTD (chapter 5) were 
investigated for clinico-pathological comparison and !inkage analysis. We 
founcl linkage to chromosome 17q21-q22 with a maximum l.od score of 
4.70 at 8=0.05 with the marker D17S932. The gene for hereditary FTD 
(HFTD) is in a region of approximately 5 cM between markers D17S946 
and D 17S791. The patients from the three families did not share a 
common haplotype for the reg ion of this disease gene. This may indicate 
that HFTD in the three families is caused by independent: mutational 
events. Three other neurodegenerative disorders with a strong clinical and 
pathological resemblance have recently been mapped to the same 
chromosomal region, suggesting that a group of clinically related 
neurodegenerative disorders may originate from mutations in the same 
gene (or genes). 
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CLINICAL HETEROGENEITY IN HFTD 
To analyze phenotypic heterogeneity, we further (chapter 5 and 6) 
compared age of onset, and clinical symptoms, neuroradiological and 
neuropathological changes in the three Dutch HFTD families. 
Frontotemporal atrophy on CT and/or MRI was usually present (91 % of 
cases). Single photon emission computerized tomography (SPECT) 
showed anterior hypoperfusion in the early phase of the disease. Moderate 
to severe atrophy of frontal and temporal cortex was seen with neuronal 
loss, gliosis and spongiosis, but no Pick bodies were seen in all autopsied 
cases of the three families. No immunohistochemical evidence for 
accumulation was found for ubiquitin, tau, B-amyloid or paired helical 
filaments. 
The mean age of onset showed interfamilial differences: in family I 
and 11 these were 50.4 and 46.5 years respectively, significantly lower 
!han in family III (63.4 years) (p < 0.001). Progressive behavioral changes 
and speech reduction were the dominant symptoms in all cases. Intra-
familial similarity and inter-familial differences were found as 
disinhibition was the presenting symptom in family land Il, and loss of 
initiative predominated early in affected cases in family 111. 
APOLIPOPROTEIN E 
The ApoE4 genotype in FTD was analyzed in our population based 
study in a subgroup of 34 FTD cases without clear evidence of autosomal 
dominant inheritance (chapter 4) and showed a significant association 
with FTD (OR=4.9; 95% Cl: 1.1-20.1). A decreased age of onset was 
found as the number of ApoE4 alleles increased, suggesting a similar 
mechanism as the ApoE effect in Alzheimer's disease (AD). A re-analysis 
of ApoE4 in a larger set of FTD patients also showed (chapter 3) a 
higher frequency of the ApoE4E4 genotype in cases, most pronounced in 
those without a family history of dementia, compared to controls. 
The predictive value of ApoE4 status for risk identification is clearly 
absent in familial FTD (none of the tested patients with linkage to 
chromosome 17 had an ApoE4 alleie), and only contributory in sporadic 
FTD. These results also imply that ApoE4 status is probably useless in 
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the differential diagnosis between AD and FTD. Since the different Apo E 
alleles may be related to the formation of hyperphosphorylated T, T-
pathology has to be further investigated in FTD. 
PSYCHOLOGICAL AND ETHICAL ASPECTS 
Genetic studies often require the cooperation of many relatives. The 
ethical and psychological effects of family studies for untreatable 
disorders preparing for later predictive testing are rarely addressed. In our 
Dutch study on FTD three types of medical-ethical dilemmas were 
encountered (chapter 7). The first is the controversy of the role of 
clinician versus researcher: scientific excitement ought to be secondary to 
good medical care. The emotional impact of information on the genetic 
nature of a disease may necessitate postponement of the request for 
participation. The second problem is unexpected outcomes like change of 
diagnosis: Huntington's disease became an alternative diagnosis in a 
patient, with far-reaching consequences for relatives. Discussing all 
possible unforeseeable findings during the information process is difficult. 
Reasons for disclosure of such unexpected information must be ideally 
given in a protocol. The third problem is the group approach to provide 
information on the disease and the study. This is often asked by a family 
and attractive to the researcher, but often fraught with risks for free 
informed consent and for safeguarding the individual inter ests . 
Genetic family studies may be supported by psychological evaluation 
and so contribute to adequate information of families and insight of 
researchers into relevant psychological factors to be addressed in family 
studies. 
The acceptability of presymptomatic testing in 21 Dutch individu als at 
50% risk for the APP-692 mutation causing presenile Alzheimer's disease 
and/or cerebral haemorrhage resulting from cerebral amyloicl angiopathy 
(FAD-CH), and in 43 people at 50% risk for HFTD was assessed 
(chapter 8). Both groups had similar demographic variables. Of the total 
group 64 % intended to request presymptomatic testing when it became 
clinically available, although two-thirds did not yet feel ready to take it. 
The most important reasons in the HFTD and FAD-CH group for taking 
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the test were: to promote basic research (42% and 47% resp.), informing 
the children (47% and 50% resp.), planning of the future (29% and 47% 
resp.) and relieving uncertainty (46% and 27% resp). An unfavorable test 
outcome was expected to increase problems for spouses (75 % and 76 % 
resp.) and children (61 % and 57% resp.). Such an unfavorable result was 
not expected to have adverse effects on personal mood or relationship. 
Prenatal testing would be considered by one third of the couples in case 
of an increased risk for HFTD or FAD-CH. Participants would encourage 
their offspring to have the test before starting a relationship (35%), and 
before family planning (44%) and would encourage (37%) their children 
to opt for prenatal diagnosis . People at risk for HFTD were significantly 
more pre-occupied with the occurrence of potential symptoms in 
themselves, compared with those at risk for FAD-CH, reflecting the 
devastating impact that disinhibition in the affected patient has on the 
family. Our findings underline the need for adequate counselling and the 
availability of professional and community resources to deal with the 
impact of test results in subjects and their relatives. 
CONCLUSION 
In conclusion, hereditary FTD and other neurological disorders 
mapped to the chromosomal region of 17 q21-q22 show an increasing and 
intriguing variability, and have great impact on the patient and the family. 
Further gene- and mutation detection will become a next step to unravel 
the disease mechanism. That knowledge will be essential for the 
development of any future therapy. 
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10.2 SAMENVATTING 
INLEIDING 
De klinische, genetische en epidemiologische aspecten van fronto-
temporale dementie (FTD) zijn onderzocht in een groep van meer dan 
honderd patiënten met FTD in Nederland. 
De dementie met achteruitgang (atrofie) van de voorste en zij (slaap) 
kwabben van de hersenen werd door Amold Pick in 1892 als eerste 
beschreven. Sindsdien (hoofdstuk 1) hebben o.a. de uit Manchester en 
Lund komende onderzoeksgroepen in 1994 aan de aandoening de naam 
gegeven van fronto-temporale dementie. Ook werden klinische, 
radiologische en pathologische criteria voor de diagnose opgesteld. De 
ziekte van Pick is een bijzondere vorm van FTD en gaat gepaard met 
ronde insluitlichaampjes in de zenuwcellen van de hersenen, de 
zogenaamde Pick bodies. 
FTD is een degeneratie van de hersenen, met verschijnselen vanaf het 
40e-60e jaar. Er zijn vanaf het begin toenemende gedragsveranderingen, 
zoals ontremd en stereotiep gedrag en verlies van initiatief. Later gaan de 
intellectuele functies achteruit. Er zijn drie types van FTD (hoofdstuk 2): 
geïsoleerde FTD, FTD met afwijkingen van de motorische voorhoom 
cellen, en progressieve afasie met gedragsveranderingen. Een 
verschrompeling van de voorkwab enlof de slaapkwab kan zowel bij 
beeldvormend onderzoek (CT of MRl scan) als bij obductie worden 
gevonden. Microscopisch ziet men een verlies van zenuwcellen in de 
hersenschors, evenals verlittekening (gliose) en verweking (spongiose). 
FTD is zeldzaam, maar vóórkomen en overerving waren onvolledig 
bekend. Een Nederlandse familie met FTD in opeenvolgende generaties, 
beschreven door Schenk, Sanders en Groen, vormde het startpunt om 
autosomaal dominante vormen van FTD te onderzoeken in drie families in 
Nederland (hoofdstuk 2). Tegelijkertijd werd gedurende 1994-1997 een 
ruim drie jaar durend genetisch en epidemiologisch onderzoek gedaan om 
zo volledig mogelijk het vóórkomen van FTD vast te stellen. 
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EPIDEMIOLOGISCHE EN GENETISCHE GEGEVENS 
Het eerste prospectieve onderzoek naar FTD in Nederland (hoofdstuk 
3) toont dat het vóórkomen toeneemt tussen het 30e en 70e jaar: van de 
4e tot 8e decade zijn er respectievelijk 1,2, 3,4, 10,7, 28,0 patiënten per 
miljoen Nederlanders. Deze gegevens werden verkregen door gedurende 3 
jaar zo nauwkeurig mogelijk alle patiënten met deze diagnose, bekend bij 
neurologen en centra met specialisten betrokken bij deze groep van 
patiënten, vast te leggen. 
Het vóórkomen van dementie in de familie, onderzocht bij 74 
patiënten met FTD en 561 controles (vergelijkbaar in leeftijd en geslacht) 
toonde een duidelijke rol van erfelijke factoren. 38 % van de FTD 
patiënten had tenminste één eerste graads familielid met dementie voor 
het 80e jaar (en slechts 15 % van de controles). Dementie bij twee of meer 
eerste graads familieleden kwam voor bij 10 % van de FTD patiënten, 
significant vaker dan bij controles (0,9%). Eerste graads familieleden van 
patiënten met FTD hebben 22 % kans op dementie voor het 80e levensjaar 
(en bij controles is dit 11 %). Deze dementie treedt vroeger op bij 
verwanten van FTD patiënten (60,9 ± 10,6 jaar) dan bij verwanten van 
controles (72,3 ± 8,5 jaar). Globaal hebben eerste graads familieleden 
van FTD patiënten 3,5 keer hoger (95% betrouwbaarheidsinterval 2,4-
5,2) risico op dementie dan verwanten van controles. Sluiten we in die 
analyse mensen uit bekende FTD families uit, dan houden eerste graads 
familieleden van FTD patiënten een 2,4 keer groter (95 % 
betrouwbaarheidsinterval 1,5-3,7) risico op dementie dan familieleden van 
controles. Naast dominant, erfelijke factoren zijn er dus waarschijnlijk 
verschillende andere genetische factoren betrokken bij het ontstaan van 
deze vorm van dementie. 
Het risico op dementie voor eerste graads familieleden is 47% in de 
drie beschreven families met dominante overerving, hetgeen past bij dat 
model. Bij FTD niet gekoppeld aan het chromosoom 17 locus hebben 
18% (versus 11 % in controles) eerste graads verwanten dementie. 
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KOPPELINGSONDERZOEK: 
plaatsbepaling van familiaire FTD op de chromosoomkaart. 
In drie Nederlandse families met dominant erfelijke FTD (hoofdstuk 
5) werden klinische en pathologische aspecten ondezocht. Tevens werd de 
plaats van de ziekte-eigenschap op de chromosoomkaart bepaald bij een 
zogenoemd koppelingsonderzoek. De eigenschap voor FTD ligt in een 
kleine regio op de lange arm van chromosoom 17 (q21-22). Dit gebied is 
ongeveer 5 centiMorgan groot, en wordt afgebakend door de markers 
D17S946 en D17S791. De series DNA-kenmerken die dit gebied in de 
betrokken families markeren (het haplotype) zijn verschillend, wat één 
gemeenschappelijke voorouder onwaarschijnlijk maakt. Dit zou kunnen 
betekenen dat de erfelijke vorm van FTD in deze drie families 
veroorzaakl: is door onafhankelijke mutaties. 
Drie andere neurodegeneratieve aandoeningen die klinisch en 
pathologisch lijken op FTD, zijn recent eveneens gelokaliseerd in dezelfde 
chromosomale regio, hetgeen erop duidt dat een groep van klinisch 
verwante neurodegeneratieve aandoeningen zijn genetische oorzaak heeft 
in mutaties in hetzelfde gen of genen in hetzelfde gebied. 
KLINISCHE VARIABILITEIT IN ERFELIJKE FTD 
De beginleeftijd van dementie en de klinische, neuroradiologische en 
neuropathologische kenmerken bij de drie Nederlandse families met 
erfelijke FTD zijn beschreven in hoofdstuk 5 en 6. 
De beginleeftijd waarop de dementie ontstond verschilt: in familie I 
en Il bij 50,4 en 46,5 jaar, hetgeen significant eerder is dan in familie III 
(63,4 jaar)(p-waarde < 0,001). Progressieve veranderingen in gedrag, en 
een verminderde spraakproductie zijn het meest opvallend. Er werd een 
sterke overeenkomst binnen de familie, en verschillen tussen de families 
gevonden. Ontremd gedrag blijkt het vroegste symptoom te zijn in familie 
I en Il, terwijl initiatiefverlies het meest op de voorgrond staat in het 
begin van de ziekte bij demente familieleden uit familie III. 
Frontotemporale atrofie is nagenoeg altijd (91 %) aanwezig bij 
beeldvormend onderzoek (CT scans en/of MRI scans). Een verminderde 
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doorbloeding van de frontotemporale regio wordt in de beginfase op 
SPEeT-scans (=single photon emission computed tomography) gevonden. 
De hersenen vertonen (na overlijden) een matige tot ernstige atrofie van 
de frontale en temporale hersenschors. Microscopisch ziet men een verlies 
van zenuwcellen in meerdere schorslagen met gliose en spongiose, zonder 
Pick insluitsels. Immunohistochemisch onderzoek met conventionele 
antilichamen heeft geen positieve reactie op eiwitten als ubiquitine, tau, 
beta-amyloid en paired helical filaments laten zien. 
APOLIPOPROTEINE E 
Apolipoproteine E is een polymorf eiwit dat in de hersenen een rol 
speelt bij de groei en regeneratie van zenuwcellen. De E4 isovorm van 
het apolipoproteine E (ApoE4) is geassocieerd met een verhoogde kans op 
de ziekte van Alzheimer. De frequentie van het ApoE4 allel en ApoE4E4 
genotype is allereerst onderzocht in een subgroep van 34 patiënten met de 
niet erfelijke vorm van FTD (hoofdstuk 4). Dit onderzoek liet een 
statistisch significant verband zien tussen het ApoE4 en FTD. De 
beginleeftijd van de aandoening was lager naarmate het aantal E4 allelen 
toenam, hetgeen een aanwijzing is voor aanwezigheid van een ApoE4-
effect net als bij de ziekte van Alzheimer. Een heranalyse van ApoE4 bij 
een grotere groep van FTD patiënten heeft eveneens een hogere frequentie 
van het ApoE4 genotype bij patiënten t.O.V. controles laten zien. Dit 
verband tussen ApoE4 en FTD is het meest uitgesproken bij FTD 
patiënten met een negatieve familie anamnese voor dementie (hoofdstuk 
3). 
De voorspellende waarde van de ApoE4 status om het risico voor 
dementie in kaart te brengen is duidelijk afwezig bij de erfelijke vorm van 
FTD (ApoE4 kwam namelijk bij deze patiënten niet voor), en slechts van 
aanvullende waarde bij de sporadische vorm van FTD. 
Het bepalen van de ApoE4 status is dus niet bruikbaar bij de 
diffentiële diagnose van de ziekte van Alzheimer en FTD. Daar de 
verschiIlende ApoE4 allelen mogelijk gerelateerd zijn aan de vorming van 
de gehyperfosforyleerde vorm van het tau-eiwit, moet de rol van deze 
afwijkende tau-eiwitten bij FTD nader onderzocht worden. 
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PSYCHOLOGISCHE EN ETHISCHE ASPECTEN 
Genetisch onderzoek binnen een familie vraagt vaak de medewerking 
van gezonde en aangedane familieleden. Deelname kan zeer belastend zijn 
vanwege de confrontatie met de ziekte en de persoonlijke risico's. De 
ethische en psychologische effecten van dergelijk onderzoek zijn echter 
zelden bestudeerd. In de huidige studie zijn wij drie medisch-ethische 
dilenuna's tegengekomen (hoofdstuk 7). 
Ten eerste was er de tegenstelling tussen de rol van clinicus en 
onderzoeker: het wetenschappelijk enthousiasme dient ondergeschikt te 
zijn aan goede medische zorg en begeleiding. De emotionele betekenis 
van de erfelijke achtergrond van een ziekte maakt het soms nodig om het 
verzoek tot deelname aan het wetenschappelijk onderzoek uit te stellen. 
Het tweede probleem betrof onverwachte bevindingen die van grote 
klinische betekenis zijn voor deelnemers of hun verwanten en nageslacht. 
Zo werden bij een patiënt aanwijzingen gevonden voor de ziekte van 
Huntington, een autosomaal dominante erfelijke aandoening met - indien 
bevestigd - grote gevolgen voor de kinderen en overige verwanten. Niet 
alle mogelijke onverwachte uitkomsten kunnen tijdens het proces van 
informatieverstrekking worden besproken. Toch moeten in het 
onderzoeksprotocol algemene richtlijnen worden opgenomen over hoe 
gehandeld moet worden bij onverwachte bevindingen. 
Het derde probleem betrof het groepsgewijs informeren over de 
aandoening en het onderzoek. Deze benadering wordt vaak door de 
familie gevraagd en lijkt aantrekkelijk en efficient voor de onderzoeker. 
Bij groepsgewijze informatie kunnen individuele vragen onvoldoende 
besproken worden. Ook de psychologische effecten voor de individuele 
deelnemers zijn niet zorgvuldig in te schatten. Genetisch familieonderzoek 
dient gepaard te gaan met psychologisch onderzoek om een evaluatie 
mogelijk te maken. 
De aanvaardbaarheid van toekomstig voorspellend onderzoek werd 
onderzocht bij 21 mensen met een 50 % risico op de aanwezigheid van een 
mutatie (APP-692) die leidt tot de ziekte van Alzheimer op jonge leeftijd 
enlof hersenbloedingen (FAD-CH), en bij 43 mensen met 50% risico op 
het krijgen van FTD (hoofdstuk 8). Beide groepen hadden 
overeenkomstige demografische kenmerken. 64 % wenste voorspellend 
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Samenvatting 
onderzoek als dat mogelijk wordt, echter tweederde was daar op dit 
moment nog niet aan toe, De belangrijkste redenen voor het laten 
verrichten van een voorspellende test waren: hulp aan wetenschappelijk 
onderzoek, informeren van kinderen, toekomstplanning en bevrijding van 
de ondragelijke onzekerheid, Als een testuitslag ongunstig zou blijken, 
dan werd verwacht dat vooral de partner en de kinderen meer problemen 
krijgen. Men verwachtte van een ongunstige uitslag geen nadelig effect op 
de eigen stemming of op de huwelijks relatie. Het verrichten van prenataal 
onderzoek werd overwogen bij eenderde van de paren in geval één van de 
ouders drager blijkt van de erfelijke eigenschap. 35 % zou hun kinderen 
aanmoedigen voorspellend onderzoek te ondergaan voordat zij een relatie 
aangaan, en 44 % voordat kinderen een eigen gezin stichten. Risicodragers 
voor FTD waren angstiger en meer gepreoccupeerd met 
ziekteverschijnselen bij zichzelf dan risicodragers voor FAD-CH. Onze 
bevindingen benadrukken het belang van goede voorlichting en 
professionele begeleiding bij genetisch familieonderzoeken en - in de 
toekomst - voorspellend onderzoek. 
CONCLUSIE 
De erfelijke vorm van FTD en andere neurologische aandoeningen die 
gekoppeld zijn aan chromosoom 17, laten een toenemende en intrigerende 
variabiliteit zien, en hebben een niet te onderschatten uitwerking op 
patiënt en familie. Verder onderzoek naar de identificatie van gen en 
mutaties zullen de volgende stap zijn in het begrijpen van het ziekte 
mechanisme. Deze kennis is belangrijk voor de ontwikkeling van 
behandeling van FTD. 
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